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Since 2004, increasing numbers of children in sub-Saharan Africa have commenced 
antiretroviral therapy (ART). This thesis reviews the outcomes of published studies of 
paediatric ART cohorts in Africa, describes outcomes for children receiving ART in South 
Africa and examines determinants of mortality and generalizability across the Southern 
African region. Temporal trends in characteristics at ART initiation are also examined. The 
measurement of treatment success in resource-limited settings is reviewed, by examining 
virological failure, and assessing the diagnostic accuracy of immunological criteria for 
identifying virological failure.  
The results chapter is presented in the form of published or submitted papers based on data 
from the International epidemiologic Databases to Evaluate AIDS-Southern Africa (IeDEA-
SA) collaboration. The first paper reviews paediatric ART studies from Africa published 
before 2008. Together with the literature review in chapter 1, it provides the background to 
this thesis. The second paper reports on mortality (8%) and retention in care (81%) by 3 years 
after ART start for >6,000 children who initiated ART in South Africa. The generalizable 
prognostic models in the third paper suggest that mortality during the first year on ART 
ranges from <2% to >45%, with the majority of children being in the group with the best 
prognosis. The fourth paper reports that 1 in 5 children meet criteria for confirmed virological 
failure by 3 years on ART. The risk is greater with triple ART containing nevirapine or 
unboosted ritonavir (in comparison with lopinavir/ritonavir or efavirenz). The fifth and sixth 
papers demonstrate that immunological criteria have low sensitivity and positive predictive 
value for virological failure. Targeted viral load measurement reduces the number of false 
positive virological failure diagnoses. The final paper shows that increasing numbers of 












2010. However, even in 2010 a substantial number of children started ART with advanced 
disease. 
The thesis concludes that access to ART for children has increased, with good outcomes. HIV 
cohort research is important in evaluating the safety and effectiveness of different models of 
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Introduction 
In 2009 when this study was conceived, Sub-Saharan Africa was home to an estimated 2.3 
million children under the age of 15 years living with HIV, with 330,000 in South Africa 
alone.1,2 Although access to antiretroviral therapy (ART) for these children was initially slow 
and lagged far behind access for adults, this had expanded rapidly in recent years, but 
continued to reach only a fraction of those in need.2,3 For example, across sub-Saharan Africa 
the percentage of children in need of ART that were receiving it increased from 6% in 2005 
to 26% in 2009.2 In South Africa, paediatric ART access had expanded particularly rapidly – 
by December 2009 an estimated 54% of the 160,000 children in need of ART were receiving 
it. Nevertheless many challenges to scaling up paediatric ART remained including poor 
access to early infant diagnosis, limited availability of suitable drug formulations, lack of 
integration of antenatal and maternal and child health programmes with HIV care 
programmes, and the complexity of providing HIV care and treatment for very sick young 
infants and children resulting in care largely centralized at urban or specialist facilities.4-6 
Since 2004, an increasing number of publications from individual treatment programmes in 
sub-Saharan Africa had demonstrated both the feasibility and effectiveness of paediatric ART 
in this setting.7-17 In addition, in 2009, the combined paediatric antiretroviral therapy in lower 
income countries (KIDS-ART-LINC) cohort collaboration demonstrated that in 2,405 
children followed for a median of 20 months, the 2-year risk of death after ART initiation 
was 6.9%, while the risk of loss to follow-up was substantially higher at 10.3%.18 
As access to paediatric ART was expanding with children remaining on therapy for longer 












and programme-level determinants in large cohorts of children treated in a range of different 
countries and programmes. Such analyses could inform clinical practice and programmatic 
roll-out of ART. In particular, analyses were needed that described ART effectiveness and 
monitoring strategies in the context of the challenges to paediatric ART scale-up. This was 
particularly important in the light of paediatric ART guidelines that had evolved substantially 
since 2004 in accordance with scientific evidence.19-22  
The International epidemiologic Databases to Evaluate AIDS in Southern Africa (IeDEA-SA) 
was initiated in 2006 and is one of seven IeDEA regional collaborations across the world 
(http://www.iedea-hiv.org).23 The IeDEA-SA paediatric cohort collaboration aims to collect 
and harmonize paediatric HIV data across the Southern African region to address research 
questions unanswerable within a single cohort.24 The IeDEA-SA paediatric combined cohort 
therefore provided a unique opportunity to examine ART outcomes and effectiveness in large 
cohorts of children from different programmes and settings across the Southern African 
region. This study therefore aimed to report on the outcomes and their determinants for 
children initiating ART both within the South African national programme and across the 














1.2. Aims and objectives 
The aim of this study was to describe the effectiveness and determinants of effectiveness of 
paediatric ART programmes across Southern Africa at the time the study was developed in 
2009.  
Specific objectives were: 
1. To review the literature on paediatric ART effectiveness and outcomes in sub-Saharan 
Africa. 
2. To describe the survival and related outcomes of ART programmes in Southern 
Africa and their determinants through two analyses as follows: 
a. To describe the survival and related outcomes of the South African ART 
programme for children, and examine determinants of these outcomes. 
b. To assess the generalizability of survival outcomes on ART across the 
Southern African region by developing a prognostic model of one–year 
mortality for children initiating ART that is generalizable across different 
treatment cohorts. 
3. To evaluate the role of different monitoring strategies for measuring treatment success 
in children retained in care in resource-limited settings, and examine the determinants 
of virological failure through three analyses as follows: 
a. To analyse the probability and determinants of virological failure and 
switching to second-line therapy in the South African ART programme. 
b. To examine the diagnostic value of immunological criteria for identifying 












c. To examine the role of targeted viral load strategies contingent on meeting 
immunologic failure criteria for identifying patients with virological failure, 
in the context of limited access to HIV-RNA measurement. 
4. To examine programmatic ART scale-up through describing the characteristics of 
children accessing ART across Southern Africa and examining temporal changes in 
these characteristics from 2004 – 2010 in relation to changes in WHO and national 












1.3 Literature review 
 
1.3.1 Introduction 
As early as 1999, studies demonstrating good outcomes of paediatric triple ART were 
published from resource rich settings.25-30 Since 2004, access to ART in resource-limited 
settings, and Africa in particular, has increased dramatically.1,31,32 This has been both due to 
increasing country and programme capacity to enrol children on ART with substantial 
external donor support, and guideline changes advocating earlier ART at higher CD4 
thresholds.20,22,32 These changes have been based on the rapid disease progression in the 
absence of ART, as well as the mortality benefit of ART in infants.33-35 Nevertheless, ART 
continues to reach only a fraction of those who need it; by the end of 2011, 42 countries 
provided ART to fewer than one in five treatment-eligible children.32  
There are a number of barriers to providing ART for children in resource-limited settings 
including poor access to early infant diagnosis, few and expensive drugs available in child-
friendly formulations, need for a reliable caregiver to administer medication, and both the 
real and perceived complexity and lack of expertise and experience with treating and 
monitoring sick infants and young children.4,5,36,37 It is therefore important to review the 
characteristics of children currently accessing ART in resource-limited settings, their 
outcomes on therapy and the determinants of these outcomes. This includes reviewing and 
evaluating the different monitoring strategies used to measure these outcomes. 
 
1.3.2 Aim  
This literature review aims to appraise all published observational studies of ART for HIV-
infected children in sub-Saharan Africa in routine clinic settings that report on mortality 












ART will be defined as a regimen of at least three drugs from two different classes. The 
review will include studies published in English until the end of 2010 in order to provide a 
context for the analyses included in this thesis at the time when they were conceptualized. A 
published literature review of all studies published until the end of 2007 is included as one of 
the published papers in this thesis (Chapter2, section 2.1 page 53). This section of the thesis 
will therefore focus on studies published between 2008 and 2010 as studies prior to 2008 are 
described and appraised in detail in the published review. In addition, studies published 
between 2008 and 2010 provide the most relevant background to this thesis, as this is the 
period during which it was conceptualized. 
 
The objectives of the review are to report the following items as well as identify needs for 
further research: 
• Characteristics of children at ART initiation and how these have changed over time and in 
different settings. 
• Response to ART including mortality and loss to follow-up, growth, opportunistic 
infections, immunological and virological response. 
• Determinants of response to ART.  
•  Virological failure and the role of clinical and immunological responses to ART in 
identifying children with virological failure in the absence of routine HIV-RNA 
monitoring.  
While the key studies to be systematically reviewed will therefore be studies of sub-Saharan 
African paediatric ART outcomes that report on mortality, I will also selectively draw upon 
other studies that include results pertinent to these objectives. These include studies from 
resource-limited settings outside sub-Saharan Africa (e.g. Jittamala et al., 200938), studies 












beyond a certain initial period after ART initiation (e.g. Kabue et al., 200839), results from 
dedicated research studies rather than routine clinic settings (e.g. Musoke et al., 200940; Reitz 
et al., 201041), reports of ART monitoring strategies (e.g. Yotebieng et al., 201042) and 
resistance (e.g. Adje-Toure et al., 200843) and comparisons of ART outcomes between 
resource-limited and wealthy countries (e.g. Kekitiinwa et al., 200944). 
 
1.3.3 Search strategy 
A search of the Medline bibliographic database using the PubMed interface (National Library 
of Medicine, Bethesda, MD) was performed using the following strategy: “(antiretroviral OR 
ART OR HAART OR cART”) AND (child* OR pediatric OR paediatric) AND Africa”. A 
key word search was used as this yielded more studies than that of Medical Subject Headings. 
In addition, the bibliographies of reviews of paediatric ART outcomes in resource-limited 
settings (identified through PubMed) were reviewed to identify additional studies. 
Inclusion criteria: 
• Articles from sub-Saharan Africa that reported at least on the mortality outcomes of 
entire cohorts of children that initiated ART in a routine clinic setting were included.  
• Published in English. 
Exclusion criteria 
• studies from countries not in sub-Saharan Africa. 
• studies that did not report on mortality. 
• studies that reported outcomes on only a subset of all children that initiated treatment. 
• studies from non-routine care settings (e.g. trials and dedicated observational cohort 
studies with inclusion criteria that could constitute a selection bias). 












Possible duplicate studies were included as it was difficult to confidently ascertain whether 
the data included was the same, and repeat studies on the same cohort frequently 
demonstrated evolution of the programme and provided additional data such as increased 
cohort size, longer follow-up and more detailed information on particular outcomes. 
Similarly collaborative studies and reports of programme level data that may include data 
from cohorts that have also published individual cohort results were all included, so data 
from some individual cohorts might be included more than once. It is important to include the 
collaborative studies as they provide valuable background to this thesis which is based on a 
collaborative dataset. Collaborative studies frequently include a broader spectrum of HIV 
care settings as programmes that are not able to undertake independent research can be 
included. In contrast, individual patient studies can frequently describe programmes to a 
greater level of detail with better data completeness. Published abstracts were reviewed to 
determine whether studies met the inclusion criteria, and the full text of articles was reviewed 
if this was not clear from the published abstract. 
 
1.3.4 Results 
Numbers of studies included  
Forty-one studies were identified that met the inclusion criteria; 18 of these were published 
prior to 2008 and are included in the published literature review; 23 studies published 
between 2008 and 2010 are reviewed in the following section. 
 
Characteristics of included studies 
The characteristics of 23 studies (2008-2010) systematically reviewed are shown in Table 1. 
(Table 1 of the published review describes studies published prior to 2008). Two of the 23 












programme in South Africa and appear to report on a largely similar paediatric dataset. 45,46 
The 21 studies that analyse individual patient data report on 20 different cohorts or cohort 
collaborations, with two studies reporting on similar data from three facilities in Zambia. 47,48 
Four are repeat studies in cohorts that were included in the published literature review, 
namely the Médecins sans Frontières (MSF) cohort collaboration,16,17,49 Kenyatta National 
Hospital, Nairobi,50,51 Academic Model for the Prevention and Treatment of HIV-AIDS 
(AMPATH), Kenya,52,53 and Lusaka, Zambia.12,54 In addition to the MSF cohort 
collaboration,49 the KIDS ART-LINC collaboration reports on several HIV programmes from 
a number of countries across Africa.18 Ten reported studies include data from more than one 
clinic within one country47,48,53-61 and eight studies are from a single clinic/health facility.51,62-
68 Eight studies are from primary health care (PHC) clinics, five from hospital-based clinics, 
seven include both PHC and hospital data, and one is from a hospice setting in which a 
multidisciplinary team provides daily care to children with very advanced disease.65 In 
addition to the two studies reporting provincial programme data, six studies were from South 
Africa, three from Kenya and two each from Zambia and Uganda. There was one study each 
from Rwanda, Democratic Republic of Congo (DRC), Côte d’Ivoire, Mali and Malawi.  
Eligibility criteria for ART initiation were mostly based on World Health Organization 
(WHO) guideline criteria in place at the time. This means that for some studies ART 
initiation criteria changed during the study with revisions in WHO guidelines and that CD4 
thresholds used for ART initiation are lower than those currently recommended in the WHO 
2010 guidelines.22 In addition, in some studies HIV DNA or RNA polymerase chain reaction 














Time of data collection  
Data collection for the majority of studies began in 2004 and mostly corresponds to the start 
of national ARV programmes. Data collection ended between 2006 and 2008, so studies do 
not include significant numbers of infants started prior to disease progression as 
recommended by the interim WHO report in 2008.21 
 
Numbers and sex of children initiated on ART  
As expected, multi-country collaborative studies included large numbers of children. The 
MSF collaborative study included 3,542 children from Africa49 while the KIDS-ART-LINC 
collaboration included nearly 2,500 children.18 The number and size of single country 
collaborative studies is increasing. For example, the AMPATH collaboration in 2009 
reported on >2,500 children on ART,53 nearly tenfold more than in 2006.52 In South Africa, 
Fatti et al.59 include 2,332 children ever started on ART, while the Western Cape Provincial 
programme report includes approximately 1,700 children.45,46 Including all studies, 21,524 
children who ever initiated ART are included, of whom nearly 6,000 are from the two multi-
country collaborative studies. Among studies that include more than one cohort from a single 
country the median (interquartile range [IQR]) number of children included is 770 (542-
1,754). Single cohort studies continue to include relatively small numbers of children with 
median (IQR) of 149 (84-345). In contrast, prior to 2008 the largest MSF multi-country study 
included 1,184 children, the median (IQR) number of children in multisite studies from one 
country was 279 (233-297) and from single cohort studies was 80 (73-244). In general boys 




























Median (IQR) age 












West, East and 
Southern 
Africa
16 until  2007 2,405 48 4.9 (2.1-8.4) NR 73d 53e NR 35 NR
Barth et al.  2008 South Africa 1 2003-2006 66 50 4.8 (2.6)a 10.6 (0.1-29.8)b NR NR NR NR 5.1 (3.0-5.7)b
Jaspan  et al.  2008 South Africa 1 2002-2006 391 47 2.2 (1.0-4.5) 13.0 (8.0-17.5) NR NR -2.5 (-4.0 to -1.2) NR 5.5 (4.8-6.0)
Kiboneka et al. 2008 Uganda 10 2004-2008 770 54 9 (5.0-13.0) NR 47 42 NR NR NR
Van Griensven et al. 
2008
Rwanda 2 2003- 2006 315 50 7.2 (4.5-10.4) 14.0 (9.0-18.0) 56 40 -1.9 (-3.0 to -0.9) NR NR
Van Winghem et al. 
2008
























Median (IQR) age 
(years)








Bock et al. 2009 South Africa many 2004-2006 1,741 NR NR NR 46 NR NR NR NR
Boulle et al.  2009 South Africa many 2002-2006 1,709 NR NR NR 45 NR NR NR NR
Callens et al.  2009 DRC; Pediatric 
Hospital
1 2004-2006 299 48 NR 12.0 (7.0-18.0) NR 76 NR 30 NR
Harding et al.  2009 South Africa, 
hospice
1 2006 37 54 5.5 (3.3)a 13.6a (8.6)c NR NR NR NR 5.4 (5.0-5.9)
Mubiana et al. 2009 Zambia 13 2004-2006 1,235 45 6.4 (2.4-9.9) 12.6a (8.2)c NR 76  -2.3a (1.7)c 34 NR
Ntanda et al. 2009 Uganda 1 2002-2008 101 56 6 (3-10)
non-orphans:                
9.0 (5.0-11.3)      




17                                                                                                                                          
orphans: 36
NR NR NR





















Median (IQR) age 
(years)








Anaky et al.  2010 Cote d'Ivoire 19 2004-2007 977 47 5.3 (2.3-9.1) 10.7 (5.6-15.0) NR 43 -3.0 (-4.7 to -1.8) NR NR
Fatti et al.  2010 South Africa 51 2003-2008 2,332 50 5.8 (3.0- 9.0) 12.2 (7.0-18.0) 73d 67
-1.51a                                                     
(-1.59 to -1.44)g 
15 NR
Germenaud et al. 
2010
Mali 1 2006-2007 97 46 2.6 (1.7-5.8) NR NR 77 -3.0 (-4.7 to -2.2) NR NR
Janssen et al.  2010 South Africa many 2004-2008 477 48 6.2 (0.3-15.0)b 17.0 (11.0-26.0) NR 67 -1.8 (-2.5 to -0.8) NR 4.2 (3.2-5.2)
Naidoo  et al.  2010 South Africa 2 2004-2005 120 46 6.5a (1.7-12.5) 9.3a (5.4)c NR NR  -1.96a (1.78)c 23
4.8a (1.1)c
Sauvageot et al. 
2010
15 countries 
in Africa, 5 in 
Asia
48 2002-2008 3,936 47 2.6 (1.7-3.7) NR 82 76  -2.3 (-3.3 to -1.2) 31 NR
Sutcliffe et al.  2010a Zambia 3 2004-2008 607 NR
urban                               
7.1 (3.6-10.2)                 
rural                                   
8.1 (3.4-10.1)
NR NR NR NR NR NR
Sutcliffe  et al.  2010b Zambia 3 2004-2008 863 NR
urban                              
6.8 (3.2-10.0)             
rural                               
3.7 (1.9-8.3)
urban                      
11.1 (6.5-16.2)           
rural                              
14.3 (9.8-19.0)
NR NR
urban                                       
-2.3 (-3.5 to  -1.4)  
rural                                      
-3.1 (-4.1 to 1.8)
NR NR
Wamalwa et al.  2010 Kenya 1 2004-2008 149 50 4.9 (2.6-6.7) 6.8 (3.6-11.4) 89 14f
-2.35 (-3.14 to -
1.49)
NR 6.0 (5.4-6.5)
Weigel et al. 2010 Malawi 1 2001-2008 497 49 8.0 (4.0-11.0)  10.8 (7.2-15.7) 77 94 -2.1 (-2.7 to -1.3) NR NR
NR Not reported;  IQR interquartile range












Missing data on characteristics at ART initiation 
While multi-site studies include large numbers of children, this may be at the expense of data 
quality and completeness. This is particularly a problem for multi-country studies and studies 
that include numerous sites within a country. For example, the KIDS-ART-LINC 
collaboration used a composite variable called ‘severe clinical status’ that combined WHO 
Clinical Stage and weight-for-age z-score (WAZ) data due to substantial missing data on both 
of these variables individually. Both WHO Clinical Stage and WAZ data were missing for 
nearly 40% of children.18 In the MSF collaborative dataset, CD4% data was only available 
for 60% of children.49 Similar proportions of missing CD4% data were noted in the study of 
>2,000 children from 44 public health facilities across South Africa.59 The reasons for 
missing data are complex and may be different for different studies. Variables may not 
actually be measured due to lack of equipment or technology (e.g. anthropometric variables, 
CD4, HIV-RNA), lack of expertise (e.g. lack of knowledge of WHO Staging), treatment 
guidelines not requiring their measurement (e.g. baseline CD4 and HIV-RNA measures are 
not routinely done in many resource-limited settings) or health care workers in busy clinics 
omitting to perform every measurement in every child. Availability of clinical and laboratory 
data according to national monitoring guidelines may be a proxy for quality of care 45,46 and 
Fatti et al.59 noted that missing laboratory result data was higher at rural facilities. Even 
where variables are measured, measurements may not be recorded in medical records and/or 
transferred to electronic databases used for analysis. As ART programmes expand and 
children are on therapy for longer durations, there is likely to be increased transfer of children 
between treatment sites, and records of treatment characteristics at ART start may not be 
available at the new treatment site. Fatti et al.59, for example, excluded 17% of children who 












collection is done by retrospective record review and there is selective access to medical 
records as was reported by two studies.54,61 
 
Characteristics at ART initiation 
Age 
The age at which children initiate treatment in routine care settings is a measure of the extent 
to which infants and young children are being timeously diagnosed and started on ART. In 
the absence of treatment, HIV disease progression and mortality is greatest in infants and 
young children,34,35,70-72 and ART initiation before clinical progression in young infants 
reduces mortality by 75%.33 In addition, in a cohort of children aged 1-10 years ineligible for 
ART according to WHO 2006 criteria, 19% progressed within two years to death, a WHO 
Stage III/IV event, or to meet WHO 2006 CD4 thresholds for ART initiation. Children with 
low CD4%, high HIV-RNA and age <3 years had the greatest risk of progression. For 
example, a child with HIV-RNA >105 copies/ml and CD4% <25 had progression probability 
of nearly 30% in one year.73  
Children in the studies reviewed continue to initiate ART at older ages with mean/median 
ranging from 4.8-9.0 years in all except three studies. One of these studies specifically only 
included children less than five years of age49 while the others are both from tertiary care 
hospital settings with median (IQR) ages at ART start of 2.6 and 2.2 years respectively.63,67 
Age ranges reported may however be misleading as they are dependent on the inclusion 
criteria for the particular cohort – for example some cohorts specifically exclude children less 
than 18 months51 while the upper limit for inclusion ranged from 12 to 18 years. 
Access to early infant diagnosis and coverage of routine infant testing is critical for 
accurately identifying infected children. In this respect some studies reported that diagnosis 












health facilities in Kenya published in 2008 showed that while a policy framework for 
identifying HIV- infected children had been established, there were a number of barriers to 
systematic diagnosis including limited postnatal follow-up of exposed children and access to 
HIV PCR testing at only four of 58 health facilities providing paediatric ART.74 While 
clinical algorithms have been proposed to aid diagnosis in infants in the absence of PCR 
testing, these lack sensitivity and specificity, although may be useful for identifying those at 
greatest risk of progression or for excluding the diagnosis.75,76 Where access to Dried Blood 
Spot (DBS) polymerase chain reaction (PCR) testing is available, it has been shown to be 
feasibly and successfully integrated into public health programmes, by, for example, 
implementing routine testing at immunization visits.77,78 Even where PCR testing is available, 
attrition from prevention of mother to child transmission (PMTCT) programmes between 
birth and the six week infant diagnosis visit is frequently high79,80 and so routine provider 
initiated testing either on hospital admission or at other health visits can increase both 
coverage of infant diagnosis and numbers of children initiating ART.78,81 
Interestingly the only study reviewed that assessed secular trends in age of children initiating 
ART found no change over time in an urban programme but a reduction in median age from 
8.1 to 3.1 years in the rural programme which included follow-up of HIV exposed uninfected 
infants suggesting that integrated PMTCT follow-up and ART services may be better at 
identifying and initiating infants and young children on ART.47 Even in this setting, the 
majority of children already had advanced disease by the time of ART start with median 
(IQR) CD4% of 13.7 (9.5 – 18.4) and 67% of children with WAZ<-2. 
The fact that the only cohorts with median age <36 months were tertiary care hospital 
settings63,67 suggests that even with good access to early infant diagnostic testing, there are 
many additional barriers to care.4-6 The same pattern was seen in studies prior to 2008 with a 












markedly younger than any of the other studies.10 These barriers include the need for syrup 
formulations of medication with regular dose adjustments due to rapid infant growth. The 
MSF Collaboration49 reported the need to use different drugs in younger children (zidovudine 
[AZT] instead of stavudine [d4T]) for formulation-related reasons and in the Rwandan study 
(median age 7.2 years) syrups were only available for the later part of the study period prior 
to which younger children had to be referred to the central hospital.56 A study of ART 
outcomes in HIV-infected Ugandan children with and without exposure to single dose 
nevirapine (sdNVP) initially only included children >12 months using fixed dose 
combination (FDC) drugs.40 However the study protocol had to be amended to include 
children 6-12 months of age using syrup formulations in order to recruit sufficient numbers of 
children with sdNVP exposure, most of whom were infants.40 
A further barrier to infant ART at primary care level is the reality of high risk of disease 
progression and mortality in young infants, especially those infected in utero or perinatally, 
even when ART is started early.82,83 Hospital referral may be required and PHC staff may be 
understandably reluctant to initiate treatment without tertiary care support. Even in the trial 
setting of the Children with HIV Early antiretroviral (CHER) Study conducted at tertiary 
hospitals, overall mortality in the early therapy group was still high at 4.9/100 person-years 




The majority of children started ART with advanced (WHO Stage III/IV) clinical disease 
across all studies that reported it. The MSF cohort collaboration49 reported 76% of children 
with known Stage having Stage III/IV disease (Stage not reported in 11% of children) and in 












WAZ<-3 (although information on both of these was missing for nearly 40% of children).18 
Seven of the ten single country multi-site cohorts reported on WHO Clinical Stage. Missing 
Stage data was minimal for four of these studies and 4%, 13% and 21% in the remaining 
three studies. Five of the single clinic studies provided information on WHO Stage with 
missing data of 20% in only one study.68 While many studies report high proportions (>65%) 
of children having Stage III/IV disease, and up to 94% in the Malawi cohort,68 four studies 
had lower proportions (40-50%) of children with advanced disease.53,55,56,58 The proportion of 
children with advanced disease seems higher in the pre-2008 studies where almost all studies 
had >70% and three cohorts >85% of children with Stage III/IV disease.10,15,84 
 
Nutritional status 
Weight-for-age z-scores (WAZ) were reported as medians/means for 11 studies and percent 
of children less than <-2 (two studies) or -3 (six studies). For most studies median WAZ was 
between -3 and -2.3, apart from three studies with median/mean WAZ >-2, all of which are 
from primary care cohorts within South Africa, possibly reflecting less severe disease in 
children treated at primary care level in South Africa.59,61,85 Similarly >30% of children had 
WAZ<-3 in all but two studies, both of which are mentioned above.59,61 Missing weight data 
was substantial and reported by six studies, ranging from 5% to 51%. This is a concern as 
weight measurement is required to determine ARV dose. However, missing weight data does 
not necessarily mean that the measurement was not done or known by the attending clinician, 
and may reflect the discrepancy between recording of electronic data and what is actually 
measured in the clinic. These findings are very similar to those reported for cohort results 
published prior to 2008. 
Height-for-age z-scores (HAZ) were reported by only five studies and were consistently 












Callens et al.64 reported 27% of children with HAZ<-3 and Weigel et al.68 69% with HAZ <-
2. Median weight-for-height z-score (WFHZ) was only reported for two studies at -0.4561 and 
-1.1351 respectively. The paucity of studies reporting on height and weight-for-height data 
suggest that this is not routinely recorded and even in those studies with this information, two 
reported missing data in approximately one quarter of children. Weight and height 
measurement, together with assessment of oedema is needed to classify nutritional status, so 
the anthropometric measures reported by these studies do not provide a comprehensive 
assessment of nutritional status of children initiating ART. WHO recommends dosing using 
weight bands except in children less than three years of age, and the lack of height 
measurement suggests that dosing is indeed largely weight-based.20 
In a comparison of children initiating therapy in Uganda with a collaborative cohort in the 
UK/Ireland, the median WAZ and HAZ in Uganda were significantly lower than in the UK  
(-2.8 vs -0.6 and -2.8 vs -0.8) respectively.39,44 Similarly, in a comparison of paediatric ART 
outcomes between resource-limited and developed countries, mean baseline WAZ was -2.2 
for resource-limited setting and -0.4 for developed countries.27 
 
Immunological status 
Eighteen studies reported some measure of immunological status (median/mean CD4 count 
or percent or proportion with values below thresholds defining immune suppression). As with 
other variables the proportion of missing data was substantial with 11 studies reporting >5% 
missing data and the proportion missing ranged from 8-40%. In most studies mean/median 
CD4% at ART start was low (range 9.3 to 14.0 for most studies.) This is, however, higher 
than for studies published pre-2008 in which the median CD4% was below 10% in all but 
two studies, both of which included relatively larger numbers of young children. In 












reported as 23% 27.  
One study reported a much lower median CD4% of 6.8, but this study only enrolled children 
with WHO Stage III/IV or CD4<15% and was based at the Kenyatta National Hospital in 
Nairobi, so perhaps likely to see children with the most severe disease.51 In contrast, in rural 
KwaZulu-Natal the highest median CD4% of 17% was reported in a relatively old cohort of 
children (median age 6.2 years) however there was substantial missing data so there may be 
selection bias.60  
Median CD4 count was variable in keeping with the different age ranges of children, but for 
most studies was between 250 and 500 cells/mm3. Notable exceptions of lower median CD4 
were reported in the subset of children >13 years of age in DRC,64 and among orphans with 
median age of seven years in Kenya.66 In the Cape Town cohort with median age of 26 
months, the median CD4 at ART start was higher at 513 cells/mm3.63 There has not been 
widespread adoption of the use of CD4 z-scores86 which would make it easier to compare 
CD4 values across different age ranges, perhaps because of the variability of normal values 
across populations and lack of reference values for different populations, and the fact that 
CD4% values are relatively comparable except in infants and very young children.  
 
Viral load 
As expected, few studies provided information on HIV-RNA as this is frequently either not 
available or not measured at ART start in resource-limited settings. Most of the studies that 
did report HIV-RNA information were single site cohorts, suggesting again that this 
information is not routinely available across a range of settings. Missing data was >50% in 
three of these cohorts, all of which are South African, where national guidelines actually 












Clinicians may have been influenced by adult guidelines that do not recommend 
measurement of baseline HIV-RNA, especially in sites where both adults and children are 
treated in the same clinic. In four of the six studies with baseline HIV-RNA measurements, 
the median (IQR) HIV-RNA was >5 log10 copies/ml; the two studies with lower values were 
both cohorts of older children (median age >6 years), in keeping with the known decline of 
HIV-RNA with increasing age.87 In particular, the study at rural PHC clinics in Kwazulu-
Natal with the lowest median HIV-RNA value of 4.2 log10 copies/ml also had the highest 
median CD4% value of 17% despite being a relatively older cohort with median age of 6.2 
years and only 12% of children <18 months of age.60 This suggests that this is a selected 
population of healthier children, with sicker children possibly starting treatment in urban 
areas or at the local district hospital.60 Prior to 2008, median HIV-RNA values were >5 log10 
copies/ml in all studies that reported it. In comparison, the mean baseline HIV-RNA in 
studies from developed countries is 4.7 log10 copies/ml.27 
 
Caregivers and orphan status 
Six studies provided information on the child’s caregiver and/or proportion of children for 
whom parents were deceased. It is difficult to compare the proportion of orphaned children 
across studies as the definition of orphanhood is different and the proportion of children who 
have been orphaned is expected to be higher in studies that include mostly older children. The 
proportion of children reported to be orphans ranged from 25% to 47%, however it is likely 
that studies with higher estimates define children who have lost one parent to be orphans 
although this is not always specifically stated.64,66 Two studies report on the proportion of 
children with both parents deceased as 7% 51 and 11% 53 respectively. There is also 












Orphans are older at ART start and may have more advanced disease in terms of Clinical 
Stage,66 immune suppression55 and WAZ53, although this is not consistent across studies. 
Using the same cohort in Western Kenya, Nyandiko et al.52 were the only researchers prior to 
2008 to compare characteristics by orphan status at ART initiation and found no significant 
differences except for older age in orphans, but did not specifically report on WAZ in that 
study. It has been argued that orphanhood predicts delayed access to ART.66 There is 
however a selection bias among older children as children are both more likely to become 
orphaned and more likely to have advanced disease as they grow older (as both their and their 
parents’ disease has had a longer time to progress). It would be more accurate to say that 
older children initiating ART are more likely to be orphans and have advanced disease, than 
to infer delayed access for orphans. The fact that almost all studies have found no differences 
in adherence or outcomes on ART between orphans and non-orphans suggests that orphan 
status does not affect quality of care on ART, and so may well not be associated with worse 
access to ART.52,53,66,88-91. The only exception is the finding of poorer adherence for double 
orphans in a study by Vreeman et al.92 There is however a selection bias when examining 




Eight studies report on tuberculosis at ART initiation with proportions in all except one study 
ranging from 2.5%-8%, which is similar to proportions reported from most studies prior to 
2008. A much higher proportion of 22% is reported from a cohort in rural Kwazulu-Natal in 
South Africa.60 While it is unclear whether the proportion in the Kwazulu-Natal cohort 
includes both children with active tuberculosis and previous tuberculosis, similar high 












and also from more detailed cohort studies of tuberculosis in HIV-infected children that did 
not meet inclusion criteria for this review.41,42,94 For example, Martinson et al.94 found that 
21% of children had a tuberculosis diagnosis either at enrolment into their study, or within 
the next few weeks. Alarmingly, in a cohort analysis of data prior to randomization on the 
NEVEREST trial of different treatment strategies in children initiating protease inhibitor (PI) 
-based ART, 24% of children aged less than two years of age were on tuberculosis treatment 
at ART start.41 Nearly 40% were co-treated for tuberculosis at some point during follow-up.41 
While such high proportions of children with tuberculosis may not be surprising in view of 
the estimated incidence of 23.4 cases per 100 HIV-infected children per year,95 they are 
concerning as treatment of children co-infected with tuberculosis may lead to increased 
medication burden with the risk of poor adherence, greater chance of drug-drug interactions 
and the need to modify regimens in children taking lopinavir/ritonavir (LPV/r)-based or 
nevirapine (NVP)-based regimens.22,96,97 There is also a risk of developing paradoxical 
worsening of tuberculosis on treatment due to the immune reconstitution inflammatory 
syndrome (IRIS). 98,99 Indeed, although most studies have not demonstrated survival 
differences between children co-treated for tuberculosis and those receiving ART alone,41,100 
tuberculosis is a significant cause of mortality in HIV-infected children with 18-44% of 
deaths attributable to tuberculosis in studies from tuberculosis endemic areas.51,101 Further, a 
lower probability of viral suppression in children on ART co-treated for tuberculosis has been 
reported.41  
 
Nevertheless, it is widely acknowledged that comparisons of proportions of children with 
tuberculosis in different studies is difficult as the proportion diagnosed with tuberculosis may 
depend on the extent of active screening for tuberculosis prior to ART initiation, access to 












integration of tuberculosis and HIV programmes and the relative importance of tuberculosis 
programmes as a referral sources to HIV/ART care. Indeed, in many studies classification of 
children as having tuberculosis is based on treatment for tuberculosis rather than confirmed 
diagnosis,41,94,105 precisely because of the diagnostic difficulties in young children. In the face 
of diagnostic uncertainty, there may well be over-treatment for tuberculosis to avoid missed 
opportunities to treat a potentially curable opportunistic infection. The proportion of children 
reported as having previous tuberculosis either at enrolment into HIV care or at ART start is 
high, ranging from 18- 42% 49,53,64,105 in all except one study from Côte d’Ivoire. 58 
 
Other illnesses at ART start 
As expected with most children having advanced clinical disease, the proportion of children 
with opportunistic infections (OI) prior to ART initiation is high in the four studies that report 
it. Callens et al.64 found that 76% of children had at least one OI diagnosis prior to ART start, 
and a similar proportion of children with at least one previous hospitalisation has been 
reported.51 A slightly lower proportion with severe disease is reported at enrolment into care 
when not all children have met ART eligibility criteria.53 Common diagnoses/symptoms 
include oral candida, respiratory illnesses, mucocutaneous conditions, gastroenteritis, failure 
to thrive and delayed milestones. Similar OIs are reported in studies of hospitalisation of 
HIV-infected children (both off and on ART),101 with the addition of malaria as a common 
diagnosis in a study from Ghana.106 In a cohort of children referred for palliative hospice 
care, diagnoses reflected the effects of chronic HIV infection such as encephalopathy, 













First-line drug regimens 
Most studies report either on the recommended first-line regimens according to programme 
or country guidelines or provide information on drugs actually prescribed. The majority of 
children across studies were initiated on a combination of two nucleoside/nucleotide reverse 
transcriptase inhibitors (NRTI) + one non-nucleoside reverse transcriptase inhibitor (NNRTI) 
with NVP dominating as the NNRTI of choice in most studies. This is both in keeping with 
WHO guidelines20 and reflects the availability of fixed dose combinations (FDC) including 
NVP that were specifically reported to be used where possible in four studies.49,54,56,68 These 
studies noted increased complexity of prescribing for younger children for whom syrup 
formulations were needed. Similar patterns of regimen use were noted in studies prior to 
2008, with a number of studies reporting use of split adult FDC tablets in children, even in 
children < 8kg.15,16,100,107 This meant once-daily dosing of d4T which is not recommended, 
but nevertheless had good outcomes and was simple, available and low cost.15 
PI use was only reported in three studies, two of which were from South Africa with 
proportions of 25% in predominantly primary care settings59 and 52% in a younger cohort 
treated at a tertiary hospital.63 One-third of children in the Côte d’Ivoire cohort started a PI-
based regimen.58 LPV/r was used in South Africa and nelfinavir in Côte d’Ivoire. In the 
KIDS-ART-LINC collaboration that includes cohorts both from West Africa and South 
Africa, 41% of children initiated PI-based regimens.18 As expected, PI use was more common 
in younger children due to lack of dosing recommendations for efavirenz (EFV) in children 
less than three years of age and higher likelihood of exposure to antiretrovirals  for PMTCT 
in children born in later years.18,63 
NRTIs used were lamivudine (3TC) and stavudine (d4T) for the majority of children as is to 
be expected from WHO guidelines 20. However, several studies reported the need to use 












formulation that does not require refrigeration.49,53 AZT use also predominated in children 
started on treatment prior to the introduction of WHO Guidelines in 2004.18,62,68 
Not surprisingly for cohorts collecting data prior to 2010, no studies reported on use of 
abacavir in first-line ART as this was only introduced in the WHO 2010 Guidelines.22 
 
Outcomes of children on ART 
Follow-up duration, mortality and loss to follow-up 
Mortality and loss to follow-up (LTFU) results are summarized in Table 2. The percentage 
probability of dying by one year or mortality rate (per 100 child years [CY]) during the first 
year on ART) are reported by 13 studies and mostly fall within the range of 4-12. Notable 
exceptions with low mortality are the studies from Rwanda56 and Uganda66 with one year 
mortality probability of 2% and mortality rate of 1.7/100 CY, and low LTFU in both studies. 
These are both older cohorts with median ages of 7.2 and 6.0 years and the Rwandan cohort 
includes a relatively low proportion of children with WHO Stage III/IV disease (40%). 
Conversely a 15% percentage probability of one-year mortality was reported from a tertiary 
care centre in Kenya where the median CD4% at ART start was only 7% and 76% of children 
had been previously hospitalized,51 and in a cohort of young children in rural Zambia.48 
Higher rural mortality (11.4/100 CY vs 5.4/100 CY during the first six months on ART) was 
also noted in one of the multi-site South African cohorts.59 Mortality outcomes appear similar 
for studies that only report on the percentage of deaths throughout the study rather than 
mortality rate or probability. Notable exceptions of low mortality (2.3% deaths overall) were 
found in a Ugandan study of older children (median age 9.0 years) with 42% having WHO 
Stage III/IV disease,55 and high mortality of 16% in the first six months in a study of children 












These outcomes are in keeping with the weighted mean mortality probability of 7.6% and 
rate of 8.0/100 CY calculated from 30 cohorts from resource-limited settings,27 which is 
notably higher than the mean probability of 1.6% and rate of 0.9/100 CY in developed 
countries. Mortality outcomes in Africa appear similar to those reported from other resource-
limited settings (Asia, Caribbean and South America) although within each continent there is 
wide variability in mortality outcomes, probably reflecting both the selection bias of children 
treated in particular settings and difference in mortality ascertainment.27,85,108,109 
Estimates of two-year mortality are reported by seven studies. In comparison only two studies 
published prior to 2008 had sufficient follow-up to report these estimates. Nevertheless the 
median follow-up duration was ≤24 months in all studies, so none reported longer term 
outcomes. Notwithstanding, across all studies mortality probabilities by two years are very 
similar to those at one year.7,8,17,18,47-49,56,57,63 Indeed almost all studies noted that mortality 
was particularly high in the first three to six months on ART, with the risk of death 
decreasing substantially in those surviving beyond this period. For example, in a South 
African tertiary care cohort 93% of deaths occurred in the first six months,63 while in DRC 
77% of deaths occurred within two months of ART start.64 Mortality rates in the first three 
months are at least four to five times greater than those in subsequent periods.51,58,60 
Only two studies reported on causes of death with common causes being pneumonia, septic 
shock, tuberculosis, gastroenteritis, malnutrition and measles.51,64 Similar findings have been 
reported from studies of mortality in HIV-infected patients admitted to hospital.40,101,106  
The interpretation of mortality outcomes reported by studies is dependent on the extent of 
censoring due to LTFU and the completeness and quality of mortality ascertainment.110-112 In 
this respect, four studies provide no information on LTFU,55,61,64,65 while Wamalwa et al.51 












studies LTFU is negligible,63,66 in many the proportion of children LTFU is similar to or 
greater than for mortality.18,48,49,51,54,57-60,62,67,68,113 The overall proportion of children LTFU or 
percentage probability of LTFU is >15% for a number of studies, however comparison of 
these figures is highly dependent on the way LTFU is defined by each study.114 Since the 
goal of ART is to retain children alive and in care, LTFU is a negative outcome. In this 
respect in the AMPATH programme in Western Kenya rates of LTFU in children on ART 
and those not on ART were similar (14.1 and 15.2 per 100 child-years respectively),115 
however in Côte d’Ivoire loss to programme (Death +LTFU) on ART was approximately half 
that in pre-ART children despite similar mortality rates.58 Differences in LTFU pre- and post-
ART include both unascertained mortality and true loss to follow-up. Differences in the latter 
may be explained by selection bias with patients needing to demonstrate adherence to clinic 
appointments and other medication such as cotrimoxazole in order to be initiated on ART. 
LTFU constitutes informative censoring and impacts on estimates of mortality. The few 
paediatric tracing studies suggest mortality amongst HIV-infected children LTFU may be 
very high. In rural Malawi 38% of pre-ART children and 50% of children on ART who were 
LTFU were found to be deceased on tracing,116 while in Kenya the proportion of deceased 
children among those LTFU in a cohort of HIV-infected children mostly not on ART was 
16%.117 These estimates of mortality are generally higher than those of children remaining in 
care. In addition, children LTFU are more likely to have characteristics associated with 
mortality.18,59,85,115 Indeed, in adults classified as LTFU in a South African ART programme 
where vital status was ascertained by linking to the national death registry, it was found that 
mortality was a major cause of LTFU with most patients’ date of death being before the 
LTFU definition would have been met.118 Only one study reviewed assessed the impact of 
unascertained mortality on overall mortality and showed that even with a modest probability 












Stage III/IV disease increased the estimated one-year probability of mortality from 4.4 to 
6.0%.60 
Comparison of mortality across different settings also requires an understanding of the 
predictors of mortality and the likely impact of the characteristics of children in a particular 
cohort on overall mortality. The most common patient-level predictors of mortality were 
young age, low CD4 % or severe immunodeficiency, low WAZ/WHZ and advanced Clinical 
Stage, although findings across studies were not always consistent.18,48,49,51,55,58-60,64 This may 
be due to substantial missing data for a number of these variables with models restricted to 
only a subset of all children in the cohort, or that a “missing” category had to be included as a 
predictor. No cohort studies found an association between viral load (VL) and mortality; 
however availability of baseline results was limited. In a cohort analysis of children less than 
two years of age initiating ART on the NEVEREST trial, mortality was associated with 
baseline HIV-RNA ≥750,500 copies/ml.41 Evidence for the impact of tuberculosis at ART 
start on mortality is conflicting.41,59,119 This may relate to the certainty of tuberculosis 
diagnosis, characteristics of children co-treated for tuberculosis and, importantly, the relative 
timing of tuberculosis and ART treatment. Adult studies have shown that delaying ART 
initiation in patients co-treated for tuberculosis results in increased mortality.120 In a causal 
modelling analysis, among children co-infected with tuberculosis, there was a trend towards a 
harmful effect of delaying ART initiation for >60 days after starting tuberculosis treatment, 
especially if severely immune suppressed.121 
Understanding programme level determinants of outcomes is challenging due to the need to 
account for the difference in child characteristics in particular programmes. For example, 
while Fatti et al.59 found that rural children had higher mortality, in Zambia there was no 
difference in mortality between urban and rural clinics after adjustment for baseline child 












clinics in the Western Cape ARV Programme is ascribed to healthier children being treated in 
these settings.45 In a comparison of mortality between resource-limited settings and 
developed countries, confounding by baseline WAZ and VL was noted.27 Nevertheless, 
programme characteristics may have important impacts on outcome. For example, a number 
of differences in outcomes were noted when comparing children in three different settings: 
urban residence and facility attendance (urban); rural residence and facility attendance 
(rural); and rural residents attending urban facilities (rural/urban).59 While the rural group 
experienced the highest mortality after adjustment for disease severity characteristics, the 
rural/urban group had highest LTFU and lowest probability of virologic suppression, 
suggesting that long travel distances adversely affected adherence. 59 
 
Clinical events 
Two studies examined incident clinical events after ART initiation and found that 68% of 
children had any incident diagnosis (most commonly mucocutaneous conditions and 
respiratory tract infections)54 while the probability of developing a new Stage IV disease was 
5% during the first six months of treatment, with the most common Stage IV conditions being 
severe bacterial infections and extrapulmonary tuberculosis.49 All incident diagnoses were 
most frequent in the first six months of starting ART. Despite this high incidence, studies 
published prior to 2008 showed that this was still lower than the incidence during the pre-
ART period.7,50 
A number of studies have specifically examined the impact of ART on tuberculosis and all 
demonstrate lower risk after ART initiation.94,99,102,105,122 While most of these studies adjust 
for factors that might increase the risk of tuberculosis such as Clinical Stage and CD4%, only 
Edmonds et al.105 adjust for confounding by indication whereby ART is more likely to be 












and found a 50% reduced risk of tuberculosis after ART initiation. It should be noted that the 
incidence of tuberculosis diagnoses in the pre-ART period may be elevated in studies that 
specifically screen for tuberculosis as part of ART preparation or where tuberculosis 
programs comprise a major source of referral for HIV/ART care, while diagnoses made soon 
after ART start may include prevalent disease undiagnosed at ART start including unmasking 
IRIS events. 98 In this respect Bakeera-Kitaka et al.122 showed that an apparent excess risk of 
tuberculosis in the first 100 days after ART start could be averted by clinical and tuberculin 
skin test screening for tuberculosis prior to starting ART, and that by 100 days after ART 
initiation risk for tuberculosis was lower than pre-ART. 
 
CD4 response 
CD4 values show marked increases on ART in the 11 studies which report on these. Increase 
is most rapid in the first six months on ART with median/mean CD4% increases of 11.3% 
and 12.6% reported, 48,62 resulting in cohort median/mean values >20% at six to twelve 
months in all studies, 53,56,60,62,63 sustained at longer periods.68 Similar responses have been 
reported in cohorts that only include children with a particular duration of follow-up on 
ART.42-44,124 Increases in CD4 absolute count in the first six months of ART for children at 
least five years of age range between 200 and 300 with cohort mean/median values >500 
cells/mm3 by six months after ART initiation among children in this age group.42,44,53,55,56,60,67 
Median/mean increases >600 cells/ are seen in younger children.42,67 No differences have 
been noted in CD4 responses on ART between resource-limited and wealthy countries, 
although mean values reached at six and twelve months are lower in resource-limited settings 
due to lower values at ART initiation.27,44 
In a detailed study of the pattern and determinants of CD4% response, it was noted that while 












after ART initiation with less brisk responses in older children and those with higher VL at 
ART initiation. There was no difference between children treated with NNRTI or PI. CD4% 
values tended to plateau at 23% overall, but were higher in younger children and those 
completely suppressed throughout ART.125 In contrast, in a study aimed at identifying 
predictors of mortality and viral response after the first six months on ART, gain in CD4% 
was stable across all age groups.42 The detailed description of CD4 responses in the latter 
study highlights that while median/mean CD4% increases may be brisk, approximately 10% 
of children experience no increase in CD4%, and values may even decline.42 
 
Growth response 
Seven studies published between 2008 and 2010 provided some information about changes in 
WAZ, and two studies about changes in HAZ. All studies noted increased mean/median 
WAZ on ART with a pattern similar to that of CD4% with an early steep increase, followed 
by slower increases thereafter.48,56,59,61,63,67,68 In Côte d’Ivoire, WAZ declined pre-ART at a 
rate of 0.31% per year, but increased at a rate of 0.61% per year after ART start.125 In a 
detailed study of growth trajectories during the first two years on ART in Malawi, the 
steepest early increases were noted in children with the lowest baseline WAZ.68 In a study of 
children remaining in care for at least six months, weight gain on ART was faster than 
reference values from a healthy population, suggesting catch-up growth.42 This study also 
showed the slowest weight gain was in children four years of age, with faster gains in infants 
and younger children as well as those approaching adolescence.42 Naidoo et al.61 noted that 
only children who were moderately and severely underweight showed improved nutritional 
status on ART. The fastest WAZ change in all studies of  +1.16 units during the first six 
months on ART was seen in a very young cohort (median age 31 months), although there 












LTFU by six months. Similar rapid WAZ increases were seen in a cohort analysis of children 
prior to randomization on the NEVEREST trial.98 
There were no differences noted in the rate of WAZ improvement between urban and rural 
children, however mean/median values at baseline and throughout follow-up were lower in 
rural children.48,59 In a comparison of growth on ART between children in Uganda and the 
UK, initial growth response in Uganda was slow with a median decline in WAZ over the first 
six months, but increased thereafter.44 There was also wider variation in weight increase in 
Uganda.44 Like the urban/rural comparison, there was no difference in rate of WAZ 
improvement, but because of much lower baseline WAZ scores in Uganda, a much greater 
proportion of children in Uganda were underweight throughout foll w-up compared to in the 
UK.44 Indeed, in Malawi it was noted that in children who start ART with a baseline  
WAZ ≤-2, which comprise a substantial proportion in many African cohorts, normal WAZ 
values are not attained even by 24 months on treatment. 
Increases in HAZ were noted in both cohort studies that reported this,67,68 but were slower 
and lagged behind WAZ increases. Yotebeing et al.42 found height gain on ART to decrease 
with increasing age. In the UK/Uganda comparison there were again no differences in rate of 
HAZ increase between the two countries, but a much greater proportion of children with 
stunting in Uganda both at ART start and follow-up.44 Although the duration of this study 
was too short to assess long term growth patterns, if results are extrapolated throughout 
childhood, the average 17-year-old boy (girl) would be 1.72 (1.60)m tall in the UK, compared 
with the general UK population average of 1.76 (1.64)m and only 1.53 (1.47)m in Uganda, a 
deficit of around 20 cm compared with HIV-infected counterparts in the UK.44 
There are several possible explanations for the poor growth in HIV-infected children 












illness and to support HIV replication.39 In resource-limited settings, poor food security and 
delayed access to health care and ART may contribute to poorer nutritional status both at 
ART initiation and thereafter. High dose micronutrient supplementation has not been shown 
to improve mortality, immunological or growth outcomes in HIV-infected children 
irrespective of ART use, but earlier initiation of ART in severely malnourished children 




































loss to follow-up 
(95%CI) 
One year 
mortality rate          
(per 100CY) 
(95%CI)
One year LTFU 













20.3 (11.7-27.9) 6.4 7.8 7.7 6.0 (5.0-7.1) 5.0 (4.1-6.1) NR NR NR NR
Barth et al.  2008 all  at least 12 months 
potential FU
9 17 NR NR NR NR NR 17.6 (14.1-21.1) 71
Jaspan  et al.  2008 PI 12.9 (3.6-23.2);           
NNRTI: 32.8 (16.7- 40.0)
7.2 2.3 NR 7.6 (5.2-10.8) 1.3 (0.5-3.4) NR NR NR 54
Kiboneka et al. 2008 12.4 2.3 NR NR NR NR NR NR 5.8c 83f
Van Griensven et al. 2008 24 (14.4 - 31.2) 2.6 3.8 9.5 2.0 3.0 NR NR NR NR
Van Winghem et al. 2008 16.3 (7.2-26.4) 4.9 10.2 16.1 4.7 NR NR NR NR NR
Callens et al.  2009 17.7 (14.0-23.7) 10.4 NR NR 10.4 (7.4-14.5) NR 11.6 (7.9-16.4) NR NR NR
Harding et al.  2009 NR 16 NR NR NR NR NR NR NR 77d
Mubiana et al. 2009 9.2 (3.6-15.1) NR NR NR NR NR 7.0 (5.5-8.8) 13.6 (11.4-16.0) NR NR
Ntanda et al. 2009
non orphans                 
14.0 (9.0-26.0)              
orphans                        
15.0 (8.0-26.0)
3.0 6.9 NR NR NR 1.66 NR NR NR































loss to follow-up 
(95%CI) 
One year 
mortality rate          
(per 100CY) 
(95%CI)
One year LTFU 











Anaky et al.  2010 NR 12.3 11.6 5.5 NR NR 14.4 (11.7-17.2)





Fatti et al.  2010 censored at 24 months 3.0 7.7 NR
urban                  
3.4 (2.4-4.8)                  
rural                       
7.7(4.5-13.0)                
urban/rural            
3.1 (1.7-5.6)b
urban                  
11.5 (9.3-14.0)        
rural                         
8.8 (4.5-16.9)            
urban/rural            
16.6 (12.4-22.6)b 
NR NR 12.0 (7.0-17.6) 81d
Germenaud et al. 2010 all  at least 6 months 
potential follow-up
9 21 NR NR NR NR NR NR 56
Janssen et al.  2010 NR 6.7 3.8 2.5 NR NR 4.4c 2.5c NR 74
Naidoo  et al.  2010 NR 5.0 NR NR NR NR NR NR NR 76b
Sauvageot et al. 2010 10.5 (3.7-20.6) 6 10 8 7 (6-8) 8 NR NR NR NR




Sutcliffe  et al.  2010b
urban                            
13.7 (3.8-29.3)                 
rural 7.6 (2.9-16.3) 
9 NR NR NR NR 6.9 (5.4-9.1) NR 14.4 (9.5-21.0) NR
Wamalwa et al.  2010e 21 (6-33) 13 7 4 15 NR 8.4c NR NR NR
Weigel et al. 2010 23.4 (11.1 - 33.7) 4.3 28.2 27.4 NR NR NR NR NR NR
Bock et al. 2009 NR NR NR NR 10.3 (8.1-12.8) 4.3 (2.9-6.1) NR NR NR 73
Boulle et al.  2009 NR 11.5 4.3 11.3 NR NR NR NR NR NR













Eight studies reported on the proportion of children that achieved viral suppression (usually 
defined as HIV-RNA<400 copies/ml), and all except one56 were from South Africa, reflecting 
inclusion of HIV-RNA in routine monitoring in this country, which is unusual for resource-
limited settings. The proportion of children with viral suppression at 6, 12 and 24 months was 
>70% in all studies, except in the young tertiary care cohorts in Mali and Cape Town.63,67 In 
Cape Town (median age 26 months) 54% and 59% of children were suppressed at 6 and 12 
months on ART.63 In this study children were less likely to attain suppression if treated with 
NNRTI-based (mostly NVP-based) compared to PI-based regimens (adjusted OR: 0.38), with 
71% and 61% of children on PI-based therapy attaining suppression at 12 and 24 months 
respectively. In a cohort analysis of the NEVEREST trial with all children initiating PI-based 
ART at less than two years of age, the probability of suppression by 39 weeks on ART was 
71% overall, but significantly lower in children co-treated for tuberculosis.41 IRIS events 
were also associated with failure to suppress.98 
Poorer virological suppression on NNRTI-based therapy could be due to previous exposure to 
NVP for PMTCT, however the P1060 study recently reported poorer virological outcomes 
with NVP-based first-line ART irrespective of prior PMTCT exposure.128-130 The proportion 
of children with previous PMTCT exposure in the Cape Town cohort was not reported, 
although most children with PMTCT exposure would have received dual therapy.63 
Notwithstanding, in Uganda >75% of children treated with NVP-based regimens achieved 
suppression irrespective of prior exposure to sdNVP, however at least six months had lapsed 
between sdNVP exposure and ART initiation. In the absence of baseline resistance, poor 
adherence is the most likely cause of failure to achieve suppression, and PI-based regimens 
may be more forgiving of non-adherence with a higher barrier to resistance.63,131 For 












regimens achieved suppression, despite only 64% having adherence >80% based on 
electronic measurement of adherence.131 Lower viral suppression rates in rural children 
treated at urban health care facilities in South Africa are ascribed to poor adherence due to 
difficulties in regularly collecting treatment for families with long travel distances to 
clinics.59 In contrast, Bock et al.45 found no difference in viral suppression between children 
treated at PHC clinics compared to secondary and tertiary hospitals. 
In the Uganda/UK comparison of treatment outcomes, similar proportions of children were 
suppressed in both countries at both six and 12 months on ART,44 and, while a review found 
a lower proportion of children achieving suppression in developed countries compared to 
resource-limited settings, this was not significant.27 Comparisons of viral efficacy between 
cohorts are challenging due to discrepancies in whether outcomes are reported on an 
intention-to-treat (ITT) compared to an “as treated” basis, selection bias if HIV-RNA is not 
measured on all children and uncertainty with respect to whether children are treatment naïve 
at ART start or not. For example, Barth et al.62 report that 53% of children had HIV-RNA 
<400 copies/ml using ITT analysis, compared to 71% in an “as treated” analysis. Similarly, 
61% of children were defined as having virological failure when defined as HIV-RNA >400 
copies/ml or LTFU or death by six months on ART, but nearly one-third of this group was 
made up of children LTFU/deceased.67 Selection bias may be important as studies done in the 
context of routine HIV-RNA monitoring report up to 40% of missing data on HIV-RNA at a 
particular monitoring time-point.60 
 
Virological failure, resistance and strategies for measuring treatment success 
While only one of the cohort studies systematically reviewed reported on virological failure 
(VF), there have been a few studies from resource-limited settings examining VF, resistance 












elevated HIV-RNA measurement38,43,67,84 or are cross-sectional surveys of patients in care at 
a particular time point,132,133 reflecting limited access to routine monitoring needed to 
determine confirmed VF. In the two studies where failure is based on confirmed elevated 
HIV-RNA measurements, 17% of children had sustained viraemia beyond 24 weeks on 
ART,134 while the probability of either failing to suppress to <1000 copies/ml after 12 months 
on ART or having two consecutive measures >1000 copies/ml after initial suppression was 
5.5% by 24 months and rose to 30.1% by 36 months.42 In studies where failure is based on a 
single HIV-RNA measurement above threshold, the proportion of patients with failure after 
one year on ART is 20-30%,38,84,124 except in the Côte d’Ivoire cohort where 51% had a 
single HIV-RNA >1000 copies/ml at one year on ART.43 The latter study included a small 
number of children on dual therapy, 67% on nelfinavir-based ART and nearly half the 
children had evidence of poor adherence.43 Two cross-sectional studies of viral efficacy 
reported VF (>400 copies/ml) in 32% of children after a median of 28 months on ART132 and 
58% after a median of 40 months on ART.133 In the latter study, however there was no access 
to second-line therapy, whereas in the former 12% of children were on second-line regimens. 
The proportion of children diagnosed as failing therapy is thus higher in cross-sectional 
studies or those based on unconfirmed elevated measurements as confirmation of elevated 
HIV-RNA after re-inforcement of adherence is critical to exclude poor adherence as a cause 
of the raised HIV-RNA. It has been argued that VL monitoring can be an important tool to 
discriminate between poor adherence and therapeutic failure.135,136 In the Rwandan cohort, 
nearly one third of children noted to have HIV-RNA >400 copies/ml after 18 months of ART 
and in whom a subsequent measurement was performed, resuppressed at subsequent 
measurement.56 
In the few studies examining child characteristics at ART start that predict non-suppression 












those with low CD4% or count.63,84,132,137 Studies also consistently show a higher risk of 
failure in children on NVP-based compared to EFV-based regimens.38,84,132 
Since access to routine HIV-RNA monitoring remains poor in many resource limited settings, 
the utility of other readily available measures to identify children failing therapy has been 
examined. Current and previous WHO20,22 or US Department of Health and Human Services 
(DHHS)138 clinical and immunological failure (IF) criteria have very low sensitivity for 
identifying VF in children.38,132,134 Emmet et al.132 showed that if one added physician 
documented maladherence and CD4%<25 to these criteria then sensitivity increased to 57% 
but specificity dropped to 70%. While low sensitivity may result in leaving a child on a 
failing first-line regimen, low positive predictive value (PPV) is als  a concern as children 
who are actually virally suppressed may be inappropriately switched to expensive and limited 
second-line regimens. PPV of IF criteria for diagnosing VF as low as 16% has been 
reported.38 
Studies of alternate surrogate markers for VF show an increased risk in patients with low 
CD4% or WAZ increase on ART.42,67 For example, there is increased risk of VF associated 
with weight or CD4% gain <33rd centile.42 Emmet et al.132 report that a single decline of CD4 
count by >30% between measurements or two declines of >10% over consecutive tests is 
associated with VF in children >5 yrs old at study enrolment. However the sensitivity, 
specificity and predictive values of these measures for accurately identifying VF have not 
been assessed.  
The key reason for identifying VF in addition to IF is to prevent accumulation of resistance 
mutations that might compromise effectiveness of second-line therapy. The reported 
proportion of children with at least 1 primary mutation among those failing NNRTI-based 












RNA after six to twelve months on therapy43 to nearly 100% at longer durations on 
ART.124,133,139,140 Resistance was rare in those defined as failing with HIV-RNA between 400 
and 1000 copies/ml, but very common in those with HIV-RNA >1000 copies/ml, suggesting 
that there may be an important opportunity to prevent resistance with improved adherence 
interventions in those with small HIV-RNA blips.67 
Mutations conferring resistance to NRTI (M184V) and NNRTI (frequently Y181C) were 
approximately equally common, with thymidine analogue mutations (TAMs) being less 
frequent and only one study reporting PI mutations,140 only one of which conferred 
resistance. However, only the Côte d’Ivoire study included a substantial proportion on PI-
based therapy. Nevertheless, distinguishing between poor adherence and true VF in children 
on PI-based therapy may be challenging and require resistance testing, especially if there is 
prior exposure to unboosted ritonavir.141 In Côte d’Ivoire, the estimated one-year probability 
of developing any class resistance mutation was 44% - 15% for those with continually 
undetectable HIV-RNA; 63% in children with detectable HIV-RNA but >0.5 log10 decline, 
and 95% if there was no virological response.43 The rate of TAM accumulation in children 
remaining on a non-suppressive regimen has been estimated at 0.59 per year.124 Not 
surprisingly resistance was associated with poor adherence133 and poorer CD4 response,124 
while the Y181C mutation was more common in those with prior exposure to sdNVP 
although this mutation was rare at ART initiation.124 
 
1.3.5 Summary 
With more than 40 studies published by the end of 2010 reporting outcomes for children on 
ART, there is now substantial data supporting mostly low mortality on ART with good 
growth, CD4 and viral responses. However, while overall mortality is low, early mortality is 












LTFU reported in some studies may hide unascertained mortality. Similarly the capacity to 
attain normal CD4 and anthropometric measures may be attenuated due to delayed access to 
ART. While increasing reported cohort size for multi-country and multi-site studies in 
comparison to studies published prior to 2008 suggests expanding access to ART, the median 
age of children at ART initiation is still high outside of tertiary care settings, indicating 
delayed ART initiation. Similarly, while there has been some improvement in disease 
severity characteristics in studies published after 2008 in comparison to earlier studies (for 
example, median CD4%, proportion with WHO Stage III/IV disease), such improvements are 
modest. Indeed, for many markers of disease severity such as WAZ, HAZ and median HIV-
RNA, there has been little change over time in the characteristics reported from published 
studies. The extent to which children are starting ART earlier since revisions to WHO 
guidelines advising earlier access to ART and impact of this on ART outcomes needs to be 
examined.21,22 Outcomes and determinants of outcomes reported by a particular cohort 
frequently reflect the selection bias of patients treated in that setting (e.g. level of care; rural 
or urban) and there is a need to examine overall outcomes and determinants across a range of 
well characterized settings and assess their generalizability. There remains very little data on 
longer term outcomes (>24 months) on ART.  
While the probability of VF is low in most studies, there are few studies with failure 
definitions based on confirmed elevated HIV-RNA measurements and most are short-term 
and in children treated exclusively with NNRTI-based regimens. Nevertheless the poor 
access to HIV-RNA monitoring, low diagnostic accuracy of non-HIV-RNA measures for 
detecting VF and high proportion of resistance mutations in children remaining on non-
suppressive therapy are concerning as more children are on ART for longer periods in a 













1.4 The IeDEA-Southern Africa Collaboration  
 
1.4.1 Background 
The global International epidemiologic Databases to Evaluate AIDS (IeDEA) network 
(www.iedea.org) is an international research consortium established in 2005 by the National 
Institute of Allergy and Infectious Diseases (NIAID) to provide a rich resource for globally 
diverse HIV/AIDS data. IeDEA Southern Africa (IeDEA-SA) is one of seven IeDEA 
regional collaborations that are part of the IeDEA network. HIV care and treatment sites that 
are part of IeDEA-SA and other IeDEA regions collaborate to collect and define key 
variables, harmonize data, and implement methodology to effectively pool data to generate 
large data sets to address unique and evolving research questions in HIV/AIDS clinical care 
and epidemiology that are unanswerable by single cohorts. 
IeDEA-SA built upon early experience with the Antiretroviral Therapy in Lower 
Income Countries (ART-LINC) and the paediatric KIDS-ART-LINC Collaborations of HIV 
cohorts.18,142,143 At inception in 2005, the overarching aims of IeDEA-SA were to conduct 
clinical, epidemiological and health services research in order to inform HIV/AIDS service 
delivery in southern Africa, to increase the capacity for delivering ART and, ultimately, to 
improve the prognosis of people living with HIV in southern Africa. IeDEA-SA successfully 
recompeted for funding in 2011. Specific aims of the recompetition proposal that are relevant 
to this project are:  
• To continue to provide the best available data related to the delivery of ART in 
children and adolescents in Southern Africa, with a focus on long-term programme 
effectiveness and outcomes. 
• To describe the long-term and temporal trends in regimen durability and tolerability 












1.4.2 Structure of the IeDEA-SA Collaboration 
IeDEA-SA is co-ordinated by a partnership of data centres at the University of Cape Town 
(UCT), South Africa and the University of Bern, Switzerland. The PhD candidate was the 
lead paediatric analyst at UCT from 2007–2011. Since 2011 she has been joint Principal 
Investigator of the project together with Professor Matthias Egger from the University of 
Bern. The number of IeDEA-SA collaborating cohorts has changed since inception, based on 
ability and willingness to contribute data and provide scientific input into combined analyses. 
By the end of 2012, IeDEA-SA was a collaboration of 18 cohorts in 6 countries, as illustrated 
in the map of IeDEA sites (figure 1) below, with data on more than 300,000 HIV-infected 
adults and 35,000 HIV-infected children ever started on ART. Cohorts provide HIV care and 
treatment for either adults only, infants and children only, or both.  
1.4.3 Data management and harmonization 
IeDEA-SA has mostly not collected de novo data but relied on existing electronic routine 
individualized data collection at collaborating cohorts. In order to participate, cohorts needed 
to electronically capture a minimum of sociodemographic, clinical, laboratory, and 
pharmacological data. Clinics have used a variety of software for collecting their data, 
including Fuchia™,TherapyEdge™, Trachealth™, Microsoft Access™, EpiInfo™ and in-














Figure 1: Map of ART sites.  
Note: urban sites denoted by red on the map and normal font in the list; rural sites denoted by blue on the map 
and italic font in the list. 
 
The PhD candidate led the development of the first version of the IeDEA-SA Data Transfer 
Protocol (DTP) in 2008 together with data managers and other staff from the data centres, as 
well as the collaborating sites. The IEDEA-SA DTP provides the format and structure for the 
collaborative IeDEA-SA database and for data imports from site databases into the IeDEA-
SA database. It was based on the HIV Cohorts Data Exchange Protocol (HICDEP) 
(www.hicdep.org) used by EuroCoord, a network of the biggest HIV cohorts and 
collaborations in Europe. A key role of the PhD candidate was to modify the HICDEP format 
for resource-limited settings and adapt it appropriately to collect paediatric data. The 












South African Data Exchange Standard for all data transfers between HIV monitoring 
software programmes in the country. 
The following types of data are collected in the IeDEA-SA DTP (subject to availability) and 
stored in six core tables and five optional tables as follows: 
CORE TABLES 
PAT: Demographic and clinical data on patients, clinical characteristics at start of ART in 
ART-treated patients, as well as information on the outcomes of patients.  
LAB: All laboratory tests including CD4, HIV-RNA, safety monitoring tests, opportunistic 
infection diagnostic tests. 
ART: data on all antiretroviral drugs that a patient has received or been exposed to including 
PMTCT (both exposure to mother as well as infant peri- or post-natally) or post-exposure 
prophylaxis. 
OI: information on all opportunistic infections or incident HIV-associated diagnoses. 
VIS: data on all clinical visits (including the first visit at the facility). Data includes weight, 
height, and treatment with prophylactic drugs such as cotrimoxazole and isoniazid. 
META: key characteristics of the data that is transferred.  
OPTIONAL TABLES 
LINK: information on family members (partners, children and siblings) also receiving HIV 
care either within the cohort or at another site so that these records can be linked.  
PREGNANCY: information on all pregnancies, including spontaneous abortions/miscarriages 
and terminated pregnancies, and their outcomes. 
PAR_HEALTH: information on parental health status for patients 15 yrs or younger. 
TUBERCULOSIS: information on all episodes of tuberculosis. 
TRIAL: information on enrolment in a trial or research study (apart from cohort analysis of 












Patient data is transferred anonymously from sites to the IeDEA-SA data centres at the 
Universities of Bern (sites from outside South Africa) or Cape Town (South African sites) at 
regular intervals using the IeDEA-SA DTP. Data managers at the data centers merge these 
data sets into a single IeDEA-SA Microsoft SQL Server database that is stored on a secure 
server at each data center, with access only to the data managers. The first data merge was 
completed in 2008 and four papers in this thesis use data from that merge.144-147 The 
remaining two papers use data from later merges.148,149  
All analyses included in this thesis used data from the combined IeDEA-SA dataset which 
was extracted via open database connectivity (odbc) download to STATA (versions 10-12, 
College Station, Texas) of the relevant tables from the IeDEA-SA DTP. The candidate 
performed all data management needed to create analysis-ready datasets including merging of 
data from the different tables, quality checking and data cleaning in consultation with 
contributing sites, calculating loss to follow-up based on site database closure dates, 
calculation of anthropometric z-scores using WHO standards150 and development of 
programming algorithms, for example, to extract data at particular intervals at or after ART 
initiation, identify instances of treatment interruption, virological and immunological failure 
and switching to second-line therapy,  
IeDEA-SA also collected data on characteristics of clinics and treatment programmes using a 
site assessment questionnaire on the WHO DataCol platform. This data was used to describe 
the characteristics of sites in these analyses.  
 
1.4.4 Funding 
IeDEA-SA has been funded by the National Institutes of Health (NIH) since 2006, with 












Shriver National Institute of Child Health and Human Development (NICHD) and the 
National Cancer Institute (NCI) have co-funded IeDEA to support the inclusion and analysis 




The IeDEA-SA study (previously known as the Observational Antiretroviral Studies in 
Southern Africa [OASIS] Collaboration) has ethical approval from the UCT Health Sciences 
Faculty Research Ethics Committee (HREC REF: 084/2006) which has been renewed 
annually. Each cohort has institutional ethical approval to contribute data to IeDEA-SA 
analyses. 
 
1.4.6 Procedure for use of data and conducting analyses 
While the IeDEA-SA data are held in a combined dataset at the data centres, ownership of the 
data remains with the contributing cohort, with the data centres acting as custodians of the 
combined dataset. To use data for an analysis, investigators must propose a concept sheet 
outlining the analysis and outputs. The concept sheet is circulated to all site investigators as 
well as the data centres for approval. For each concept sheet, sites may choose to have their 
data included or excluded at the concept approval stage, but not once the analysis results are 
available. For each of the analyses included in this thesis, the PhD candidate was responsible 
for developing, circulating and finalizing the concept sheet and ascertaining which sites 
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2.1 Paediatric antiretroviral treatment programmes in sub-Saharan 
Africa: a review of published clinical studies 
 
Paper overview 
This is a systematic review of the characteristics and outcomes of studies of paediatric ART 
programmes published prior to 1 January 2008. It forms part of the literature review and 
provides the background and context of the study at the time it was first conceived. It has 
been supplemented by a further more detailed literature review of papers published from 
2008 to 2010 in chapter 1, section C. 
Contribution to the thesis and novelty 
Together with the updated literature review, this paper addresses the first objective of the 
thesis, and provides background to the subsequent analyses undertaken. While other analyses 
of paediatric ART studies from resource-limited settings have been published,13,27 this 
includes a review of characteristics of paediatric ART programmes, such as staffing, funding 
sources, eligibility criteria and drug regimens and formulations used. This highlighted 
heterogeneity in ART programmes and the finding that the good outcomes of paediatric ART 
programmes in Africa have been achieved despite enormous health service and drug access 
constraints. Heterogeneity in programme and child characteristics are a key feature in the 
analyses included in this thesis, and form part of the rationale for development of a 
generalizable prognostic model.148 The review also identified the need for studies of the 
outcomes of infants and young children initiated on ART who were not well represented in 
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The candidate wrote the manuscript, incorporated input from co-authors who critically 
reviewed the manuscript, and submitted the final manuscript. 
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Introduction
The burden of paediatric HIV infections is greatest in 
sub-Saharan Africa, where as of December 2007 almost 
90% of the world’s two million HIV-infected children were 
living, with approximately 370 000 new paediatric infections 
having occurred in the preceding year (UNAIDS, 2008). In 
the absence of antiretroviral therapy (ART), HIV-related 
illnesses account for approximately 10% of childhood 
mortality across the continent and up to 50% of childhood 
mortality in southern Africa (UNAIDS, 2006; Little, Thorne, 
Luo, Bunders, Ngongo, McDermott & Newell, 2007). ART 
is highly effective in reducing morbidity and mortality in 
HIV-infected children in the developed world; however, until 
very recently, its availability to children in Africa has been 
limited (Patel, Hernan, Williams, Seeger, McIntosh, Van 
Dyke & Seage, 2008). For example, according to the most 
recent available paediatric ART coverage estimates, in 
more than half of sub-Saharan African countries, less than 
15% of children needing ART were receiving it at the end of 
2006 (WHO/UNAIDS, 2006). Coverage was below 35% for 
the remainder of the subcontinent, apart from Namibia and 
Botswana (WHO/UNAIDS, 2006).
Encouragingly, access to ART for children in sub-Saharan 
Africa is increasing, with more than 2 500 facilities providing 
treatment and nearly 160 000 children receiving ART by 
December 2007 (WHO, UNICEF & UNAIDS, 2008). Nine of 
the ten countries in which the vast majority of HIV-infected 
children live are in sub-Saharan Africa, and access to ART 
in these countries increased dramatically between 2005 
and 2007. For example, in South Africa, Kenya, Malawi and 
Zimbabwe, the numbers of children receiving ART increased 
2.6 times, 3 times, 4 times and nearly 5 times in that period, 
respectively (WHO et al., 2008). The corresponding total 
numbers of children on ART in those countries by the end 
of 2007 were 32 000 (South Africa), 15 000 (Kenya), 10 000 
(Malawi) and 8 000 (Zimbabwe) (WHO et al., 2008).
ART provision for children in sub-Saharan Africa — with 
its enormous health service constraints — needs to be 
tailored to local circumstances. Outcomes may also be 
different to those in the developed world due to different 
socio-economic circumstances and background burden of 
disease. Information from observational cohorts of children 
receiving ART in Africa is therefore vital to demonstrate 
programmatic issues, such as the nature of ART provision 
on the continent and the effectiveness of different models 
Paediatric antiretroviral treatment programmes in sub-Saharan Africa: a 
review of published clinical studies
Mary-Ann Davies1*, Matthias Egger2, Olivia Keiser2 and Andrew Boulle1 
1 Infectious Diseases Epidemiology Unit, School of Public Health and Family Medicine, University of Cape Town, Anzio Road, 
Observatory 7925, Cape Town, South Africa
2 Institute of Social and Preventive Medicine, Finkenhubelweg 11, Bern CH-3012, Switzerland 
* Corresponding author, e-mail: mary-ann.davies@uct.ac.za
Knowledge of the experience and outcomes of current paediatric antiretroviral treatment (ART) programmes in 
sub-Saharan Africa can inform new programmes in the region as well as enhance existing ones. This is urgently 
needed to facilitate the scale-up of treatment, which is needed to address the burden of paediatric HIV cases on 
the continent. We reviewed the characteristics and outcomes of programmes with clinical paediatric ART studies 
published prior to 1 January 2008. The outcomes of the studies were comparable to similar ones from developed 
countries; however, the duration of follow-up was relatively limited in almost all the studies reviewed. One-year 
survival probability was between 84% and 91%, and considerable improvement in the clinical, immunologic and 
viral status of the paediatric patients was generally recorded. Loss to follow-up was less than 10% in all but two 
studies. Adherence to treatment was good and few adverse events were reported. This is despite the fact that many 
programmes were subject to enormous constraints in terms of health services, and despite widespread use of adult 
fixed-dose combinations for paediatric patients, including young infants. While the majority of children commencing 
ART were severely ill, most children were old (median age >5 years for almost all studies) with relatively few infants 
and young children (age <2 years) receiving treatment. This is in contrast to knowledge of rapid disease progression in 
the majority of HIV-infected infants and despite the World Health Organization’s recent recommendations to commence 
ART in all HIV-infected infants less than one year old. There is an urgent need to address barriers to ART for infants. 
Studies of the outcomes of programmes treating infants as well as those with longer-term follow-up are also needed.
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of care for children, as well as the outcomes of children 
receiving ART. 
Since 2004, reports from isolated cohorts of children 
receiving ART in Africa have been published with progres-
sively increasing frequency and greater numbers of 
children on treatment. To our knowledge, there is one 
published review of clinical studies in the medical literature 
demonstrating good outcomes, but with little emphasis on 
the characteristics of individual programmes (i.e. Sutcliffe, 
Van Dijk, Bolton, Persaud & Moss, 2008). 
Our study was funded by the International Epidemiological 
Databases to Evaluate AIDS (IeDEA) Southern Africa cohort 
collaboration. We aimed to review published paediatric ART 
clinical studies in order to contextualise future paediatric 
ART cohort analyses, assess the feasibility of ART for 
children in Africa, and inform context-specific guidelines 
on treatment for children, as well as highlight areas for 
additional relevant research. 
Our specific objectives were to review the following:
• The characteristics of paediatric ART programmes, in 
terms of funding, user fees, ART eligibility criteria and 
regimens used;
• The characteristics of patients at ART initiation across 
different programmes;
• Outcomes among children receiving ART, specifically 
vital status and retention in care, as well as clinical and 
laboratory outcomes in those who remained in care; 
and,
• Treatment durability and adherence.
Methods
We searched the literature through the PubMed database 
using the search terms ‘antiretroviral children Africa’ and 
‘antiretroviral’ AND (‘paediatric’ OR ‘pediatric’) AND ‘Africa.’ 
Eligibility criteria were observational studies published 
prior to 1 January 2008 with a cohort including at least 25 
children treated with three-drug ART and reporting on vital 
status outcomes. The children needed to be part of an 
observational cohort and not participants in an antiretro-
viral (ARV) drug trial. Data were extracted onto a standard 
form and summarised as described under the following 
subheadings.
Data on treatment programmes
Variables extracted from the studies included the number 
of facilities at which ART was provided, external funding 
sources, user fees, clinical care providers, availability of 
laboratory testing facilities, criteria used to determine patient 
eligibility for ART, and ART regimens used. 
Patient characteristics at ART initiation
In addition to the age and gender profile of the participants 
in each study, disease severity was summarised using as 
many of the following measures as were reported: CD4 cell 
count and CD4 percentage (CD4%), anthropometric data 
reported as age- and sex-standardised z-scores, viral load, 
WHO clinical stage of disease, and opportunistic infections. 
The relationship of caregivers to the patients was also 
recorded. 
Outcomes on ART
We extracted information on overall mortality and loss to 
follow-up (as defined by each study individually), and specif-
ically mortality at one year in those studies where this was 
reported. We also noted changes in markers of disease 
severity, including clinical events, growth, immune and 
virological response. We describe treatment durability in 
terms of proportion of children requiring treatment changes 
and the reasons for this, and report on adherence for those 
studies where this was measured. 
Results
Characteristics of the treatment programmes
Overview of the studies reviewed and their countries of 
origin
The characteristics of 18 studies (15 cohorts) that met 
eligibility criteria are shown in Table 1. Most (13 of 18; 
60%) were reports from a single health facility, with three 
of the remainder being from multiple sites within a country 
and the other two being reports of the Médecins Sans 
Frontières (MSF) HIV programmes from multiple resource-
limited countries (including non-African sites). Most reports 
are from southern Africa and East Africa (see Figure 1). The 
Malawi Paediatric Antiretroviral Treatment Group (2007) 
reports on national aggregate cohort data, not individual-
ised outcomes. Two studies were reported by each of the 
following programmes: Agence Nationale de Recherches 
sur le SIDA, Abdijan, Cote d’Ivoire (i.e. Fassinou, Elenga, 
Rouet, Laguide, Kouakoussui, Timite et al., 2004; Rouet, 
Fassinou, Inwoley, Anaky, Kouakoussui, Rouzioux et al., 
2006); Red Cross Children’s Hospital, Cape Town, South 
Africa (i.e. Eley, Nuttall, Davies, Smith, Cowburn, Buys 
& Hussey, 2004; Eley, Davies, Apolles, Cowburn, Buys, 
Zampoli et al., 2006), and the MSF multi-site cohort (i.e. 
O’Brien, Sauvageot, Zachariah & Humblet, 2006; O’Brien, 
Sauvageot, Olson, Schaeffer, Humblet, Pudjades et al., 
2007).
Funding and payment
Sixteen of the 18 studies report on funding sources, and 15 
of these received external funding for the ART programme 
in addition to state health-service resources. The most 
common funders were the U.S. President’s Emergency Plan 
for AIDS Relief (PEPFAR) and the Global Fund to Fight 
AIDS, Tuberculosis and Malaria (contributing to 25% and 
31% of the studies, respectively). Eight studies acknowl-
edged additional support for research activities. 
Only McCord Hospital (in Durban, South Africa) did not 
provide free care and ART for HIV-infected children; rather 
a standard co-payment of approximately US$10 per month 
(irrespective of number of consultations, treatment or 
laboratory testing needed) was required per family receiving 
care (Reddi, Leeper, Grobler, Geddes, France, Dorse et al., 
2007). However, the provision of laboratory testing as part 
of routine care varied widely in the programmes reviewed. 
Outside of South Africa and the research settings, viral-
load testing was not provided, and in some of the Malawian 
studies CD4 testing needed to be paid for by the patients 
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Providers of medical care
Half of the studies provided information on the main 
providers of medical care. Doctors are the exclusive 
providers in four of nine (44%) studies, and doctors provided 
care in combination with clinical officers and/or primary care 
nurses in another four of nine studies (44%). In a single 
study from Zambia, the focus for care provision was specifi-
cally from nurses and clinical officers (i.e. Bolton-Moore, 
Mubiana-Mbewe, Cantrell, Chintu, Stringer, Chi et al., 
2007). This was an explicit strategy of ‘task shifting’ aimed 
at extending the reach of HIV services and the programme 
successfully provided care to 4 975 HIV-infected children 
(2 938 on ART) via primary healthcare (PHC) facilities. This 
contrasts starkly to most of the other studies from hospital-
based settings. Indeed, most studies that did not report on 
which cadre of staff provided clinical care are from hospital 
settings, suggesting a reliance on doctors. 
Eligibility criteria for ART and the regimens used
Most of the studies used the World Health Organization 
(WHO) guidelines (e.g. WHO, 2004 and 2006) available at 
the time (or a local modification thereof) as criteria for ART 
commencement. Where ART was commenced prior to 
the publication of the 2003 WHO guidelines, the criteria in 
use were similar to those of WHO relating to clinical and/
or immunological disease severity. In three studies, from 
Zambia and Malawi, access to virological testing to confirm 
diagnosis in children age ≤18 months was extremely limited, 
so presumptive diagnoses were made and treatment 
commenced in children with severe clinical and/or immuno-
logical disease (Bolton-Moore et al., 2007; Ellis & Molyneux, 
2007; Malawi Paediatric Antiretroviral Treatment Group, 
2007). Ellis & Molyneux (2007) noted that in Malawi CD4 
testing had to be paid for by the patient, so immunological 
eligibility criteria could only be considered in those who 
could afford testing. 
The main first-line ART regimens used are shown in Table 
2. Notably, four studies exclusively used adult fixed-dose 
combination (FDC) tablets. 
Patient characteristics at the start of ART
Considering the 18 studies reviewed, a total of 7 477 
children commenced ART, with the median (IQR) number 
per study being 236 (interquartile range: 79–381). Gender 
representation was essentially equal, with females 
comprising 49.1% of the total cohort. 
Age
The median/mean age of the children ranged from 4.2 to 
9.2 years, in all except two studies. One of these specifi-
cally included only children aged 18 months to 5 years (i.e. 
O’Brien et al., 2007), while the median age of 1.9 years for 
the Cape Town cohort (i.e. Eley et al., 2006) was markedly 
younger than all the others. 
Where age categories are reported, it is clear that 
there are few infants and young children (age <2 years) 
on ART. Less than 12% were under 18 months old in all 
studies — except in one study each from South Africa and 
Mozambique, where 50% and 22% of children, respec-
tively, were under age 2 years (Eley et al., 2006; Marazzi, 
Germano, Liotta, Buonomo, Guidotti & Palombi, 2006). 
Overall, approximately 9.5% (650 of 6 777) of children in all 
cohorts of those studies reporting age category were under 
age 18 months. 
Disease severity
The majority of children had severe disease at ART 
commencement (Table 1). In most studies more than 70% 
of children had advanced clinical HIV disease (WHO stage 
3 or 4, or CDC category C) and their median/mean weight-
for-age (WFA) and height-for-age (HFA) z-scores were 
well below 0. Only three studies provided data on weight-
for-height (WFH) z-scores, with medians between –0.6 and 
–1.64. The median CD4% was below 10% in all but two 
studies, both of which included relatively larger numbers 
of young children (i.e. Eley et al., 2004; Bolton-Moore et 
al., 2007). Indeed, in the Zambian cohort, median CD4% 
declines with increasing age at the start of ART (Bolton-
Moore et al., 2007). Similarly, the proportion with CD4% 
<15% is high (≥79%) in all studies except those including 
many young children (i.e. Eley et al., 2006; Marazzi et al., 
2006). Only seven of the 18 studies report on baseline viral 
load, indicating poor access to this technology, and the 
median/mean log10 viral load ranges were high. Studies 
from the Northern Cape Province (South Africa) and from 
Mozambique reported 80% and 55% of children having 
>5log10 viral load, respectively. 
Seven studies reported on current or past opportun-
istic infections at the start of ART. Prevalence of TB 
at entry into the programme was 33% in Durban, South 
Africa (Reddi et al., 2007), and 46% in Dodoma, Tanzania 
Figure 1: Map of paediatric ART sites with published studies 
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(Blé, Floridia, Muhale, Motto, Giuliano, Gabbuti et al., 
2007). The Tanzanian cohort, however, comprised a 
small group of institutionalised children and it is unclear 
whether TB was ‘active’ or previous. Other studies, from 
Zambia, Malawi and Côte d’Ivoire, reported lower propor-
tions (6–7%) of active TB at commencement of ART, with 
previous TB in 13–24% of the children (Fassinou et al., 
2004; Bolton-Moore et al., 2007; Bong, Chen, Jong, Tok, 
Hsu, Schouten et al., 2007). Nutritional/gastro-intestinal 
illnesses, fever, recurrent pneumonia and dermatitis were 
not uncommon. 
Caregivers
Two studies from South Africa and one each from Malawi 
and Kenya reported on the child’s main caregiver (i.e. 
Eley et al., 2004; Reddi et al., 2007; Ellis & Molyneux, 
2007; Wamalwa, Farquhar, Obimbo, Selig, Mbori-Ngacha, 
Richardson et al., 2007). This caregiver was the mother 
for between 38% and 79% of the children, with the greater 
proportion occurring in the studies that included younger 
children. Fathers were the primary caregivers for up to 21% 
of children in some studies, but for far fewer children in 
other settings (e.g. Eley et al., 2004). Grandparents (mostly 
grandmothers) and other family members comprised 
the third-most-common primary caregivers, respectively 
providing care for 6–21% and 7–26% of children. Only 
2–7% of the children were cared for by an institution. 
Response to ART
Survival and retention in care
In all but four studies less than 10% of the children died 
during the follow-up period, with a maximum of 15.4% 
deaths in the study with the highest mortality (see Table 3). 
Loss to follow-up was also low (<10% in all but two studies). 
One-year survival probabilities are only reported by six 
studies and are all within a small range (0.84–0.91) (Figure 
2). In general, lower probabilities of survival are seen in 
those studies where children were younger at commence-
ment of ART. 
Response to treatment in survivors
Clinical events
Fassinou et al. (2004) reported decreased incidence of 
pneumonia and diarrhoea after commencement of ART in 
children age <6.5 years from Côte d’Ivoire, with no change 
in older children, while Wamalwa et al. (2007) showed 
reduced hospitalisation during the six months after initiation 
of ART in a Kenyan programme. However, in that cohort, 
58% of the children had been hospitalised during the six 
months preceding the start of ART. 
Growth
The most consistent observation regarding growth in 
the 12 studies that reported this is improvement in WFA 
z-scores and/or reduced proportion underweight, with the 
latter being reduced by 30–80% (Eley et al., 2006; Marazzi 
et al., 2006; Ellis & Molyneux, 2007; O’Brien et al., 2007). 
Improvement in WFH z-score (reduced proportion with 
wasting) also appears consistent across the studies, with 
the proportion wasted reduced to a similar degree (cf. Eley 
et al., 2006; Ellis & Molyneux, 2007). There is conflicting 
data with regard to height response: three studies showed 
improvement, albeit smaller than for other growth parame-
ters, while three studies showed no change. It appears that 
while significant improvements in all growth parameters do 
occur after commencement of ART, it is rare for these to 
normalise. 
Immune response
The median/mean increase in CD4% at 12 months was 
between 11% and 17.5% (Table 3). Rouet et al. (2006) 
found CD4% to increase during the first 18 months on 
treatment and then stabilise, with better immune recovery 
in those children on Nelfinavir as compared to Efavirenz-
based regimens. Nyandiko, Ayaya, Nabakwe, Tenge, Sidle, 
Yiannoutsos et al. (2006) similarly found CD4% to increase 
rapidly during the first 30 weeks of ART, after which 
increases were much less pronounced. 
Virological response
Ten studies reported on virological outcome at varying time 
intervals (see Table 3). This is a relatively high proportion 
as viral monitoring is not routinely available in sub-Saharan 
Africa outside South Africa and Botswana. At one year, 
the proportion of children with suppressed viral load (<400 
copies/ml) in most studies was between 70% and 80%, but 
it was strikingly lower in the Côte d’Ivoire cohort at 49% 
(Fassinou et al., 2004). The Côte d’Ivoire cohort was the 
only one reporting on viral suppression beyond one year, 
with approximately half the children being suppressed at 
both age 24 months and age 36 months (Fassinou et al., 
2004; Rouet et al., 2006). 
Table 2: First-line ART regimen used (d4T = Stavudine; EFV = Efavirenz; FDC = fixed-dose combination; NRTI = nucleoside reverse 
transcriptase inhibitor; NVP = Nevirapine; PI = protease inhibitor; 3TC = Lamivudine) 
Main first-line regimen used Study reference
Adult FDC d4T/3TC/NVP O’Brien et al., 2006; Bong et al., 2007; Ellis & Molyneux, 2007; Malawi Paediatric Antiretroviral 
Treatment Group, 2007
2 NRTIs + NVP Marazzi et al., 2006; Nyandiko et al., 2006; Bolton-Moore et al., 2007; O’Brien et al., 2007; Song et al., 
2007; Wamalwa et al., 2007 
2 NRTIs + EFV/PI Eley et al., 2004; Eley et al., 2006; Fassinou et al., 2004; Rouet et al., 2006; Reddi et al., 2007; Jooste 
et al., 2008
2 NRTIs + NVP/PI Blé et al., 2007
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Treatment changes, adverse effects and failure
No studies reported specifically on the criteria used to 
ascertain treatment failure; however, 13 studies reported 
the proportion of children requiring treatment changes 
due to failure, toxicity or other reasons. Changes due to 
toxicity were minimal (<10% of children) in most studies, 
except the Zambian cohort where single drug substitutions 
were required for 17.6% of the children. Reasons for these 
substitutions, however, included toxicity and dosing issues 
(Bolton-Moore et al., 2007). There were few adverse events 
reported in the six studies providing this data. Most common 
were skin rash, hepatotoxicity and anaemia. Two cases of 
Stephens-Johnson Syndrome occurred overall, one of which 
was fatal (Marazzi et al., 2006; Bolton-Moore et al., 2007). 
Switching treatment regimes due to failure was extremely 
rare (<5% in all studies that reported it) being highest in the 
Côte d’Ivoire cohort, with extended follow-up as expected 
(Rouet et al., 2006). This is in strong contrast to the propor-
tion of children with viral suppression in that study by Rouet 
et al. (2006): 50–70% throughout follow-up. 
Adherence
Adherence to ART was measured in eight cohorts, mostly 
by self-report alone (four studies). Supplementary pill 































ml at one 
year
Fassinou et al., 
2004
21a 78 11.5 5.1 NR NR NR NR 49.3
Rouet et al., 2006 36 (30–42) 78 11.5 NR NR NR NR 15.6e 46.5e
O’Brien et al., 
2006
6 (2–12) 1 184 3 8 0 0 3 NR NR
O’Brien et al., 
2007
14 (7–20) 568 6 8 4 2 1 16 (11–22.6)f NR
Eley et al., 2004 NR 80 8.8 5 0 1.3 0 NR 75h
Eley et al., 2006 12b 409 15.4d 4.6 d 11.2 d 2.9 d 0 d NR 69.7
Jooste et al., 
2005
6b 100 9d 3d 1d 3d 0 d NR 67h
Nyandiko et al., 
2006
8 (7–10)c 279 3.6 11 0 0 0 11a NR
Marazzi et al., 
2006
10 (5–16) 297 9.5 4.2 0 0 0 NR 46h
Blé et al., 2007 12b 59 0d 0d 0d 0d 0d 15a 
(10.3–19.7)c
NR
Reddi et al., 2007 8 (4–14) 151 8.6 0 0 0 0 16.2 
(9.6–20.3)
80.3
Song et al., 2007 15b 29 1d 3d 0d 0d 0d NR 55i
Wamalwa et al., 
2007
9 (3–15)j 67 9 NR NR NR NR 11.3 67h
Kamya et al., 2007 12b 250 5d 1d 0d 0d 0d 14.7;11.3g 74
Malawi Paediatric 
ART Group, 2007
12b 233 13d 9d 6d 0d 0d NR NR
Bolton-Moore et 
al., 2007
12 (5–23) 2 938 6.7 13 5.4 0 0 14a 
(13.4–14.7)c
NR
Ellis & Molyneux, 
2007
6b 238 8d 8d 2d 0d 0d NR NR
Bong et al., 2007 Variable 
up to 12 
months
439 NR NR NR NR NR NR NR
a Mean value.
b Only includes children with specified number of months potential follow-up duration; all children who were not lost to follow-up, transferred 
out, or deceased were followed up for this duration.
c 95% confidence interval.
d Total percentage with given outcome in specified follow-up period.
e At 36 months.
f Children with baseline CD4 percentage between 5% and 15%.
g Children with and without viral suppression, respectively.
h At six months.
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counts were used in two studies, while pill counts and drug 
pick-up information were the primary instruments for one 
study each. Overall, adherence was good, with significant 
interruptions (more than two missed doses per month) noted 
for less than 11% of children in any cohort. 
Discussion
This review demonstrates overwhelmingly the feasibility 
and effectiveness of providing ART to children in 
sub-Saharan Africa despite enormous health-service and 
socio-economic constraints. Dramatic improvements in 
survival, and clinical, immune and virologic status were 
achieved. It is difficult to make valid comparisons with 
studies from the developed world due to differences in 
socio-economic context, prior treatment experience, 
criteria for treatment initiation, ART regimens, and access 
to laboratory testing and specialist care (Patel et al., 2008). 
For example, while viral suppression rates of 70–80% in 
most of the cohorts with access to viral load testing were 
certainly at least as good as, if not better than, those from 
rich countries, this may be due to the relatively older age 
of the children commencing ART and the fact that most 
children in Africa are treatment naïve (Van Rossum, Fraaij 
& De Groot, 2002). Nevertheless, it is notable that the 
good outcomes seen in these studies are similar across 
a range of settings, including those with limited access 
to ART drugs and laboratory technology as well as those 
where ART is not provided by doctors and care is adminis-
tered from PHC facilities (such as in Zambia and Malawi) 
(see Bolton-Moore et al., 2007; Ellis & Molyneux, 2007; 
Malawi Paediatric Antiretroviral Treatment Group, 2007). 
However, this review also highlights numerous aspects of 
the nature of current ART delivery in Africa, as described 
in the following sections. 
Follow-up duration, mortality and retention in care
Due to the relatively recent availability of ART for children in 
Africa, follow-up periods are generally short, and long-term 
outcomes are as yet unexplored (except in the single small 
cohort from Côte d’Ivoire) (Rouet et al., 2006). Nonetheless, 
most deaths occurred within the first few months after 
commencing ART, thus estimates of mortality are not 
likely to increase significantly, at least in the medium term. 
This is supported by the single longer-term study reported 
by Rouet et al. (2006) where at 42 months there were 
no deaths additional to those reported at 12–24 months 
(Fassinou et al., 2004). Still, low mortality estimates should 
be viewed with caution in the five cohorts where short-term 
loss to follow-up (LFU) equaled or exceeded mortality (i.e. 
O’Brien et al., 2006; Nyandiko et al., 2006; Bolton-Moore et 
al., 2007; Ellis & Molyneux, 2007; O’Brien et al., 2007), as 
many of those classified as ‘LFU’ may have been deceased 
(Maskew, MacPhail, Menezes & Ruel, 2007; Krebs, Chi, 
Mulenga, Morris, Cantrell, Mulenga et al., 2008). It is 
notable that all except one of the studies with this limita-
tion were from multi-site collaborations, suggesting that 
it may be easier to have definite outcome ascertainment 
within a single site — as these may have specific patient-
tracing and follow-up systems in place, or else may have 
made a conc rted effort to ensure outcome ascertainment 
for the purposes of publication. Notwithstanding this, LFU in 
children in Africa is far lower than that of adults (Stringer, 
Zulu, Levy, Stringer, Mwango, Chi et al., 2006). Interestingly, 
two cohorts (from Tanzania and Kenya, respectively) 
reported zero deaths and very low (3.4%) LFU (Blé et al., 
2007; Song, Jelagat, Dzombo, Mwalimu, Mandaliya, Shikely 
& Essajee, 2007). Both of these were small cohorts (59 and 
29 children, respectively). The first was a residential institu-
tion for orphaned HIV-infected children with a medical doctor 
on site daily, while the second, in addition to providing free 
ART, also provided transport re-imbursement to the clinic 
attendees. 
Age at ART initiation
The overall low mortality reported by the studies reviewed 
also needs to be viewed in context of the children being 
relatively old at the start of ART, with less than 10% overall 
initiating treatment before 18 months of age. In contrast, we 
know that HIV disease progression to death or advanced 
disease occurs in 50% of perinatally HIV-infected children 
by age 2 years (Little et al., 2007). Many infants and young 
children in Africa clearly need but are not receiving ART. 
Indeed, ART-treated children in Africa represent a cohort of 
survivors with relatively slower progression of disease, and 
good outcomes are to be expected. It is not surprising that 
the study reporting the highest percentage of deaths after 
one year on treatment (15.6% mortality) is from a tertiary 
institution, with over 50% of that cohort having been less 
than age 2 years at ART commencement, and 99% of the 
children having advanced disease (Eley et al., 2006). Yet, 
even in this group of very ill children, mortality on ART was 
relatively low.
A number of factors explain the fact that in these studies 
children generally commenced ART at older ages than in 
developed countries (Patel et al., 2008). First, this reflects 
Figure 2: Summary of survival probability as reported by nine 
paediatric ART studies from southern Africa
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the difficulty in diagnosing HIV infection in children under 
18 months old where access to virologic testing is limited 
(Bolton-Moore et al., 2007; Ellis & Molyneux, 2007; Malawi 
Paediatric Antiretroviral Treatment Group, 2007). This is 
also a consequence of poor access to appropriate ART 
formulations for children and the difficulty in dosing young 
children even where liquid formulations and refrigera-
tion are available, due to the requirement for surface-area 
dosing. In fact, in Malawi, the site of three of the cohorts, all 
children were treated with split doses of the adult fixed-dose 
combination (FDC) Triomune (d4T/3TC/NVP) according to 
weight bands (Bong et al., 2007; Ellis & Molyneux, 2007; 
Malawi Paediatric Antiretroviral Treatment Group, 2007), 
while one of the multi-country MSF cohort studies had the 
specific aim of demonstrating feasibility and good outcomes 
with use of adult FDCs in children (O’Brien et al., 2006). . 
While the Malawian studies highlight the problems of dosing 
the smallest children (<8 kg) with ¼ tablet once daily (which 
is not recommended, as d4T should be given twice daily: 
WHO, 2006), Ellis & Molyneux (2007) argue that the good 
outcomes reported support use of this regimen due to the 
benefits of low cost, availability and simplicity. 
Many clinicians feel inadequately trained for the perceived 
complicated care of the very young (Eley & Nuttall, 2007; 
Meyers, Moultrie, Naidoo, Cotton, Eley & Sherman, 2007). 
In fact, the Malawian ART scale-up programme specifi-
cally treated young children only in health facilities where 
paediatricians or medical doctors skilled in paediatric care 
were available (Ellis & Molyneux, 2007). In South Africa, 
paediatric care, particularly of young infants, remains 
centered in tertiary-care institutions (Eley & Nuttall, 2007; 
Meyers et al., 2007).
The relative lack of young children receiving ART in 
Africa may also be an indication of the poor integration of 
HIV services for children and shortage of prevention-of-
mother-to-child-transmission (PMTCT) programmes and 
general child health services, which although they clearly 
have overlapping target patient groups, are often run as 
separate vertical programmes within the health system. 
This may result in poor systems for detection and referral to 
ART care for HIV-infected infants and young children before 
disease progression. Many children with HIV infection are 
only diagnosed once they are severely ill, or die before an 
HIV diagnosis is made. 
Severity of illness at ART initiation
Despite the relatively old age of children in these studies 
(age >5 years) and the fact that they represent survivors with 
slower disease progression, most children in the total cohort 
were severely ill at commencement of therapy. At least half 
of the children commencing treatment had advanced clinical 
disease and the median CD4% at ART initiation was low. This 
is in keeping with the use of WHO guidelines for treatment 
eligibility by most programmes. However, in the multi-country 
MSF cohort, the final CD4% after one year remained lower in 
those with greater baseline immune suppression, suggesting 
that immune recovery may be limited if treatment is delayed 
until illness is advanced (O’Brien et al., 2007). 
It has been suggested that the background burden of 
disease in Africa may exacerbate disease progression 
in HIV-infected children and thus complicate ART. In this 
regard, it is notable that two studies reported very high 
prevalence of TB at entry into the programme (i.e. Blé et al., 
2007; Reddi et al., 2007). However, those figures may have 
been over-estimates. The difficulty of making a definitive 
diagnosis of TB in children, particularly when dually infected 
with HIV, may lead to over-diagnosis to avoid missed 
opportunities to treat a potentially curable opportunistic 
infection. Nevertheless, a high prevalence of TB in children 
is cause for concern. The medication burden and potential 
for TB immune reconstitution inflammatory syndrome (IRIS) 
may complicate ART (Smith, Kuhn, Coovadia, Meyers, Hu, 
Reitz et al., 2009). Furthermore, where lopinavir/ritonavir is 
used in the first-line regimen for young children, concomi-
tant TB therapy requires additional ritonavir-boosting of the 
regimen. Notwithstanding, in Malawi, there was no differ-
ence in survival between children commencing ART with 
active TB, previous TB or a non-TB diagnosis (Bong et al., 
2007); however, only Nevirapine (NVP)-based regimens 
were used, and ART was delayed until the continuation 
phase of TB treatment to avoid Rifampicin–NVP interactions 
and the risk of IRIS (B ng et al., 2007).
Treatment durability
Treatment was well-tolerated with few adverse effects 
overall and few drug substitutions required. The rate of 
switching to second-line regimens was very low. This, 
however, needs to be viewed in the context of many of 
the cohorts not having access to virologic testing and/or 
second-line medication for children, as well as there being 
no current virologic guidelines for switching therapies in 
children (WHO, 2006). It is clear that a number of children 
are being maintained on first-line therapy despite ongoing 
viraemia, and the effects of this need to be examined in 
the long term. Furthermore, it would be useful to determine 
whether access to virologic testing has any implications for 
programme outcomes.
Growth response to treatment
Growth response as measured by scores for WFA and 
WFH was consistently good, despite probable poorer 
access to food in developing-country contexts, with very 
few programmes providing nutritional supplementation 
(Marazzi et al., 2006). Still, the failure to attain normal z-score 
values for these parameters may reflect the residual insult 
of advanced disease. This is possibly also the reason for 
conflicting measures for growth response in terms of height-
for-age (HFA), a reflection of chronic illness.
Representativeness
An important limitation of this review is that these studies 
may not be representative of all routine programmes across 
Africa. Although all are observational cohorts, many are 
from research settings, where care, monitoring, access to 
drugs and laboratory testing may be markedly better than 
what is available in routine services. The relatively high 
proportion of studies with follow-up information on patients’ 
viral load supports this. In addition, there is a probable 
publication bias in favour of successful programmes; hence, 











African Journal of AIDS Research 2009, 8(3): 329–338 337
may have selected programmes with better outcomes. It is 
plausible that country-level data, programme reports, and 
social-science literature may portray a different picture. 
Furthermore, all but one of the cohorts reporting on funding 
had received some form of external support in addition to 
that from state health services, albeit through the national 
programme in some cases. Nevertheless, two of the studies 
reported on the outcomes of routine national programmes 
(i.e. Malawi Paediatric Antiretroviral Treatment Group, 2007; 
Jooste, Van Zyl, Baker, Crawford & Jassen, 2008), with one 
using only routinely collected data, yet their findings are 
consistent with those from research settings. 
In addition to financial programme support, there was 
evidence of considerable international academic collabora-
tion within these studies. While one-third of these published 
studies have both local senior and lead authorship, in an 
almost equal proportion (five of 16), both these roles are 
taken by international academics, and all except four of the 
publications (three cohorts) included at least one interna-
tional collaborator. It is therefore possible that patient care 
at these sites may have been enhanced through the involve-
ment of research institutions from wealthy countries, and 
thus may not be replicable on a massive scale. This also 
demonstrates the need to develop research and analytic 
capacity in sub-Saharan Africa so that lessons learned can 
be disseminated.
Conclusions
The feasibility and benefits of ART provision for children in 
sub-Saharan Africa have been clearly shown in a range of 
settings; however, infants and young children remain largely 
excluded from ART programmes, and commencement 
of ART occurs mostly in older children with advanced HIV 
disease. Emerging evidence of rapid progression of disease 
in children failing PMTCT regimens, and the survival 
benefit with early initiation of ART, has led to the revision 
of WHO guidelines to recommend ART commencement 
for all HIV-infected children under age 1 year (Mphatswe, 
Blanckenberg, Tudor-Williams, Prendergast, Thobakgale, 
Mkhwanazi et al., 2007; Violari, Cotton, Gibb, Babiker, 
Steyn, Madhi et al., 2008; WHO, 2008). There is an urgent 
need both to address barriers to the care of young children 
with HIV infection and to acquire a better understanding of 
the outcomes for children on ART and the determinants in 
this group. 
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2.2 Outcomes of the South African National Antiretroviral 




This paper analysed data from >6,000 children who initiated ART at one of the seven South 
African paediatric ART programmes collaborating in IeDEA-SA at that time. Survival, 
retention in care, immunological, virological and growth outcomes are described for up to 
three years on treatment. Associations with survival are modelled and compliance with South 
African National ART guidelines regarding CD4 and HIV-RNA monitoring is assessed.151 At 
the time this study represented more than 20% of all children who had initiated ART across 
South Africa and thus reflected on the effectiveness of the national programme. 
Contribution to the thesis and novelty 
This paper addresses the second objective of the thesis. At the time of publication, this was 
the largest paediatric ART cohort from a single country setting, and remains the largest 
cohort to publish survival, retention in care, immunological, virological and growth outcomes 
for up to three years on ART using individualized data. A further unique contribution was 
inclusion of the largest cohort of children initiating ART at <18 months of age published at 
the time. Due to the large size of the cohort, inclusion of a large number of infants and young 
children and availability of HIV-RNA results, we were able to demonstrate independent 
associations between all measured markers of disease severity and mortality that had not been 













Role of the candidate 
The candidate was responsible for all data management to generate the IeDEA paediatric data 
set for analysis. She was solely responsible for the analysis. The candidate presented the 
analysis at the South African AIDS Conference in April 2009. She drafted the manuscript, 
incorporated input from co-authors and was responsible for finalising and submitting the final 
version of the manuscript for publication. 
Publication status 










October 2009, Vol. 99, No. 10  SAMJ
ORIGINAL ARTICLES
730
Outcomes of the South African National Antiretroviral 
Treatment Programme for children: The IeDEA Southern 
Africa collaboration
Mary-Ann Davies, Olivia Keiser, Karl Technau, Brian Eley, Helena Rabie, Gilles van Cutsem, Janet Giddy, Robin Wood,  
Andrew Boulle, Matthias Egger, Harry Moultrie, for the International epidemiologic Databases to Evaluate AIDS Southern 
Africa (IeDEA-SA) collaboration 
South Africa’s paediatric antiretroviral treatment (ART) 
programme is the largest in the world, with an estimated 
32 000 children <15 years of age on treatment at the end of 
2007.1 Nevertheless the programme reaches less than half 
of the children estimated to need ART according to national 
guidelines,2 and an even lower proportion if need is defined 
using revised 2008 World Health Organization (WHO) 
guidelines for early treatment of HIV-infected infants.3
Despite the size of the national programme, few individual 
cohorts have published treatment outcomes, with follow-up 
limited to 1 year.4-6 Similar to other African countries, these 
cohorts have demonstrated good short-term outcomes.7,8 
However, the small size of any individual South African cohort 
has limited statistical power to robustly describe associations 
with mortality for all markers of disease severity.9-14 
Furthermore, the lack of routinely collected national 
monitoring data means that South Africa has lagged behind 
other southern African countries in publishing programme 
outcomes, and more importantly, has no mechanism to assess 
the effectiveness of this enormous health service 
intervention.9,15 South Africa could potentially generate 
valuable paediatric ART data, not only because of the size of 
the programme but also due to the uniform approach to 
treatment shaped by national guidelines, as well as good access 
to laboratory testing facilities, particularly viral load. 
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Objectives. To assess paediatric antiretroviral treatment (ART) 
outcomes and their associations from a collaborative cohort 
representing 20% of the South African national treatment 
programme.
Design and setting. Multi-cohort study of 7 public sector 
paediatric ART programmes in Gauteng, Western Cape and 
KwaZulu-Natal provinces.
Subjects. ART-naïve children (≤16 years) who commenced 
treatment with ≥3 antiretroviral drugs before March 2008.
Outcome measures. Time to death or loss to follow-up were 
assessed using the Kaplan-Meier method. Associations 
between baseline characteristics and mortality were assessed 
with Cox proportional hazards models stratified by site. 
Immune status, virological suppression and growth were 
described in relation to duration of ART. 
Results. The median (interquartile range) age of 6 078 children 
with 9 368 child-years of follow-up was 43 (15 - 83) months, 
with 29% being <18 months. Most were severely ill at ART 
initiation. More than 75% of children were appropriately 
monitored at 6-monthly intervals with viral load suppression 
(<400 copies/ml) being 80% or above throughout 36 months 
of treatment. Mortality and retention in care at 3 years were 
7.7% (95% confidence interval 7.0 - 8.6%) and 81.4% (80.1 - 
82.6%), respectively. Together with young age, all markers of 
disease severity (low weight-for-age z-score, high viral load, 
severe immune suppression, stage 3/4 disease and anaemia) 
were independently associated with mortality.
Conclusions. Dramatic clinical benefit for children accessing 
the national ART programme is demonstrated. Higher 
mortality in infants and those with advanced disease 
highlights the need for early diagnosis of HIV infection and 
commencement of ART. 
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The International epidemiologic Databases to Evaluate AIDS 
(IeDEA) Southern Africa Collaboration includes 8 sites in South 
Africa providing paediatric ART at different levels of care in 3 
provinces. More than 6 000 children had commenced ART at 
these sites by the end of 2007, representing >20% of children 
in the national programme at that time. This collaboration 
therefore provides a unique opportunity to examine the 
effectiveness of the South African paediatric ART programme 
and the extent to which national guidelines are being followed.
Our objectives were to describe for this combined cohort the 
outcomes of children receiving ART, factors associated with 
these outcomes, and the extent to which national programme 
guidelines are being followed. 
Methods
Study, design, setting and population
Data for this cohort analysis were collected prospectively at 
sites and transferred anonymously to the IeDEA data centre in 
a standard format between May 2007 and February 2008. Each 
site has institutional ethical approval for contribution of data to 
IeDEA collaborative analyses. 
HIV-infected, ART-naïve children with known gender 
and date of birth who initiated treatment with at least 3 
antiretroviral drugs at age ≤16 years on a documented date 
between 1 June 1999 and 29 February 2008 were included. Sites 
where less than 25 children met these criteria were excluded. 
Key variables
Information describing ART programmes was provided on 
standardised questionnaires by site representatives. Child 
characteristics included measures of disease severity (WHO 
stage, weight, height, haemoglobin (Hb), CD4 percentage or 
count, viral load) at ART initiation and at 6-monthly follow-up 
intervals, together with initiating regimen. CD4 percentage 
and absolute counts are reported, with the worst of these 
being used to determine whether the child was severely 
immunosuppressed according to WHO criteria.16 Primary 
caregiver and exposure to prevention of mother-to-child 
transmission (PMTCT) regimens were recorded. 
As sites changed from the WHO 3-stage to WHO 4-stage 
classification of disease severity during the latter half of 2004, 
all children with stage 3 or 4 disease under either system were 
considered to have clinically advanced disease.17 Viral loads 
and CD4 counts were performed by local laboratories using 
standard methods. A viral load <400 copies/ml was considered 
undetectable. Sex- and age-standardised z-scores for weight 
and height were calculated for children ≤10 years at time of 
measurement using WHO 2007 growth reference standards.18
Sites provided data on known deaths and transfers out 
(TFO). Children were deemed lost to follow-up (LFU) if the last 
visit date was more than 6 months before date of closure of the 
site database, with the last visit date used as date of LFU. 
Analysis
Kaplan-Meier estimates of mortality, LFU and TFO were 
determined. Cox proportional hazards models stratified 
by site were used to assess associations between baseline 
characteristics and mortality. Multivariate models were built by 
sequentially adding the next most significant predictor variable 
from univariate analysis, and variables with a p-value <0.1 after 
adjustment for those already in the model, or that changed the 
hazard ratio (HR) for variables in the model by more than 10%, 
were retained. Separate models were generated excluding the 
weight-for-age z-score (WAZs) as this could only be calculated 
for children ≤10 years of age, and viral load, as this is not 
routinely available in most resource-limited settings. Since Hb 
at ART initiation was only available for a third of children, this 
was excluded from the main model, but a separate model was 
generated to assess the effect of anaemia on mortality. Age was 
categorised as <12 months, 12 - 35 months and ≥36 months. 
WAZs were categorised as <–3, –3 to –2 and ≥–2, according to 
United Nations Children’s Fund (UNICEF) definitions.19  Viral 
load was categorised as ≤100 000, 100 000 to 1 million and >1 
million copies/ml, and year of starting ART as ≤2005 and ≥2006 
as these thresholds explained the largest amount of variability 
in mortality. Anaemia was defined as Hb <8 g/dl. 
As these data include a substantial proportion of children 
who received ART through donor-funded programmes before 
commencement of National Department of Health provision 
on 1 April 2004, a sensitivity analysis was performed on 
descriptions of baseline characteristics and survival models 
with data limited to those children who started ART after 31 
March 2004. All statistical analyses were performed using Stata 
version 10 (STATA Corporation, College Station, TX).
Results
Exclusions
Of the 8 South African IeDEA sites, 1 was excluded because the 
cohort comprised <25 children. The remaining data included 
6 266 children on ART. Of these, 85 did not meet inclusion 
criteria due to missing or inconsistent baseline data. Non-naïve 
patients (N=39) and those commenced on <3 drugs (N=64) 
were excluded. The final data-set therefore comprised 6 078 
children (49.1% female) from 7 sites with 9 368 child-years of 
follow-up, and median (interquartile range (IQR)) follow-up 
duration of 16 (6 - 29) months.
Contributing sites
Site characteristics are shown in Table I. Of note, sites are all 
urban and represent major centres in 3 provinces (Western 
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are represented. There is a wide variation in the number of 
children being treated with ART at different sites, from  
>2 000 at a site providing all levels of care in Gauteng to <300 
at a smaller primary care clinic in Cape Town. The median age 
of children from tertiary care sites is less than that of children 
from sites providing other levels of care (18.4 v. 51.9 months; 
p<0.0001).
Characteristics at ART start
Most children were severely ill with advanced clinical disease, 
immunosuppression, high viral load and impaired growth at 
the start of ART (Table II). The median (IQR) age of children 
commencing ART was 42.7 (14.7 - 82.5) months, with nearly 
30% of children less than 18 months of age. The starting 
regimen included stavudine (d4T) and lamivudine (3TC) with 
either efavirenz or lopinavir/ritonavir (Kaletra) as the third 
drug for 81% of children. 
Data were incomplete for many key variables. In particular, 
WHO stage was unknown for nearly a third of children, while 
caregiver and PMTCT exposure information was provided by 
only a few sites at which exposure status was still unknown 
for nearly 50%. Characteristics at start of ART were not 
substantially different when the data were limited to those 
initiating treatment after formal commencement of the national 
programme (N=5 601, results not shown).
Survival and retention in care
Mortality at 3 years was 7.7% (95% confidence interval (CI) 7.0 
- 8.6%), and 81.4% (95% CI 80.1 - 82.6%) of children were alive 
and in care at 3 years (Fig. 1, a, b). There was rapid transfer 
from sites providing exclusively tertiary care to lower levels 
after the first 6 months of ART, with the tertiary cohort reduced 
by nearly 50% at 2 years (Fig. 1, c). LFU at 1 year increased 
from 2.2% (95% CI 1.1 - 4.7%) in those who commenced 
ART before 2004 to 8.2% (95% CI 7.1 - 9.4%) in those who 
commenced during or after 2006.
Mortality was higher for younger children, those with 
more advanced disease and those who were more severely 
immunosuppressed (Fig. 1). All markers of disease severity 
were independent predictors of mortality in multivariate 
analysis (Table III). Use of a protease inhibitor versus a non-
nucleoside reverse transcriptase inhibitor as the third drug 
had no effect on mortality (p=0.572). Similarly, Hb <8 g/dl 
independently predicts mortality after adjustment for disease 
severity, age and programme year (adjusted hazard ratio 
1.65; 95% CI 1.07 - 2.55%; p=0.024). Models excluding WAZ 
and viral load as predictors yielded similar results to the full 
model, as did models limited to those children treated after 
commencement of the national programme (results not shown). 
Table I. Characteristics of facilities providing ART
           Median (IQR)  Number of
      Main level                  No. of  age (mo.) of children (%) 
Cohort name      of care  Type of clinic   Target              First year of            children children at <1 yr of age
and location     provided and payment  population         ART provision         on ART ART initiation at ART initiation
Harriet Shezi Clinic,    All levels Public and   Children only    2001             2 183        55.9  328 (15.0)
Soweto    research, free ART          (21.9 - 90.3)
Rahima Moosa,     All levels Public, free ART  Children and     1999             1 023        44.0  202 (19.8)
Mother and      pregnant women       (15.9 - 84.4)
Child Hospital
Johannesburg
Red Cross Children’s   Tertiary Public and   Children only    2001             839        16.1  351 (41.8)
Hospital, Cape Town  research, free ART         (6.3 - 50.2)
Tygerberg Hospital,     Tertiary Public and,  Adults and    2000             690        21.6  240 (34.8)
Cape Town   research free ART  children, separate      (8.5 - 59.0)
       clinics
Khayelitsha     Primary Public, free ART  Adults and     2001             650        41.7  94 (14.5)
Community Health       children, separate      (20.3 - 74.2)
Centre, Cape Town      clinics
Gugulethu      Primary Public and,  Adults and    2001             262        47.1  42 (16.0)
Community Health   research free ART  children, separate       (18.3 - 82.4)
Centre, Cape Town      clinics
McCord Hospital,      Secondary Government-  Adults and    2003             431        72.4  33 (7.7)
Durban     subsidised mission   children, separate      (33.0 - 109.2) 
    hospital, small co-  clinics 
    payment 











Table II. Characteristics of children at ART initiation (N=6 078)
Year of ART start (%)
≤2003         321 (5.3)
2004         1 076 (17.7)
2005         1 809 (29.8)
2006         1 707 (28.1)
≥2007         1 165 (19.2)
Female (%)        2 981 (49.1)
Age
Median (IQR) age (mo.)       42.7 (14.7 - 82.5)
Less than 18 mo. (%)       1 758 (28.9)
WHO stage (%) 
1         263 (4.3)
2         745 (12.3)
3/4         3 073 (50.1)
WHO stage unknown       1 997 (32.9)
PMTCT exposure (%) (N=4 695)*
Known exposed        596 (12.7)
Known unexposed       1 764 (37.6)
Exposure status unknown       2 335 (49.7)
Primary caregiver (%) (N=4 045)†
Mother         2 449 (60.5)
Father         141 (3.5)
Grandmother        204 (5.0)
Other family        712 (17.6)
Other         123 (3.0)
Institution        225 (5.6)
Unknown        191 (4.7)
Laboratory measurements
Median (IQR) CD4% by age group (N=4 592)
≤11 mo. (N=1 045)       16.4 (10.0 - 23.6)
12 - 35 mo. (N=1 089)       13.0 (9.0 - 18.1)
36 - 59 mo. (N=712)       12.0 (7.2 - 16.5)
≥5 yrs (N=1 746)       10.0 (4.7 - 15.0)
Median (IQR) CD4 absolute count (cells/µl) by age group (N=4 852)
≤11 mo. (N=1 062)       642 (280 - 1 132)
12 - 35 mo.  (N=1 145)       636 (345 - 1 014)
36 - 59 mo. (N=750)       437 (251 - 691)
≥5 yrs (N=1 895)       435 (81 - 241)
Severely immunosuppressed (%) (N=4 934)‡     4 024 (81.6)
Median (IQR) log viral load (N=4 063)     5.36 (4.74 - 5.89)
Viral load >1million copies/ml (%) (N=4 063)     850 (20.9)
Haemoglobin <8 g/dl (%) (N=1 803)      220 (12.2)
Anthropometry§ 
z-scores 
Median (IQR) weight-for-age z-score (N=3 892)    –1.89 (–3.20 - –0.93)
Median (IQR) height-for-age z-score (N= 3 690)    –2.39 (–3.37 - –1.44)
Median (IQR) weight-for-height z-score (N=3 186)    –0.46 (–1.73 - 0.55)
Weight-for-age z-scores (N=3 892)
–3 - –2 (%)        747 (19.1)
<–3 (%)        1 096 (28.2)
Height-for-age z-score (N=3 690) 
–3 - –2 (%)        1 011 (27.4)
<–3 (%)        1 242 (33.7)
Weight-for-height z-score (N=3 186) 
–3 - –2 (%)        312 (9.8)
<–3 (%)        365 (11.5)
Regimen (%) (N=5 484)
Most common regimens
d4T+3TC+efavirenz       2 839 (51.8)
d4T+3TC+lopinavir/ritonavir¶      1 603 (29.2)
First NRTI
d4T-based regimen       4 856 (88.5)
Third drug
Lopinavir/ritonavir-based regimenıı     1 808 (33.0)
Ritonavir-based regimen       191 (3.5)
Regimen not recorded       594
*Data only available for Rahima Moosa, Harriet Shezi, Khayelitsha and Red Cross. 
†Data only available for Rahima Moosa, Harriet Shezi and Red Cross; for Harriet Shezi caregiver information was collected at first visit – may be different from caregiver at ART start.
‡WHO criteria for severe immune suppression (CD4% <25 or CD4 count <1 500/µl if age ≤11months; CD4% <20 or CD4 count <750/µl if age between 12 and 35 months; CD4% <15 or 
CD4 count <350/µl if age between 36 and 59 months; CD4% <15 or CD4 count <200/µl if age ≥60 months. 
§Only calculated for children ≤120 months (N=5 535).
¶Includes 201 children with additional ritonavir boosting. 
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Monitoring of viral and immune response to 
treatment
Follow-up measurements of CD4 and viral load are shown 
in Fig. 2. Notably, measurements of CD4 and viral load at 
6-monthly intervals were available for over 80% and 75% of 
children respectively through to 36 months, with ≥80% of 
children virologically suppressed throughout (82.4% at 3 years; 
95% CI 79.4 - 85.5%). The percentage (95% CI) of children 
severely immunosuppressed at 1 and 3 years dropped to 16.9% 
(15.4 - 18.3%) and 6.4% (4.2 - 8.6%), respectively.
Growth response to treatment
There was initial rapid weight gain from a median WAZ of 
–1.80 to –0.75 by 12 months, remaining relatively constant 
thereafter (Fig. 3). Height increased more slowly but was still 
increasing at 36 months, 
when a quarter of children 
still had a height-for-age z-
score <–2. 
Discussion
Main findings of the 
study
Outcomes of this cohort 
of ART-treated children in 
South Africa, the largest 
from a single country in 
Africa to date, were good 
with mortality of 7.7% and 
81.1% of children alive and in 
care at 3 years. As expected, 
young age together with all 
markers of disease severity 
were independent predictors 
of mortality. These findings 
are strikingly similar to those 
of a similar combined cohort 
analysis of sub-Saharan 
paediatric ART programmes, 
the Kids’ Antiretroviral 
Treatment in Lower-Incomes 
Countries (KIDS-ART-LINC) 
Collaboration.8 Furthermore, 
follow-up monitoring of 
laboratory parameters was 
excellent, with more than 
75% of children tested 
6-monthly according 
to national guidelines. 
Although comparisons with 
rich countries are difficult 
owing to the older age of ART 
commencement in the South African children and inherent 
survival bias, the high level of virological suppression is 
encouraging and compares favourably with cohorts from 
Europe20 and North America21 and other African studies.7,14 
Similarly, children remaining in care experienced dramatic 
improvements in growth and immune status. While the 
proportion and absolute number of nearly 2 000 very young 
children accessing ART are much greater than in most other 
African studies, across the country older children are still 
preferentially accessing treatment with more than 70% of the 
cohort being over 18 months of age.7,8,22 
Strengths and generalisablity of findings
This study is valuable because of the large number of children 
and length of follow-up, but particularly because of the high 
Fig. 1. Kaplan-Meier estimates for outcomes of (a) death, (b) death and loss to follow-up, and (c) transfer out. Kaplan-
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absolute number of those under 18 months of age. With new 
WHO guidelines encouraging early ART initiation in infants, 
a better understanding of clinical outcomes in this age group 
is required.3 In addition, the availability of regular viral load 
information is unusual in the African context. Inclusion 
of children from a number of different sites in 3 provinces 
and at different levels of care enhances representivity, while 
uniformity of treatment protocols lends itself to collation into a 
single analysis.
Limitations
Although the study includes some of the busiest routine 
public sector clinics, it should be acknowledged that 
IeDEA collaboration sites must have capacity for electronic 
collection of routine data, which is not the norm. Some high-
burden provinces are not included in the study, and there 
is disproportionate representation of sites with tertiary care 
capacity. The thorough monitoring and high number of infants 
on ART therefore probably represent best-practice examples in 
well-resourced clinics.
While LFU in this study is relatively low compared with 
adult publications of routine cohort data,23 there is variation 
in LFU at different sites. This is of concern as many of those 
who are LFU are likely to have died, resulting in under-
ascertainment of mortality. Indeed, while there are various 
plausible explanations for the apparent protective effect on 
mortality of starting ART after 2005 (including that children 
starting earlier are ‘sicker’ in ways not captured by markers of 
disease severity available for this analysis), the contribution of 
increasing LFU in later years as programmes expand should 
not be underestimated. In this respect, the effect of choice of 
first drug (zidovudine v. stavudine) on mortality could not be 
definitively assessed owing to changes in prescribing patterns 
after the introduction of national treatment guidelines in 2004 
and increasing LFU over time. The high transfer rate from 
tertiary sites to lower levels of care limits duration of follow-up 
for these patients. Systems of data collection integrated across 
sites are needed to ascertain outcomes for transferred patients. 
Poor integration of health information systems is also 
reflected in the paucity of PMTCT exposure data. This reflects 
poor integration of antenatal, routine child care and HIV 
services themselves within the health system, a major barrier 
to timeous HIV diagnosis and referral for care of those infants 
infected despite PMTCT exposure.7,22,24 Completeness and 
accuracy of other exposure variables is also limited, while 
historical changes in the WHO staging system limit its value as 
a measure of disease advancement.
Reflections on the South African national paediatric 
ART programme
This study indicates that the programme is successful for 
those children who access it. The latter caveat is important, as 
the fact that 20% of all children are treated at a handful of 
sites, all in large urban centres, suggests that considerable 
inequities in access are likely. Nevertheless the fastidious 
monitoring, utilisation of first-line regimens recommended 
in national guidelines, good survival, high proportions of 
children with viral suppression and favourable immune and 
growth responses – at least at these sites – are encouraging. 
The Western Cape has the specific aim of treating children at 
their nearest health centre whenever possible, with only those 
warranting specialist care remaining at tertiary facilities.24 
Table III. Predictors of mortality using Cox-proportional hazards model stratified by site (adjusted for year of ART start)
           Adjusted HR
           Full model
Characteristic at ART start        Crude HR        95% CI     p-value    (N=2 449) 95% CI         p-value
WAZ           <0.001*             <0.001*
>–2                1                1
–3 - –2           1.93       1.29 - 2.89         1.13  0.69 - 1.87 
< –3           5.23       3.84 - 7.12         2.44  1.65 - 3.59 
Viral load (copies/ml)         <0.001*              0.010*
<100 000               1                 1
100 000 to 1 million         1.75       1.24 - 2.45         1.68  1.02 - 2.76 
>1 million          3.30       2.32 - 4.70         2.22  1.31 - 3.77 
Severe immunosuppression 
(WHO definition)          4.23      2.55 - 7.00      <0.001        3.83  1.68 - 8.72            0.001
WHO stage 3 or 4 (v. 1 or 2)          3.01      2.00 - 4.54      <0.001        2.16  1.28 - 3.62            0.004
Age            <0.001*                0.002*
>3 yrs               1                 1
1 - 3 yrs          1.31      0.98 - 1.74         1.17  0.76 - 1.84 
<1 yr           3.38       2.65 - 4.31         2.00  1.30 - 3.07 
ART commenced before 2006         1.28      1.02 - 1.60        0.036        1.68  1.18 - 2.39            0.004
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In this respect, the rapid 
transfer of children from 
exclusive tertiary to primary 
care sites, together with the 
difference in ages of children 
starting ART at different 
levels of care, indicate that 
children are indeed receiving 
care at the appropriate level.
Although the cohort 
includes several infants, 
the number is negligible 
compared with the estimated 
64 000 new infections 
that occur perinatally and 
through breastfeeding every 
year.25 Together with lack 
of integration of antenatal 
PMTCT and paediatric HIV 
services, perceived and 
actual lack of expertise in the 
care of young HIV-infected 
infants pose significant 
barriers to access for infants, who are still 
largely cared for at tertiary sites. These 
problems need to be addressed urgently if 
South Africa seeks to implement revised 
WHO guidelines recommending early ART 
for infants irrespective of disease severity.3 
In this respect it should be noted that 
the relatively poor outcomes for infants 
in this study would not necessarily be the 
scenario should infant ART initiation be 
prioritised. Disease progression is rapid 
in HIV-infected infants, and in this study 
children commencing ART at a young 
age are those whose disease progressed 
rapidly enough to meet previous WHO 
disease severity criteria while they were 
still young and who were able to access 
treatment before otherwise inevitable early 
death.26 Better outcomes for older children 
represent a survivor effect, with older age 
at ART initiation being a proxy for slower 
disease progression. In contrast, other 
South African studies have shown excellent 
outcomes for infants commencing ART 
before disease progression.27,28 
Conclusion
This study of a substantial proportion of 
the South African national ART programme 
for children demonstrates the dramatic Fig. 3. Growth response to ART (only includes children with measurement at ART start and at least 
one subsequent measurement).
*z-scores only calculated for children <10 years at time of measurement.
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clinical benefit for those accessing the programme. The higher 
mortality in infants and young children and those with 
advanced disease highlights the need to identify HIV-infected 
infants and commence ART before disease progression.
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2.3 Prognosis of children with HIV-1 infection starting antiretroviral 




This paper analysed data from >12,000 children who initiated ART at IeDEA-SA sites to 
develop a prognostic model of one-year mortality for children initiating ART in the region. 
Weibull survival models were used to construct two prognostic models with and without CD4 
measures respectively because these are not routinely measured in many programs. A method 
of internal-external cross-validation was used to identify the model of mortality that was most 
generalizable across the cohorts. Multiple imputation was used to account for missing data at 
ART start. 
Contribution to the thesis and novelty 
This paper addresses the second objective of the thesis, by examining the generalizability of 
survival outcomes and their associations across the Southern African region. Unique 
contributions include the development of the first generalizable prognostic model of mortality 
for children initiating ART in resource-limited settings. The model showed good 
discrimination and prognostic separation. It provides absolute predictions of mortality for up 
to one year on ART for children with particular age and disease severity characteristics. 
Development and comparison of models that included and excluded CD4% as a marker of 
disease severity suggested that low cost prognostic markers such as anaemia and WAZ score 
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Background: Prognostic models for children starting antiretroviral therapy (ART) in Africa 
are lacking. We developed models to estimate the probability of death during the first year on 
ART in Southern Africa. 
Methods: We analyzed data from children ≤10 years old that started ART in Malawi, South 
Africa, Zambia or Zimbabwe from 2004-2010. Children lost to follow-up or transferred were 
excluded. The primary outcome was all-cause mortality in the first year of ART. We used 
Weibull survival models to construct two prognostic models: one with CD4%, age, WHO 
clinical stage, weight-for-age z-score (WAZ) and anemia and one without CD4%, because it 
is not routinely measured in many programs. We used multiple imputation to account for 
missing data.  
Results: Among 12,655 children, 877 (6.9%) died in the first year of ART. 1780 children 
were lost to follow-up/transferred and excluded from main analyses; 10875 children were 
included.  With the CD4% model probability of death at 1 year ranged from 1.8% (95% CI: 
1.5–2.3) in children 5-10 years with CD4% ≥10%, WHO stage I/II, WAZ ≥-2 and without 
severe anemia to 46.3% (95% CI: 38.2–55.2) in children <1 year with CD4% <5%, stage 
III/IV, WAZ< -3 and severe anemia. The corresponding range for the model without CD4% 
was 2.2% (95% CI: 1.8–2.7) to 33.4% (95% CI: 28.2-39.3).  Agreement between predicted 
and observed mortality was good.  
Conclusion: These models may be useful to counsel children/caregivers, for programme 
planning and to assess programme outcomes after allowing for differences in patient disease 













Prognosis of children with HIV-1 infection starting antiretroviral therapy 




Despite the impressive increase in access to antiretroviral therapy (ART) for HIV-infected 
children in low-income settings, mortality is still high. In 2010, an estimated  230,000 
children died of AIDS in sub-Saharan Africa.1 While many deaths occur in untreated 
patients,2 mortality remains high during the first year of ART, especially for children starting 
therapy with advanced disease.3-5 Knowing the short term prognosis associated with particular 
disease severity characteristics is important for the individual child initiating ART and his/her 
caregiver, as well as for clinicians and for program planning. Further, comparison of actual 
mortality outcomes with predictions from a prognostic model that is generalizable across 
settings may be useful for benchmarking the quality of health care provision. Prognostic 
models for mortality on ART have to date been developed for adults in high and low-income 
settings,6-8 but not for children.  
 
The characteristics associated with mortality in children starting ART have been well 
described from a range of settings across sub-Saharan Africa.3-5,9-13 However, the combined 
power of different markers of disease severity to predict mortality and the absolute mortality 
risk associated with these markers remains unknown. Young children and those with a low 
CD4% or advanced clinical disease are at particularly risk of high morbidity and 
mortality.3,4,9,14 WHO Guidelines for ART eligibility are thus based on age, CD4 measures 
and disease stage.15 Other variables also predict mortality and have been used to decide when 
to start ART: e.g. in high income countries in children >1 year old with minimal/no clinical 
symptoms HIV-1 RNA is used to determine ART eligibility16 and HIV-1 RNA level and 












settings, measurement of many of these prognostic factors, including CD4, is often 
unavailable due to lack of equipment, logistic constraints, personnel or high costs.18 
The International epidemiologic Databases to Evaluate AIDS in Southern Africa (IeDEA-SA) 
Collaboration includes data from children starting ART at 11 treatment programs in a range of 
settings in four countries.3,14 We aimed to use these data to develop a prognostic model that 
estimates the cumulative probability of death at 3, 6 and 12 months after starting ART in 
children in Southern Africa according to age, and prognostic factors commonly measured in 
resource-limited settings. Separate models were developed for settings with and without 
access to CD4% at ART initiation. 
 
METHODS 
Treatment programs  
IeDEA-SA is a regional collaboration of ART programs, which is part of a larger international 
network.19 Data are collected at ART initiation and follow-up visits, using standardized 
instruments, and transferred at regular intervals to data centers at the Universities of Cape 
Town, South Africa, and Bern, Switzerland. All sites have ethical approval to collect data and 
participate in IeDEA-SA. The current analyses were based on data from 11 programs in four 
countries (Figure 1), including eight clinics in three provinces in South Africa (Red Cross 
Children’s Hospital, Khayelitsha and Gugulethu ART Programs in Cape Town and Tygerberg 
Academic Hospital in Stellenbosch, Western Cape; Sinikithemba Clinic at McCord Hospital 
in Durban and Hlabisa HIV Treatment and Care Programme, Kwazulu-Natal; Harriet Shezi 
Children’s Clinic at Chris Hani Baragwanath Hospital in Soweto and Rahima Moosa Mother 
and Child Hospital in Johannesburg, Gauteng) and one treatment program each in Zambia 












CIDRZ]  in Lusaka), Malawi (Lighthouse Trust Clinic at Kamuzu Central Hospital in 
Lilongwe) and Zimbabwe (Newlands Clinic in Harare). 
Inclusion criteria 
All HIV-infected, ART-naïve (except for antiretroviral exposure to prevent vertical 
transmission) children who initiated treatment with ≥3 antiretrovirals at age ≤10 years 
between 1 January 2004 and 31 January 2010 were eligible. Children with <1 year of 
potential follow-up (ART initiation <1 year prior to site database closure) were excluded. 
Children were excluded from the main analysis if, within 6 months of starting ART, they were 
lost to follow-up (LTFU) or transferred out (TFO) to a different treatment site. As clinic visits 
may be up to 6 months apart, LTFU was defined as the last visit being ≥270 days before 
database closure.  
Outcomes and prognostic models 
We used an intention-to-continue-treatment analysis, ignoring treatment changes and 
interruptions. The outcome was all-cause mortality during the first year on ART. Follow-up 
was censored on the earliest of: date of death, last visit date +90 days in children LTFU/TFO, 
or 1 year after ART initiation. The 11 cohorts were grouped into five geographic regions as 
some cohorts had small patient numbers (Figure 1). Three regions were provinces within 
South Africa where ART programs at different sites are co-ordinated by provincial 
Departments of Health (Western Cape, Kwazulu-Natal and Gauteng). The fourth region 
comprised two cohorts with similar patient characteristics in Malawi and Zimbabwe, while 
the MoH-CIDRZ cohort (Zambia) comprised the 5th region.  
The following prognostic variables measured at ART initiation were considered for inclusion 
in a prognostic model and associations with mortality were explored using Kaplan-Meier 












years, 5-10 years); WHO Clinical Stage (I/II compared to III/IV); CD4% (<5, 5-9.9, 10-14.9; 
≥15); anemia (defined as severe, moderate, mild/none using CDC classification of adverse 
events that incorporates both hemoglobin and age20); weight-for-age z-score (WAZ) 
calculated using WHO 2006 standards (<-3.00; -3.00 to -2.01, -2.00 to -1.01 and ≥-1.00 
standard deviations below mean).21 Apart from age and gender, data on prognostic variables 
were not recorded for all patients. Missing data were modeled using multiple imputation by 
chained equations using the ice command in STATA, with 25 imputed datasets.22-24 The 
following variables were used in imputation equations: cohort, sex, age, WHO Stage, CD4%, 
WAZ, hemoglobin, interactions between age, CD4% and WAZ, as well as the outcome 
(death).  Log or square root transformations were used for non-normally distributed variables. 
Weibull proportional hazards models were used to explore crude and adjusted associations 
between prognostic variables and mortality.  
A set of candidate models (with and without CD4%) were selected using the Akaike 
Information Criterion (AIC) that penalizes m del complexity. These were all flexible 
parametric survival models25 with spline smoothing of the baseline hazard in order to model 
the steep mortality during the first 3 months of treatment. We used a system of leave-one-out 
cross-validation to select the most generalizable models with and without CD4%.26,27  This 
method fits the model in four regions and tests discrimination of predictions of the fitted 
model when applied to the omitted fifth region. This is repeated sequentially rotating around 
the omitted region. Discrimination was assessed using the D-statistic (averaged across the 
imputed datasets) that measures the prognostic separation between the survival distributions 
for two independent prognostic groups.27 We calculated the D-statistic for the model fitted on 
the four regions and applied to the excluded region (Dtest) and compared this to the D-statistic 
for the model when co-efficients were re-estimated using data only from the excluded region 












when applied to independent data compared with when applied to the data that was used to 
estimate the model coefficients. Models with a low AIC score, high Dtest and low Dr-Dtest were 
favored. 
Concordance between predicted mortality and observed mortality for the final selected models 
was assessed using Harrell’s C-statistic (0.5 = agreement expected by chance; 1 = perfect 
agreement). The explained variation (R2) of the final selected models was calculated.28 Model 
calibration was assessed by comparing Kaplan-Meier curves of observed mortality with 
curves predicted from the model for groups with poor to good prognosis, and for each region. 
All analyses were conducted in STATA version 12.0 (STATA Corporation, College Station, 
Texas). Results are reported as Kaplan-Meier estimates or modeled estimates of mortality and 
crude and adjusted hazard ratios (HR), with 95% confidence intervals (CI). 
Sensitivity analyses 
In sensitivity analyses we included children LTFU/TFO within the first six months of 
treatment. We examined Kaplan-Meier estimates of one-year mortality first censoring their 
follow-up time at the last visit date +90 days, and then assuming 30% and 50% mortality in 
those LTFU/TFO with time to death randomly assigned based on the distribution in those not 
LTFU/TFO. Finally, we developed models including children LTFU/TFO, censoring their 
follow-up time at the last visit date +90 days.  
 
RESULTS 
A total of 12,655 children started ART in the 11 treatment programs. 1780 children (14%) 
were lost to follow-up or transferred and excluded from the main analyses. The main analysis 
included 10,875 children (70% ≥2 years old) with 10,204 child-years of follow-up (Table 1). 












median [IQR] CD4%: 13% [8-19]). There was considerable between-region heterogeneity in 
age and disease severity; the percentage of children <1 year old ranged from 3% to nearly 
30%; the percentage with WHO Stage III/IV disease ranged from approximately 60% to 
>90%. There was also substantial missing data on many covariates; anemia and CD4% were 
not reported for 37% (range across regions:18-88%) and 32% (16-56%) of children 
respectively. The estimated cumulative mortality by 1 year after ART start was 8.6% (95% 
CI: 8.0-9.2) (range across regions: 5.8%-10.5%).  
The Kaplan-Meier curves of death for the different prognostic characteristics are shown in 
Figure 2. Mortality was highest in the first three months on ART especially for those with the 
worst prognosis. Age was strongly associated with mortality, with much higher mortality in 
those <2 years compared to older children. The other prognostic variables were therefore 
examined separately for these two age groups. Advanced disease stage, lower CD4% and 
WAZ and more severe anemia were all associated with mortality. While CD4% and WAZ had 
a graded association with mortality across all categories in younger children, in those >2 years 
old there was a large impact of an increase in CD4% from <5 to 5-9.9% and WAZ from <-3 
to -3 to -2 with smaller reductions in mortality associated with further increases.  
The associations between prognostic variables and mortality are shown in Table 2 (using 
multiple imputation to account for missing data) and Appendix Table S1 (using available data 
only). In mutually adjusted analyses there were associations between all disease severity 
characteristics and mortality, however the association between HIV-1 RNA and mortality was 
substantially attenuated by adjustment. Since HIV-1 RNA was missing for most children from 
outside South Africa, it was excluded from further analyses. In both available data and 
imputed data there was a significant interaction between age and both CD4% (p=0.007 
[available data]; p=0.028 [imputed data]) and WAZ (p<0.001 [available data]; p=0.002 












reducing mortality risk in older children compared to younger children (appendix Table S2), 
although mortality overall was lower for older children.  
The two final models selected by internal-external cross-validation included age (in four 
categories), clinical stage (two), WAZ (three) and anemia (two), with one model additionally 
including CD4% (in three categories, Table 3). There were thus 144 risk groups (model with 
CD4%) or 48 risk groups (model without CD4%). The C-statistics over the entire first year on 
ART were 0.753 and 0.745 for the models with and without CD4% respectively. Concordance 
was lower when restricting to the second six months on ART (C-statistics of 0.708 and 0.705 
for models with and without CD4% respectively). The R2 values were 32.1% and 31.1% for 
the whole first year and 23.6% and 23.9% for the second six months for the models with and 
without CD4% respectively.  
For both models, predicted mortality closely followed actual mortality for five prognostic 
groups of children with approximately 20% of deaths in each group (Figure 3[a]). The 
majority of children (57% [model with CD4%] and 58% [model without CD4%] were in the 
group with a good prognosis and one-year mortality <5%. Predicted mortality from the model 
with CD4% closely approximated actual mortality for all regions except Kwazulu-Natal 
(observed>predicted) and Malawi & Zimbabwe (observed<predicted) (Figure 3[b]). Predicted 
mortality from the model without CD4% only approximated observed mortality closely for 
CIDRZ (figure 3[b]). This was the only region where <20% of hemoglobin values were 
missing. In other regions, hemoglobin may not have been well imputed, particularly in 
Gauteng and Malawi & Zimbabwe where >60% of values were missing.  
Children aged <1 year in clinical stage III/IV with WAZ <-3, severe anemia and CD4% <5 
had the highest predicted cumulative mortality at one year (46.3%) and children aged 5-10 
years in stage I/II with WAZ ≥-2, no severe anemia and CD4% > 10 the lowest mortality 












Predictions for all possible combinations of prognostic variables are shown in appendix Table 
S3. A risk calculator based on the prognostic models is available at the collaboration’s 
website (www.iedea-sa.org). 
The 1780 children LTFU/TFO within the first six months of treatment were younger and had 
more advanced disease compared to those included (appendix Table S3). When including 
these children in sensitivity analyses, Kaplan-Meier one-year mortality estimates ranged from 
7.2% (censoring children LTFU/TFO at last visit date +90 days) to 11.6% and 14.4% 
(assuming 30% and 50% mortality in those LTFU/TFO respectively). When developing the 
prognostic models including all children (censoring children LTFU/TFO as above) the 
predicted cumulative one-year mortality ranged from 1.72% to 39.0% (CD4% model) and 




These prognostic models that predict one year mortality in HIV-infected children on ART are 
generalizable and show good discrimination and prognostic separation. These models 
demonstrate that the majority of children (>55%) starting ART and remaining in care have a 
one year mortality risk of ≤3%, with 6% of children having >20% predicted risk of dying 
within the first year on ART. For predicting mortality on ART, low cost prognostic markers 
such as WAZ and anemia may be almost as good as CD4%. In busy scale-up programs 
without access to CD4%, this may allow for risk-stratification of children initiating ART. 
Overall mortality, loss to follow-up and transfer out 
There was substantial heterogeneity between regions both in overall mortality rate and disease 












only treatment sites providing exclusively tertiary care were located and which has the highest 
proportion of children <2 years old initiating treatment. These sites also rapidly transfer 
children to primary care once they are getting better (12.7% TFO from Western Cape 
exclusively tertiary care sites between six and twelve months on ART)29 which may result in 
an over-estimate of overall mortality. We excluded children who were LTFU/TFO within six 
months of starting ART to reduce bias by underascertainment of deaths if these patients had 
been censored, and more closely reflect the situation of children remaining in care. This does 
not completely remove bias as children classified as LTFU may have died before meeting the 
LTFU definition and mortality might be higher in children LTFU compared to children 
remaining in care.8 Tracing studies have demonstrated that a substantial proportion of children 
LTFU may have died.30,31 For example, in Malawi 33% of children traced after being LTFU 
had died31. Our sensitivity analysis including children LTFU/TFO in the first six months of 
ART showed that assumptions about their mortality impact on estimated overall mortality, 
and their exclusion may result in underestimated predicted mortality at the program level. 
Indeed, excluded children were more likely to have characteristics associated with mortality 
compared to those included in the main analysis. 
Comparison to pre-ART prognostic model 
While this is the first prognostic model for children on ART, a similar model for pre-ART 
mortality has been developed in children from high income settings.32 A weighting system 
incorporating weight percentile, WHO stage, symptoms, general health rating, total 
lymphocyte count, packed cell volume and albumin predicted mortality well with a C-statistic 
of 0.852 (higher than the values of 0.753 and 0.745 for our models with and without CD4% 
respectively). The study also showed that CD4% can be replaced by simpler measures to 












advanced disease. Furthermore, the mothers of all children participated in a randomized trial 
and the model may not be applicable to routine care in resource-limited settings. 
Comparison with adult model 
Our pediatric model compares favorably with the adult model for resource-limited settings 
(higher R2 and C-statistic) although the range of predictions and the number of strata is more 
limited.8 This is probably due to the powerful prognostic value of age in children. Mortality 
declines rapidly with increasing age in all children, irrespective of HIV-infection. In the 
context of ART eligibility in a peri-natally HIV-infected child only after “waiting” for certain 
disease severity criteria to be met, the age at which a child starts therapy is a proxy for rate of 
disease progression since birth and thus a strong prognostic factor.3 The model predictions 
would therefore not be applicable to children <2 years old who start ART before 
clinical/immunological progression as recommended in the WHO 2010 guidelines.15 These 
guidelines are based on the Children with HIV Early Antiretroviral Therapy (CHER) trial 
which demonstrated a favorable prognosis in children <1 year old starting ART before disease 
progression.33  
Strengths and limitations 
To our knowledge this is the first pediatric prognostic model of mortality on ART and is 
based on a very large cohort across a range of settings. The large number of missing values 
for some variables (e.g. hemoglobin) is a limitation but reflects the reality of many ART 
programs in the region. In particular, this limited our ability to determine whether a model 
based on hemoglobin alone was as good as including both CD4% and hemoglobin for 
prognostic purposes. Due to imputation of a large proportion of hemoglobin values for all 
regions except Zambia, there was misfit of predicted mortality at the level of the region for 
the model without CD4% (Figure 3[b]). However, there was very little difference in measures 












models with and without CD4% were comparable in Zambia for which <20% of hemoglobin 
values were imputed. In addition, associations with mortality were similar if missing values 
were imputed or a complete case analysis was performed. This, together with the cross 
validation, underlines the robustness of our findings.  
The majority of children in this analysis started ART with advanced disease, hence we were 
unable to examine mortality for higher values of CD4% and WAZ. This would have been 
particularly useful in children <2 years old where mortality predicted by this model is high 
even in those with the best prognostic markers. Nevertheless, the model predictions are 
applicable to most children starting ART as, even after introduction of the WHO 2010 
guidelines, the majority of children in this region still commence ART with advanced 
disease.34(Davies, personal communication) 
Despite the fact that many sites from different settings are represented, the analysis was 
dominated by one large cohort in Zambia where the fit of predicted and observed mortality is 
best. Discrepancies between predicted and observed mortality for other regions may be due to 
differences in LTFU and mortality ascertainment, proportion of imputed data, differences in 
prognostic variables not measured or included in the models or differences in background 
mortality, access to health services and models of care. Other factors including nutrition 
supplements, co-trimoxazole prophylaxis, co-infections, choice of first-line ART, adherence, 
HIV-1 RNA and exposure to vertical transmission prevention regimens have been shown to 
be associated with outcomes in children.11,35-38 However, these factors are often not easily 
available or recorded in low-income settings, and were indeed not available for many children 
in this analysis. There is a trade-off between models which would be more accurate but less 
applicable and useful in general health care settings in low-income countries. We did not 
consider treatment interruptions and did not adjust for possible temporal improvements in 












must have medical record systems available, so generalizability to less well-resourced cohorts 
may be limited.  
In conclusion, this model demonstrates that the majority of children starting ART in Southern 
Africa have a low risk of one-year mortality, despite many having characteristics of severe 
disease. As more children are diagnosed and initiate ART early and the duration of follow-up 
increases, it is important to continue to monitor ART outcomes and develop prognostic 
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Malawi & ZimbabweCIDRZ, Zambia
Figure 1: Location of the 11 treatment programs included in the analysis and their 













Table 1: Pediatric ART programs with number of patients, characteristics at ART initiation, follow-up 
duration, status by 1 year after ART initiation and Kaplan-Meier estimates of mortality by 1 year after ART 
initiation. 
 




Number of children 1505 (14%) 2015 (19%) 791 (7%) 706 (6%) 5858 (54%) 10875
Sex  
    Female 720 (48%) 997 (49%) 396 (50%) 364 (52%) 2883 (49%) 5360 (49%)
    Male 785 (52%) 1018 (51%) 395 (50%) 342 (48%) 2975 (51%) 5515 (51%)
Age group
    < 1 year 441 (29%) 306 (15%) 74 (9%) 23 (3%) 583 (10%) 1427 (13%)
    1 year 290 (19%) 282 (14%) 128 (16%) 71 (10%) 1008 (17%) 1779 (16%)
    2-4 years 412 (27%) 629 (31%) 224 (28%) 219 (31%) 1809 (30%) 3293 (30%)
    5-10 years 362 (24%) 798 (40%) 365 (46%) 393 (56%) 2458 (40%) 4376 (40%)
WHO Stage
    I/II 241 (18%) 461 (41%) 98 (19%) 37 (6%) 1746 (31%) 2583 (28%)
    III/IV 1078 (82%) 669 (59%) 428 (81%) 538 (94%) 3964 (69%) 6677 (72%)
    Not reported 186 (12%) 885 (44%) 265 (34%) 131 (18%) 148 (3%) 1615 (15%)
Anaemia
   Mild/none 903 (83%) 209 (87%) 464 (85%) 196 (87%) 3736 (78%) 5508 (80%)
   Moderate 114 (10%) 18 (8%) 54 (10%) 18 (8%) 590 (12%) 794 (12%)
   Severe 72 (7%) 13 (5%) 31 (6%) 11 (5%) 461 (10%) 588 (9%)
   Not reported 416 (28%) 1775 (88%) 242 (31%) 481 (68%) 1071 (18%) 3985 (37%)
Median (IQR) CD4% 13 (9 to 19)% 11 (7 to 15)% 13 (8 to 17)% 14 (9 to 20)% 14 (9 to 20)% 13 (8 to 19)%
    Not reported 460 (31%) 313 (16%) 230 (29%) 397 (56%) 2080 (36%) 3480 (32%)
Median (IQR) WAZ -1.9 (-3.5 to -0.8) -2.0 (-3.1 to -1.1) -1.4 (-2.5 to -0.5) -1.8 (-2.9 to -0.8) -2.2 (-3.3 to -1.1) -2.0 (-3.2 to -1.0)
    Not reported 537 (36%) 385 (19%) 168 (21%) 213 (30%) 319 (5%) 1622 (15%)
Median (IQR) log10HIV-RNA 
(copies/ml)
5.56 (4.97 to 6.09) 5.23 (4.69 to 5.79) 4.52 (3.81 to 5.26) 5.09 (4.62 to 5.45) 5.27 (4.69 to 5.84)
   Not reported 430 (29%) 516 (26%) 459 (58%) 578 (82%) 5856 (>99%) 7839 (72%)
Follow-up (child years) 1377.9 1920.5 754 671.7 5480.2 10204.3
AT 1 YEAR1
    % in follow-up        86.4 92.3 92.0 89.7 87.3 88.6
    % transferred 3.3 0.8 0.3 2.5 0 0.8
    % LTFU 0.7 1.1 1.3 2.3 3.7 2.5
    % deceased 9.6 5.8 6.4 5.5 9.0 8.1
1-year mortality rate
    K-M estimate (95% CI) 10.5 (8.9 to 12.4) 6.0 (5.0 to 7.2) 6.8 (5.1 to 8.9) 5.8 (4.2 to 7.9) 9.6 (8.8 to 10.5) 8.6 (8.0 to 9.2)
1Note that LTFU and transferred outcomes refer to children LTFU or transferred between 6 and 12 months after ART start as children LTFU/TFO within 6 









































4376 4286(90) 4251(35) 4213(33) 4084(11)5-10 yrs
3293 3190(103) 3156(34) 3122(31) 3006(19)2-4 yrs
1779 1636(143) 1578(58) 1537(38) 1451(22)1 yr
1427 1262(165) 1213(49) 1181(26) 1094(20)<1 yr
Number at risk
0 3 6 9 12
Months from start of ART
  


















































































































, II , I " i ~ , ~m , r.!g 
, 
" - ., B£aiI ~In nt o " 
• 0 0 " , ~ \SJ n " B 0 ~ . O ~ H " m~ " HI '0 :;:; I " 
,
I ' ~ . • " , ,
5 a ~~ ~ iI Ii ~n ~ Uill ~ ug 
• • • • ·1 g ·1 m~ I "p "! ,L, ·1 ~~ i 
I ., i t£H i H£B i ~i~ 
~ " 
R~ " li ~ l ~ • " m§ " "~i 0 • • ,Q \ , ~ . un lm , '" • « , E , ! • ~ 3 ~ " 0 II u :m m~ u l . . . . , , , , , , , "' , , , , , , , ! f~!~ , , , , , , , -" " , , , , , , , " Ii ,,, rw -i i • : ~ ! • I 
I I I I 
, Ii , ~ ~ H , ;. n , H~ 
, .1 iBn Un .. , , - ! , • • -
~~ " C , 
,
~ ~ " 





• , . " , 0 , , · ., ~ iliiU ~ ~££. ~ ng • • • • ·1 H \ . 1 ;; "!l~ .1 UH J .1 ! !i~ 
I " i tm i m. 1m 
~ \\: 
,1 ~ " ~~H • ~ " 
U!l~ 
\ : 
~ ~ ~ 
0 • • ,Q , I ! \\ . m t U~fi 
, 
n~ • , E , ! 3 • ~ 






















Crude mortality HR  
n=10875
Adjusted mortality HR 
n=10875
Age (years) 877
  < 1 1427 1221 260 1 1
  1 1779 1588 261 0.74 (0.62 to 0.88) 0.72 (0.39 to 1.33)1
  2-4 3293 3152 187 0.27 (0.23 to 0.33) 0.31 (0.17 to 0.57)1
  5-10 4376 4243 169 0.18 (0.15 to 0.22) 0.28 (0.17 to 0.46)1
Sex
  Male 5515 5178 438 1 1
  Female 5360 5026 439 1.04 (0.91 to 1.18) 1.06 (0.93 to 1.21)
Stage 1615 (15)
  Less advanced 2583 2503 111 1 1
  Advanced 6677 6179 650 2.21 (1.80 to 2.71) 1.93 (1.58 to 2.37)
CD4 percent 3480 (32)
   less than 5 854 766 114 1 1
   5 to 9 1588 1479 143 0.72 (0.57 to 0.91) 0.84 (0.51 to 1.38)2
   10 to 14 2036 1936 141 0.59 (0.47 to 0.75) 0.57 (0.34 to 0.96)2
   ≥ 15 2917 2733 238 0.64 (0.52 to 0.79) 0.59 (0.38 to 0.92)2
Anaemia 3985 (36)
   Severe 588 509 104 1 1
   Moderate 794 710 113 0.80 (0.62 to 1.03) 0.83 (0.64 to 1.08)
   Mild/none 5508 5206 401 0.43 (0.35 to 0.53) 0.61 (0.49 to 0.75)
Weight-for-age z-score 1622 (15)
   ≤ - 3 2715 2373 451 1 1
   -3 to -2 1975 1852 163 0.51 (0.43 to 0.61) 0.90 (0.62 to 1.29)3
   -2 to -1 2258 2191 87 0.27 (0.21 to 0.33) 0.83 (0.57 to 1.21)3
     ≥ -1 2305 2251 70 0.21 (0.17 to 0.27) 0.52 (0.35 to 0.80)3
Analysis based on imputed data                                                  
(25 multiple imputation datasets)
1 HRs are shown for a child with CD4 percent <5%; 2 HRs are shown for a child < 1 year of age;3 HRs are shown for a 




















Model with CD4% Model without CD4%
Variable Adjusted HR (95% CI) Adjusted HR (95% CI)
Age
   <1 year 1 1
   1 year 0.78 (0.66 to 0.93) 0.78 (0.66 to 0.93)
   2 to 4 years 0.34 (0.28 to 0.41) 0.35 (0.29 to 0.43)
   5 to 10 years 0.22 (0.18 to 0.27) 0.25 (0.2 to 0.3)
WHO Clinical Stage
   I or II 1 1
   III or IV 1.39 (1.13 to 1.71) 1.39 (1.13 to 1.72)
CD4%
   <5% 1 not in model
   5-9.9% 0.69 (0.54 to 0.87) not in model
   ≥10% 0.56 (0.45 to 0.68) not in model
Weight-for-age z-score
   <-3 1 1
   -3 to -2 0.66 (0.55 to 0.79) 0.63 (0.53 to 0.76)
   ≥ -2 0.35 (0.29 to 0.42) 0.33 (0.27 to 0.4)
Anemia
   Severe 1 1












Figure 4 (a): Cumulative mortality predicted from prognostic models (dashed coloured lines) compared with 
Kaplan-Meier observed mortality (solid black lines) for five prognostic groups of children commencing 
ART, ranging from worst to best prognosis. Each group contains approximately 20% of deaths.  
Number of patients (%) is shown. 
 
 
Figure 4 (b): Cumulative mortality predicted from prognostic models (dashed red lines) compared with 
Kaplan-Meier observed mortality for each region for patients with the most commonly occurring values of 
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Table S1: Prognostic variables and mortality for children starting ART and not LTFU or TFO during the 









N deaths Crude mortality HR1 Crude mortality HR2 Adjusted mortality HR2 
Age (years) 877 n=9259 n=6428 n=6428
  < 1 1427 1221 260 1 1 1
  1 1779 1588 261 0.73 (0.61 to 0.88) 0.66 (0.53 to 0.82) 0.59 (0.30 to 1.19)3
  2-4 3293 3152 187 0.28 (0.23 to 0.34) 0.28 (0.22 to 0.35) 0.29 (0.16 to 0.56)3
  5-10 4376 4243 169 0.16 (0.13 to 0.20) 0.16 (0.12 to 0.2) 0.23 (0.13 to 0.39)3
Sex n=9259 n=6428 n=6428
  Male 5515 5178 438 1 1 1
  Female 5360 5026 439 0.97 (0.84 to 1.12) 0.99 (0.84 to 1.17) 1.04 (0.88 to 1.23)
Stage 1615 (15) n=9259 n=6428 n=6428
  Less advanced 2583 2503 111 1 1 1
  Advanced 6677 6179 650 2.39 (1.95 to 2.93) 2.65 (2.09 to 3.37) 2.38 (1.87 to 3.03)
CD4 percent 3480 (32) n=6428 n=6428 n=6428
   less than 5 854 766 114 1 1 1
   5 to 9 1588 1479 143 0.72 (0.55 to 0.94) 0.72 (0.55 to 0.94) 0.88 (0.51 to 1.51)4
   10 to 14 2036 1936 141 0.54 (0.41 to 0.71) 0.54 (0.41 to 0.71) 0.49 (0.28 to 0.84)4
   ≥ 15 2917 2733 238 0.57 (0.45 to 0.74) 0.57 (0.45 to 0.74) 0.49 (0.30 to 0.79)4
Plasma HIV-RNA 7839 (72) n=18526 n=17066 n=17066
   <5 log 10 1127 797 31 1 1 1
   5 - 5.99 log 10 1337 1051 80 2.40 (1.45 to 3.96) 2.58 (1.51 to 4.42) 1.73 (1.00 to 3.00)
   ≥ 6 log 572 486 81 4.72 (2.85 to 7.79) 5.10 (2.98 to 8.73) 1.98 (1.12 to 3.51)
Anaemia 3985 (36) n=6307 n=4888 n=4888
   Severe 588 509 104 1 1 1
   Moderate 794 710 113 0.76 (0.58 to 1.00) 0.71 (0.52 to 0.96) 0.71 (0.52 to 0.97)
   Mild/none 5508 5206 401 0.37 (0.30 to 0.47) 0.38 (0.29 to 0.48) 0.51 (0.40 to 0.66)
Weight-for-age z-score 1622 (15) n=8342 n=6120 n=6120
   ≤ - 3 2715 2373 451 1 1 1
   -3 to -2 1975 1852 163 0.49 (0.41 to 0.59) 0.48 (0.39 to 0.60) 1.10 (0.74 to 1.65)5
   -2 to -1 2258 2191 87 0.22 (0.17 to 0.28) 0.22 (0.17 to 0.29) 1.05 (0.68 to 1.61)5
     ≥ -1 2305 2251 70 0.17 (0.13 to 0.22) 0.16 (0.12 to 0.22) 0.45 (0.27 to 0.74)5
Analysis based on available data
1 Only includes patients with complete data on age, sex and stage; 2 Limited to children with complete date on age, sex, stage, CD4% and adjusted for 
these in adjusted analyses; 3 HRs are shown for a child with CD4 percent <5%; 4 HRs are shown for a child age <1 year;    5 HRs are shown for a child <1 year of 













Table S2: Hazard ratios for the associations between age, CD4% and WAZ adjusted for these variables as 
well as WHO Clinical Stage and sex, taking into account the interactions between age and CD4% and age 
and WAZ for (a) complete case data (N=6,428) and (b) data with missing covariate values modeled using 




AGE WAZ CD4% <5 CD4% 5-9.9 CD4% 10-14.9 CD4% ≥ 15
 < 1 year < -3 1 0.68 (0.38 to 1.21) 0.47 (0.27 to 0.82) 0.45 (0.27 to 0.74)
-3 to -2 1.1 (0.74 to 1.65) 0.75 (0.38 to 1.49) 0.52 (0.27 to 1) 0.49 (0.27 to 0.9)
-2 to -1 1.05 (0.68 to 1.61) 0.71 (0.36 to 1.41) 0.49 (0.25 to 0.96) 0.47 (0.25 to 0.87)
≥ -1 0.45 (0.28 to 0.74) 0.31 (0.15 to 0.65) 0.21 (0.1 to 0.44) 0.2 (0.1 to 0.4)
1 year < -3 0.69 (0.34 to 1.42) 0.44 (0.24 to 0.8) 0.61 (0.35 to 1.05) 0.3 (0.17 to 0.53)
-3 to -2 0.53 (0.24 to 1.16) 0.33 (0.17 to 0.64) 0.46 (0.25 to 0.86) 0.23 (0.12 to 0.42)
-2 to -1 0.22 (0.09 to 0.53) 0.14 (0.06 to 0.3) 0.19 (0.09 to 0.41) 0.1 (0.04 to 0.2)
≥ -1 0.12 (0.05 to 0.32) 0.08 (0.03 to 0.19) 0.11 (0.05 to 0.25) 0.05 (0.02 to 0.12)
2-4 years < -3 0.44 (0.22 to 0.85) 0.38 (0.21 to 0.68) 0.22 (0.12 to 0.42) 0.26 (0.15 to 0.47)
-3 to -2 0.14 (0.06 to 0.3) 0.12 (0.06 to 0.24) 0.07 (0.03 to 0.15) 0.08 (0.04 to 0.17)
-2 to -1 0.04 (0.02 to 0.12) 0.04 (0.02 to 0.1) 0.02 (0.01 to 0.06) 0.03 (0.01 to 0.07)
≥ -1 0.09 (0.04 to 0.2) 0.08 (0.04 to 0.16) 0.04 (0.02 to 0.1) 0.05 (0.03 to 0.11)
5-9 years < -3 0.3 (0.17 to 0.55) 0.15 (0.08 to 0.3) 0.1 (0.05 to 0.21) 0.1 (0.05 to 0.21)
-3 to -2 0.16 (0.08 to 0.31) 0.08 (0.04 to 0.17) 0.05 (0.02 to 0.12) 0.05 (0.03 to 0.11)
-2 to -1 0.07 (0.03 to 0.16) 0.04 (0.02 to 0.08) 0.02 (0.01 to 0.06) 0.02 (0.01 to 0.06)
















AGE WAZ CD4% <5 CD4% 5-9.9 CD4% 10-14.9 CD4% ≥ 15
 < 1 year < -3 1 0.87 (0.52 to 1.44) 0.60 (0.36 to 1.00) 0.62 (0.40 to 0.98)
-3 to -2 0.90 (0.62 to 1.29) 0.78 (0.41 to 1.45) 0.54 (0.29 to 0.98) 0.56 (0.32 to 0.97)
-2 to -1 0.83 (0.57 to 1.21) 0.72 (0.38 to 1.36) 0.50 (0.26 to 0.95) 0.52 (0.29 to 0.92)
≥ -1 0.52 (0.35 to 0.80) 0.45 (0.24 to 0.87) 0.31 (0.16 to 0.60) 0.33 (0.18 to 0.59)
1 year < -3 0.88 (0.47 to 1.65) 0.60 (0.35 to 1.02) 0.73 (0.43 to 1.22) 0.49 (0.30 to 0.80)
-3 to -2 0.66 (0.34 to 1.31) 0.45 (0.26 to 0.81) 0.55 (0.31 to 0.98) 0.37 (0.22 to 0.63)
-2 to -1 0.31 (0.15 to 0.67) 0.22 (0.11 to 0.43) 0.26 (0.12 to 0.51) 0.18 (0.09 to 0.33)
≥ -1 0.26 (0.11 to 0.57) 0.17 (0.09 to 0.35) 0.21 (0.11 to 0.41) 0.14 (0.07 to 0.27)
2-4 years < -3 0.50 (0.27 to 0.92) 0.43 (0.25 to 0.73) 0.26 (0.15 to 0.46) 0.32 (0.19 to 0.52)
-3 to -2 0.21 (0.11 to 0.42) 0.18 (0.10 to 0.33) 0.11 (0.06 to 0.15) 0.13 (0.07 to 0.24)
-2 to -1 0.09 (0.04 to 0.20) 0.08 (0.04 to 0.16) 0.05 (0.02 to 0.10) 0.06 (0.03 to 0.12)
≥ -1 0.10 (0.05 to 0.22) 0.09 (0.04 to 0.17) 0.05 (0.03 to 0.11) 0.06 (0.03 to 0.12)
5-9 years < -3 0.41 (0.25 to 0.68) 0.20 (0.11 to 0.35) 0.14 (0.08 to 0.27) 0.14 (0.08 to 0.26)
-3 to -2 0.22 (0.12 to 0.40) 0.11 (0.06 to 0.20) 0.07 (0.04 to 0.15) 0.08 (0.04 to 0.15)
-2 to -1 0.12 (0.06 to 0.23) 0.06 (0.03 to 0.11) 0.04 (0.02 to 0.08) 0.04 (0.02 to 0.08)












Age < 1 year
WHO Stage I or II
WAZ Months Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI
<-3 3 23.1 17.5 to  30.1 17.4 13.6 to  22.0 17.4 13.2 to  22.7 12.9 10.2 to  16.3 14.0 10.8 to 18.0 10.4 8.4 to 12.8
<-3 6 31.3 24.1 to 40.0 23.8 18.9 to 29.9 23.9 18.4 to 30.7 18.0 14.3 to 22.4 19.4 15.1 to 24.7 14.5 11.8 to 17.7
<-3 12 38.5 30.1 to 48.4 29.7 23.8 to 36.8 29.8 23.1 to 37.8 22.6 18.2 to 28.0 24.4 19.2 to 30.7 18.4 15.0 to 22.3
-3 to  -2 3 15.3 11.2 to 20.6 11.3 8.6 to 14.9 11.3 8.3 to 15.3 8.4 6.4 to 10.9 9.1 6.8 to 12.0 6.7 5.2 to 8.5
-3 to  -2 6 21.1 15.6 to 28.1 15.8 12.0 to 20.5 15.8 11.7 to 21.1 11.7 9.0 to 15.1 12.7 9.6 to 16.6 9.4 7.4 to 11.8
-3 to  -2 12 26.4 19.8 to 34.7 19.9 15.3 to 25.7 20.0 15.0 to 26.4 14.9 11.6 to 19.2 16.1 12.3 to 21.0 12.0 9.5 to 15.0
>=-2 3 9.4 6.9 to 12.9 7.0 5.3 to 9.1 7.0 5.1 to 9.4 5.1 4.0 to 6.5 5.5 4.2 to 7.3 4.1 3.3 to 5.0
>=-2 6 13.2 9.7 to 17.9 9.8 7.5 to 12.7 9.8 7.3 to 13.2 7.2 5.6 to 9.2 7.8 6.0 to 10.2 5.7 4.7 to 7.1
>=-2 12 16.8 12.4 to 22.6 12.5 9.6 to 16.1 12.5 9.3 to 16.7 9.2 7.3 to 11.7 10.0 7.7 to 13.1 7.4 6.0 to 9.0
WHO Stage III or IV
WAZ Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI
<-3 3 28.5 22.8 to 35.3 21.6 17.9 to 25.9 21.6 17.2 to 27.0 16.2 13.5 to 19.4 17.5 14.4 to 21.3 13.0 11.3 to 15.0
<-3 6 38.1 31.0 to 46.2 29.4 24.7 to 34.7 29.4 23.7 to 36.1 22.3 18.8 to 26.4 24.1 19.9 to 28.9 18.1 15.9 to 20.6
<-3 12 46.3 38.2 to 55.2 36.3 30.8 to 42.5 36.3 29.6 to 44 27.9 23.7 to 32.7 30.0 25.1 to 35.7 22.8 20.1 to 25.8
-3 to  -2 3 19.0 14.6 to 24.7 14.2 11.2 to 17.9 14.2 10.9 to 18.5 10.5 8.4 to 13.2 11.4 9.0 to 14.4 8.4 7.0 to 10.1
-3 to  -2 6 26.1 20.2 to 33.3 19.7 15.7 to 24.5 19.7 15.2 to 25.3 14.7 11.8 to 18.3 15.9 12.7 to 19.9 11.8 9.9 to 14.1
-3 to  -2 12 32.4 25.4 to 40.8 24.7 19.9 to 30.5 24.8 19.3 to 31.4 18.6 15.1 to 23 20.1 16.1 to 25.0 15.1 12.6 to 17.9
>=-2 3 11.9 8.9 to 15.9 8.8 6.9 to 11.2 8.8 6.6 to 11.7 6.5 5.1 to 8.1 7.0 5.5 to 9.0 5.1 4.3 to 6.2
>=-2 6 16.6 12.5 to 21.9 12.3 9.7 to 15.5 12.3 9.3 to 16.2 9.1 7.3 to 11.4 9.9 7.7 to 12.6 7.3 6.1 to 8.6
>=-2 12 20.9 15.8 to 27.3 15.7 12.4 to 19.6 15.7 11.9 to 20.5 11.6 9.4 to 14.4 12.6 9.9 to 16.0 9.3 7.9 to 11.0
CD4 percent <5% CD4 percent 5-9.9% CD4 percent ≥10%
Severe anaemia Severe anaemia Severe anaemiaModerate/mild/no anaemia Moderate/mild/no anaemia Moderate/mild/no anaemia





















WHO Stage I or II
oderate/mild/no anaemia oderate/mild/no anaemia oderate/mild/no anaemia
WAZ Months Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI
<-3 3 18.5 13.9 to 24.3 13.8 10.7 to 17.6 13.8 10.4 to 18.1 10.2 8.0 to 12.9 11.1 8.5 to 14.3 8.2 6.5 to 10.1
<-3 6 25.3 19.3 to 32.8 19.1 14.9 to 24.2 19.1 14.6 to 24.7 14.3 11.3 to 17.9 15.4 12.0 to 19.7 11.4 9.2 to 14.1
<-3 12 31.5 24.3 to 40.2 24.0 18.9 to 30.1 24.0 18.5 to 30.8 18.1 14.4 to 22.5 19.5 15.3 to 24.8 14.6 11.8 to 17.9
-3 to  -2 3 12.1 8.8 to 16.4 8.9 6.7 to 11.8 8.9 6.6 to 12.0 6.6 5.0 to 8.5 7.1 5.4 to 9.4 5.2 4.1 to 6.6
-3 to  -2 6 16.8 12.4 to 22.5 12.5 9.5 to 16.4 12.5 9.3 to 16.7 9.2 7.1 to 11.9 10.0 7.6 to 13.1 7.4 5.8 to 9.3
-3 to  -2 12 21.2 15.7 to 28.2 15.9 12.1 to 20.7 15.9 11.9 to 21.1 11.8 9.1 to 15.2 12.8 9.7 to 16.7 9.4 7.5 to 11.9
>=-2 3 7.4 5.4 to 10.2 5.4 4.1 to 7.1 5.4 4.0 to 7.4 4.0 3.1 to 5.1 4.3 3.3 to 5.7 3.2 2.5 to 3.9
>=-2 6 10.4 7.6 to 14.2 7.7 5.9 to 10.0 7.7 5.7 to 10.3 5.6 4.4 to 7.2 6.1 4.7 to 8.0 4.5 3.6 to 5.5
>=-2 12 13.3 9.8 to 18.0 9.8 7.6 to 12.8 9.9 7.3 to 13.2 7.3 5.7 to 9.2 7.9 6.0 to 10.3 5.8 4.7 to 7.1
WHO Stage III or IV
WAZ Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI
<-3 3 22.9 18.2 to 28.7 17.2 14.2 to 20.8 17.2 13.7 to 21.5 12.8 10.7 to 15.4 13.9 11.4 to 16.9 10.3 8.9 to 11.9
<-3 6 31.1 25.0 to 38.2 23.7 19.7 to 28.3 23.7 19.1 to 29.2 17.8 15.0 to 21.1 19.2 15.9 to 23.2 14.4 12.5 to 16.5
<-3 12 38.3 31.2 to 46.4 29.5 24.8 to 35.0 29.6 24.0 to 36.1 22.5 19.0 to 26.4 24.2 20.1 to 29.0 18.2 16.0 to 20.7
-3 to  -2 3 15.1 11.5 to 19.7 11.2 8.8 to 14.2 11.2 8.6 to 14.6 8.3 6.6 to 10.4 9.0 7.1 to 11.3 6.6 5.5 to 8.0
-3 to  -2 6 20.9 16.1 to 26.9 15.6 12.4 to 19.6 15.7 12.1 to 20.1 11.6 9.4 to 14.4 12.6 10.0 to 15.8 9.3 7.8 to 11.1
-3 to  -2 12 26.2 20.4 to 33.3 19.8 15.8 to 24.6 19.8 15.4 to 25.2 14.8 12.0 to 18.2 16.0 12.8 to 19.9 11.9 10.0 to 14.1
>=-2 3 9.4 7.0 to 12.6 6.9 5.4 to 8.8 6.9 5.2 to 9.2 5.1 4.0 to 6.3 5.5 4.3 to 7.0 4.0 3.3 to 4.8
>=-2 6 13.1 9.8 to 17.4 9.7 7.6 to 12.3 9.7 7.4 to 12.8 7.1 5.7 to 8.9 7.8 6.1 to 9.9 5.7 4.8 to 6.8
>=-2 12 16.7 12.6 to 21.9 12.4 9.8 to 15.6 12.4 9.4 to 16.2 9.2 7.4 to 11.4 9.9 7.8 to 12.6 7.3 6.2 to 8.7
CD4 percent <5% CD4 percent 5-9.9% CD4 percent ≥10%














WHO Stage I or II
oderate/mild/no anaemia oderate/mild/no anaemia oderate/mild/no anaemia
WAZ Months Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI
<-3 3 8.8 6.5 to 11.8 6.5 5.0 to 8.4 6.5 4.8 to 8.6 4.7 3.7 to 6.1 5.2 3.9 to 6.8 3.8 3.0 to 4.8
<-3 6 12.3 9.2 to 16.4 9.1 7.1 to 11.7 9.1 6.9 to 12.1 6.7 5.3 to 8.5 7.3 5.5 to 9.6 5.3 4.2 to 6.7
<-3 12 15.7 11.8 to 20.7 11.7 9.1 to 14.9 11.7 8.8 to 15.3 8.6 6.8 to 10.9 9.3 7.1 to 12.2 6.9 5.5 to 8.6
-3 to  -2 3 5.6 4.1 to 7.7 4.1 3.1 to 5.5 4.1 3.0 to 5.6 3.0 2.3 to 3.9 3.3 2.4 to 4.4 2.4 1.9 to 3.1
-3 to  -2 6 8.0 5.8 to 10.8 5.8 4.4 to 7.7 5.9 4.3 to 7.9 4.3 3.3 to 5.5 4.7 3.5 to 6.2 3.4 2.7 to 4.3
-3 to  -2 12 10.2 7.5 to 13.8 7.5 5.7 to 9.8 7.5 5.6 to 10.1 5.5 4.3 to 7.1 6.0 4.5 to 7.9 4.4 3.4 to 5.6
>=-2 3 3.4 2.5 to 4.7 2.5 1.9 to 3.2 2.5 1.8 to 3.4 1.8 1.4 to 2.3 2.0 1.5 to 2.6 1.4 1.2 to 1.8
>=-2 6 4.9 3.5 to 6.6 3.5 2.7 to 4.6 3.6 2.6 to 4.8 2.6 2.0 to 3.3 2.8 2.1 to 3.7 2.1 1.7 to 2.5
>=-2 12 6.2 4.6 to 8.5 4.6 3.5 to 5.9 4.6 3.4 to 6.1 3.3 2.7 to 4.2 3.6 2.8 to 4.8 2.7 2.2 to 3.3
WHO Stage III or IV
WAZ Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI
<-3 3 11.1 8.6 to 14.2 8.2 6.6 to 10.1 8.2 6.4 to 10.5 6.0 4.9 to 7.3 6.5 5.2 to 8.2 4.8 4.0 to 5.7
<-3 6 15.5 12.1 to 19.7 11.5 9.4 to 14.0 11.5 9.0 to 14.6 8.5 7.0 to 10.3 9.2 7.4 to 11.5 6.8 5.7 to 8.0
<-3 12 19.6 15.4 to 24.7 14.6 12.0 to 17.8 14.6 11.6 to 18.5 10.9 9.0 to 13.1 11.8 9.4 to 14.6 8.7 7.4 to 10.2
-3 to  -2 3 7.1 5.4 to 9.5 5.2 4.1 to 6.7 5.2 4.0 to 6.9 3.8 3.0 to 4.8 4.2 3.2 to 5.4 3.0 2.5 to 3.7
-3 to  -2 6 10.1 7.6 to 13.2 7.4 5.8 to 9.4 7.4 5.7 to 9.7 5.4 4.3 to 6.8 5.9 4.6 to 7.5 4.3 3.6 to 5.3
-3 to  -2 12 12.8 9.8 to 16.7 9.5 7.5 to 11.9 9.5 7.3 to 12.4 7.0 5.6 to 8.7 7.6 5.9 to 9.6 5.6 4.6 to 6.7
>=-2 3 4.3 3.2 to 5.9 3.2 2.5 to 4.1 3.2 2.4 to 4.2 2.3 1.8 to 2.9 2.5 1.9 to 3.3 1.8 1.5 to 2.2
>=-2 6 6.2 4.6 to 8.2 4.5 3.5 to 5.7 4.5 3.4 to 6.0 3.3 2.6 to 4.1 3.6 2.8 to 4.6 2.6 2.2 to 3.1
>=-2 12 7.9 5.9 to 10.5 5.8 4.6 to 7.3 5.8 4.4 to 7.7 4.3 3.4 to 5.3 4.6 3.6 to 5.9 3.4 2.8 to 4.0
CD4 percent <5% CD4 percent 5-9.9% CD4 percent ≥10%


















WHO Stage I or II
oderate/mild/no anaemia oderate/mild/no anaemia oderate/mild/no anaemia
WAZ Months Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI
<-3 3 6.2 4.6 to 8.3 4.5 3.5 to 5.8 4.5 3.3 to 6.1 3.3 2.6 to 4.2 3.6 2.7 to 4.8 2.6 2.1 to 3.3
<-3 6 8.7 6.5 to 11.6 6.4 5.0 to 8.2 6.4 4.8 to 8.6 4.7 3.7 to 6.0 5.1 3.8 to 6.8 3.7 2.9 to 4.7
<-3 12 11.1 8.3 to 14.8 8.2 6.5 to 10.4 8.2 6.1 to 11.0 6.0 4.7 to 7.7 6.6 4.9 to 8.7 4.8 3.8 to 6.1
-3 to  -2 3 3.9 2.9 to 5.4 2.9 2.2 to 3.8 2.9 2.1 to 3.9 2.1 1.6 to 2.7 2.3 1.7 to 3.1 1.7 1.3 to 2.1
-3 to  -2 6 5.6 4.1 to 7.6 4.1 3.1 to 5.3 4.1 3.0 to 5.6 3.0 2.3 to 3.9 3.2 2.4 to 4.4 2.4 1.8 to 3.0
-3 to  -2 12 7.2 5.3 to 9.7 5.3 4.0 to 6.8 5.3 3.9 to 7.2 3.8 3.0 to 5.0 4.2 3.1 to 5.6 3.1 2.4 to 3.9
>=-2 3 2.4 1.7 to 3.3 1.7 1.3 to 2.2 1.7 1.3 to 2.4 1.3 1 .0 to 1.6 1.4 1.0 to 1.8 1.0 0.8 to 1.2
>=-2 6 3.4 2.5 to 4.6 2.5 1.9 to 3.2 2.5 1.8 to 3.4 1.8 1.4 to 2.3 2.0 1.5 to 2.6 1.4 1.1 to 1.8
>=-2 12 4.4 3.2 to 5.9 3.2 2.5 to 4.1 3.2 2.4 to 4.3 2.3 1.8 to 2.9 2.5 1.9 to 3.4 1.8 1.5 to 2.3
WHO Stage III or IV
WAZ Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI Probability (%) 95% CI
<-3 3 7.8 6.1 to 10.0 5.7 4.7 to 7.0 5.7 4.4 to 7.5 4.2 3.4 to 5.1 4.6 3.6 to 5.9 3.3 2.8 to 4.0
<-3 6 11.0 8.6 to 14.0 8.1 6.7 to 9.8 8.1 6.3 to 10.5 5.9 4.9 to 7.2 6.5 5.1 to 8.2 4.7 4.0 to 5.7
<-3 12 14.0 11.0 to 17.7 10.4 8.6 to 12.5 10.4 8.1 to 13.3 7.6 6.3 to 9.3 8.3 6.5 to 10.5 6.1 5.1 to 7.3
-3 to  -2 3 5.0 3.8 to 6.6 3.7 2.9 to 4.6 3.7 2.7 to 4.9 2.7 2.1 to 3.4 2.9 2.2 to 3.8 2.1 1.7 to 2.6
-3 to  -2 6 7.1 5.4 to 9.3 5.2 4.1 to 6.5 5.2 3.9 to 6.9 3.8 3.0 to 4.7 4.1 3.2 to 5.4 3.0 2.5 to 3.7
-3 to  -2 12 9.1 6.9 to 11.8 6.7 5.4 to 8.3 6.7 5.0 to 8.8 4.9 3.9 to 6.1 5.3 4.1 to 6.9 3.9 3.2 to 4.7
>=-2 3 3.0 2.2 to 4.1 2.2 1.8 to 2.8 2.2 1.6 to 3.0 1.6 1.3 to 2.0 1.8 1.3 to 2.3 1.3 1.0 to 1.6
>=-2 6 4.3 3.2 to 5.8 3.1 2.5 to 3.9 3.1 2.3 to 4.2 2.3 1.8 to 2.9 2.5 1.9 to 3.3 1.8 1.5 to 2.2
>=-2 12 5.5 4.1 to 7.4 4.1 3.2 to 5.0 4.1 3.0 to 5.4 3.0 2.4 to 3.7 3.2 2.5 to 4.2 2.3 1.9 to 2.8
CD4 percent <5% CD4 percent 5-9.9% CD4 percent ≥10%




















Appendix Table S3 (b): Estimates of cumulative mortality at 3, 6 and 12 months after ART 
start from the model without CD4%  
 
Age < 1 year
WHO Stage I or II
WAZ Months Probability (%) 95% CI Probability (%) 95% CI
<-3 3 15.8 12.3 to 20.2 11.6 9.4 to 14.2
<-3 6 21.8 17.2 to 27.5 16.1 13.2 to 19.5
<-3 12 27.3 21.7 to 34.0 20.3 16.8 to 24.5
-3 to -2 3 10.0 7.5 to 13.1 7.2 5.7 to 9.1
-3 to -2 6 13.9 10.6 to 18.1 10.1 8.1 to 12.7
-3 to -2 12 17.6 13.5 to 22.8 12.9 10.3 to 16.1
>=-2 3 6.0 4.5 to 7.9 4.3 3.5 to 5.3
>=-2 6 8.4 6.4 to 11.0 6.1 5.0 to 7.5
>=-2 12 10.8 8.3 to 14.0 7.8 6.4 to 9.5
WHO Stage III or IV
WAZ Probability (%) 95% CI Probability (%) 95% CI
<-3 3 19.7 16.3 to 23.8 14.5 12.7 to 16.5
<-3 6 26.9 22.5 to 32.0 20.1 17.8 to 22.6
<-3 12 33.4 28.2 to 39.3 25.2 22.4 to 28.2
-3 to -2 3 12.5 9.9 to 15.7 9.1 7.6 to 10.9
-3 to -2 6 17.4 13.9 to 21.6 12.8 10.7 to 15.1
-3 to -2 12 21.9 17.7 to 27.1 16.2 13.7 to 19.1
>=-2 3 7.6 5.9 to 9.7 5.5 4.6 to 6.5
>=-2 6 10.6 8.3 to 13.5 7.7 6.5 to 9.1
>=-2 12 13.5 10.7 to 17.1 9.9 8.3 to 11.7
Age 1 year
WHO Stage I or II
WAZ Months Probability (%) 95% CI Probability (%) 95% CI
<-3 3 12.5 9.7 to 16.0 9.1 7.4 to 11.2
<-3 6 17.4 13.6 to 22.0 12.7 10.4 to 15.5
<-3 12 21.9 17.3 to 27.5 16.2 13.3 to 19.6
-3 to -2 3 7.8 5.9 to 10.3 5.6 4.4 to 7.1
-3 to -2 6 11.0 8.4 to 14.3 8.0 6.3 to 10.0
-3 to -2 12 14.0 10.7 to 18.1 10.2 8.1 to 12.8
>=-2 3 4.7 3.5 to 6.1 3.4 2.7 to 4.1
>=-2 6 6.6 5.0 to 8.6 4.8 3.9 to 5.8
>=-2 12 8.5 6.5 to 11.0 6.1 5.0 to 7.5
WHO Stage III or IV
WAZ Probability (%) 95% CI Probability (%) 95% CI
<-3 3 15.7 12.9 to 19.0 11.5 10.0 to 13.1
<-3 6 21.6 18.0 to 25.8 16.0 14.1 to 18.1
<-3 12 27.1 22.7 to 32.1 20.2 17.9 to 22.7
-3 to -2 3 9.9 7.8 to 12.4 7.1 6.0 to 8.6
-3 to -2 6 13.8 11.0 to 17.2 10.0 8.4 to 11.9
-3 to -2 12 17.5 14.1 to 21.6 12.8 10.8 to 15.2
>=-2 3 5.9 4.6 to 7.6 4.3 3.6 to 5.1
>=-2 6 8.3 6.5 to 10.6 6.0 5.1 to 7.2


















WHO Stage I or II
WAZ Months Probability (%) 95% CI Probability (%) 95% CI
<-3 3 6.1 4.6 to 7.9 4.4 3.5 to 5.5
<-3 6 8.6 6.6 to 11.1 6.2 5.0 to 7.7
<-3 12 11.0 8.5 to 14.1 8.0 6.4 to 9.8
-3 to -2 3 3.7 2.8 to 5.0 2.7 2.1 to 3.4
-3 to -2 6 5.3 4.0 to 7.0 3.8 3.0 to 4.8
-3 to -2 12 6.8 5.2 to 9.0 4.9 3.9 to 6.2
>=-2 3 2.2 1.7 to 2.9 1.6 1.3 to 2.0
>=-2 6 3.2 2.4 to 4.1 2.3 1.8 to 2.8
>=-2 12 4.1 3.1 to 5.3 2.9 2.4 to 3.6
WHO Stage III or IV
WAZ Probability (%) 95% CI Probability (%) 95% CI
<-3 3 7.7 6.2 to 9.6 5.6 4.7 to 6.5
<-3 6 10.8 8.7 to 13.3 7.8 6.7 to 9.1
<-3 12 13.8 11.2 to 16.9 10.0 8.7 to 11.6
-3 to -2 3 4.8 3.7 to 6.1 3.4 2.8 to 4.1
-3 to -2 6 6.7 5.3 to 8.5 4.8 4.0 to 5.8
-3 to -2 12 8.6 6.8 to 10.9 6.2 5.2 to 7.5
>=-2 3 2.8 2.2 to 3.6 2.0 1.7 to 2.4
>=-2 6 4.0 3.1 to 5.2 2.9 2.4 to 3.4
>=-2 12 5.2 4.0 to 6.6 3.7 3.1 to 4.4
Age < 5-10 years
WHO Stage I or II
WAZ Months Probability (%) 95% CI Probability (%) 95% CI
<-3 3 4.6 3.5 to 6.0 3.3 2.6 to 4.1
<-3 6 6.5 4.9 to 8.5 4.7 3.8 to 5.8
<-3 12 8.3 6.3 to 10.8 6.0 4.8 to 7.4
-3 to -2 3 2.8 2.1 to 3.8 2.0 1.6 to 2.6
-3 to -2 6 4.0 3.0 to 5.3 2.9 2.3 to 3.6
-3 to -2 12 5.1 3.9 to 6.8 3.7 2.9 to 4.6
>=-2 3 1.7 1.2 to 2.2 1.2 1.0 to 1.5
>=-2 6 2.4 1.8 to 3.1 1.7 1.4 to 2.1
>=-2 12 3.1 2.3 to 4.0 2.2 1.8 to 2.7
WHO Stage III or IV
WAZ Probability (%) 95% CI Probability (%) 95% CI
<-3 3 5.8 4.6 to 7.3 4.2 3.6 to 4.9
<-3 6 8.2 6.5 to 10.2 5.9 5.1 to 6.9
<-3 12 10.5 8.4 to 13.0 7.6 6.5 to 8.8
-3 to -2 3 3.6 2.8 to 4.6 2.6 2.1 to 3.1
-3 to -2 6 5.1 3.9 to 6.5 3.6 3.0 to 4.4
-3 to -2 12 6.5 5.1 to 8.3 4.7 3.9 to 5.6
>=-2 3 2.1 1.6 to 2.8 1.5 1.3 to 1.8
>=-2 6 3.0 2.3 to 3.9 2.2 1.8 to 2.6
















Table S4: Characteristics of children included in the main analysis compared to those 
excluded due to being LTFU or TFO within the first 6 months of treatment. P-values derived 
from Wilcoxon rank sum tests and chi2 tests for differences in medians and proportions 
between the 2 groups for continuous variables and categorical variables respectively. 
 
 
No (N=10875) Yes  (N=1780) p-va lue
AGE
    Median age in months  (IQR) 47 (21 to 80) 27 (14 to 64) <0.001
     <24 months  of age (%) 29% 46% <0.001
STAGE
    WHO Stage II I/IV disease (%) 72% 78% <0.001
CD4 PERCENT
    Median CD4% (IQR) 13.0 (8.3 to 18.5) 14.3 (9.4 to 21.2) <0.001
ANAEMIA
    Severe anaemia  (%) 9% 13% <0.001
WAZ
    Median WAZ (IQR) -2.03 (-3.23 to -1.01) -2.64 (-3.99 to -1.40) <0.001
    WAZ <-3 (%) 29% 43% <0.001












2.4 Virologic Failure and Second-Line Antiretroviral Therapy in 
Children in South Africa—The IeDEA Southern Africa Collaboration 
 
Paper overview 
This paper reports on the probability and predictors of confirmed virological failure (VF) 
(>1000 copies/ml) for up to three years on ART among children treated at South African 
IeDEA SA sites. It also describes the proportion of children with VF switched to second-line 
therapy and predictors of switch.    
Contribution to the thesis and novelty 
This paper examines the measurement of treatment success in South Africa and thus 
addresses the third objective of the thesis. It remains the largest published study of VF in 
children and one of two studies152 to provide estimates of confirmed VF over an extended 
period of time in the context of a programme with routine HIV-RNA monitoring. The finding 
that 20% of children will meet the definition of VF by three years after ART initiation is 
useful for programme planning. The paper also identified that VF was more likely in children 
treated with NVP- based compared to LPV/r-based regimens irrespective of PMTCT 
exposure, a finding that has now been confirmed by the P1060 trial.130 Triple ART including 
unboosted RTV was also associated with a higher risk of VF compared to EFV-based or 
LPV/r-based regimens. Delayed switching and between-site heterogeneity in switching 
practice highlighted the need for clearer guidelines for management of patients with 
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Children in South Africa—The IeDEA Southern
Africa Collaboration
Mary-Ann Davies, MD, MMed,* Harry Moultrie, MD, MSc,† Brian Eley, BSc (Hons), MD,‡
Helena Rabie, MD, MMed,§ Gilles Van Cutsem, MD, DTM&H, MPH,*k
Janet Giddy, MD, DipPHCEd, MMed,¶ Robin Wood, BSc, BM, MD, MMed,#
Karl Technau, MD, DCH, Dip HIV Man, MSc,** Olivia Keiser, PhD,††
Matthias Egger, MD, MSc, DTM&H,†† and Andrew Boulle, MD, PhD* for the International
Epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) Collaboration
Background: With expanding pediatric antiretroviral therapy
(ART) access, children will begin to experience treatment failure
and require second-line therapy. We evaluated the probability
and determinants of virologic failure and switching in children in
South Africa.
Methods: Pooled analysis of routine individual data from children
who initiated ART in 7 South African treatment programs with
6-monthly viral load and CD4 monitoring produced Kaplan-Meier
estimates of probability of virologic failure (2 consecutive unsup-
pressed viral loads with the second being .1000 copies/mL, after
$24 weeks of therapy) and switch to second-line. Cox-proportional
hazards models stratified by program were used to determine
predictors of these outcomes.
Results: The 3-year probability of virologic failure among 5485
children was 19.3% (95% confidence interval: 17.6 to 21.1). Use of
nevirapine or ritonavir alone in the initial regimen (compared with
efavirenz) and exposure to prevention of mother to child transmission
regimens were independently associated with failure [adjusted hazard
ratios (95% confidence interval): 1.77 (1.11 to 2.83), 2.39 (1.57 to
3.64) and 1.40 (1.02 to 1.92), respectively]. Among 252 children
with $1 year follow-up after failure, 38% were switched to second-
line. Median (interquartile range) months between failure and switch
was 5.7 (2.9–11.0).
Conclusions: Triple ART based on nevirapine or ritonavir as
a single protease inhibitor seems to be associated with a higher risk of
virologic failure. A low proportion of virologically failing children
were switched.
Key Words: antiretroviral therapy, children, resource-limited setting,
second-line therapy, virologic failure
(J Acquir Immune Defic Syndr 2011;56:270–278)
INTRODUCTION
With expanding access to antiretroviral therapy (ART)
for HIV-infected children, increasing numbers are likely to
experience treatment failure and require second-line regimens.
Before 2010, WHO pediatric guidelines did not define
virologic failure (VF) and viral load monitoring remains
unavailable in most resource-limited settings.1,2 In contrast,
industrialized country guidelines stipulate strict viral load
criteria for switching at thresholds as low as 2 consecutive
measurements .400 copies per milliliter.3,4
Due to poor access to viral load monitoring in resource-
limited settings, there is limited published data on VF in
children.1 Existing studies are limited by cohort size, exclusive
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use of non-nucleoside reverse transcriptase inhibitor (NNRTI)–
based regimens and/or failure definitions based on a single
elevated viral load measurement.5–9 Poor access to and lack of
experience with second-line therapy, and national policies that
may restrict second-line use, have resulted in low numbers and
proportions of children being switched even in larger
cohorts.5,6,10–14 Predictors of which children are switched in
resource-limited settings have therefore not been examined.
The International epidemiologic Databases to Evaluate
AIDS (IeDEA) Southern Africa collaboration includes 7 South
African pediatric ART programs with data on more than 6000
children who had initiated treatment before 2008.15,16 Regular
viral load monitoring (at least 6-monthly) is part of routine
ART care in South Africa.17 However, until 2010, national
pediatric treatment guidelines did not provide clear direction
on management of VF.17 We aimed to examine the probability
of VF and its associations, and, in children with VF, to
determine the probability of switching to second-line and
identify factors that predicted which children were switched.
METHODS
Study Design, Setting and Population
Data for this multicenter analysis were collected
prospectively at sites. Each site has institutional ethical
approval for contribution of data to IeDEA analyses and
transferred data anonymously to the IeDEA data center
between May 2007 and February 2008. The analysis included
treatment-naive children (,16 years) initiating ARTwith $3
antiretroviral drugs between June 1999 and February 2008.
Treatment Regimens
All treatment sites are part of the South African national
treatment program that commenced in April 2004 with the
following first-line regimen guidelines: stavudine (d4T),
lamivudine (3TC), and either efavirenz (EFV) or if ,3
years/,10kg, a protease inhibitor (PI).17 For most children,
this was lopinavir/ritonavir (LPV/r), however, ritonavir alone
(RTV) was recommended for childre with tuberculosis or,6
months old.17 The latter 2 recommendations changed during
2007; LPV/r with additional RTV boosting was introduced for
children with tuberculosis, and LPV/r dosing recommenda-
tions became available for children ,6 months old.18,19 Some
cohorts introduced these practices before 2007, and also used
more varied regimens before commencement of the national
program, including NNRTI-based regimens in children
,3 years old, RTV alone as the ‘‘third drug’’ in children of
all ages, and zidovudine (ZDV) instead of d4T. National
guidelines were otherwise adhered to in all provinces and
permitted restricted individual drug substitution for intoler-
ance or nonavailability of the recommended drug in suitable
formulation.17
National guidelines second-line regimens were ZDV +
didanosine with either LPV/r (EFV-based first line), or an
NNRTI (PI-based first line).17 The NNRTI was nevirapine
(NVP) for children ,3 years old at switch, and EFV for
older children.17
Decisions to switch could be made by the program
clinician without formal Department of Health approval.
Second-line regimens were accessible at all sites.
National guidelines advised single dose NVP (sdNVP)
for mother and infant for prevention of mother to child
transmission (PMTCT), with triple ART for pregnant women
with WHO stage 4 disease or CD4 #200 cells per
microliter.20,21 However, in the Western Cape province,
PMTCT programs began before national roll-out, with
a variety of regimens being used including sdNVP or ZDV
from 34 weeks 6 sdNVP. Similarly, after national implemen-
tation of the sdNVP regimen, the Western Cape province and
McCord Hospital used more effective PMTCT regimens
(Table 1).22
Key Variables
Sociodemographic and clinical data at ART start
included age, gender, clinical stage [stage 3 (2002 3-stage
WHO classification) and stages 3/4 (2005 4-stage WHO
classification) were combined],23,24 exposure to PMTCT
regimens and starting regimen. Weight, viral load, CD4
absolute count and percent were available at ART start and
6-monthly thereafter. Access to viral load and CD4 measure-
ment was similar across sites. Viral load measurements were
performed using Amplicor 1.5 (Roche Diagnostics, Basel,
Switzerland) or NucliSens EasyQ assays (bioMerieux,
Durham, NC), which have good comparability.25 Severe
immune suppression was defined according to WHO guide-
lines.2 ‘‘Baseline’’ measurements were those taken closest to
ART initiation and within 6 months (CD4 and viral load) or 2
weeks (weight) prior, to 1 week after commencing ART. Sex-
adjusted weight-for-age z scores (WAZ) were calculated using
WHO 2007 reference values for children #10 years of age.26
Outcomes
VF was defined as 2 consecutive (#12 months apart)
viral load measurements $400 copies per milliliter with the
second being.1000 copies per milliliter, and both taken after
24 weeks on ART, and not during a treatment interruption.
Sensitivity analyses used different thresholds (400, 5000 and
10,000 copies/mL) to define VF. Children were considered to
have switched to second-line if any of the following occurred
,1 year after a viral load measurement .400 copies per
milliliter: (1) commencement of $2 new drugs including
a class switch from PI to NNRTI or vice versa; (2) class switch
from NNRTI to PI or vice versa only, with reason documented
as treatment failure; or (3) change of both NRTIs and change
from RTV to LPV/r with reason documented as treatment
failure. Immunologic failure was defined according to South
African guidelines criteria for switching as either CD4%
below baseline value after 24 weeks of therapy or CD4%
,50% of peak value during preceding treatment.
Analysis
Continuous and categorical variables were summarized
using medians and interquartile ranges (IQR) and proportions,
respectively. Kaplan-Meier probabilities of virologic and
immunologic failure and switch were estimated. Predictors
of failure and switch were determined using Cox-proportional
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hazards models stratified by site to account for between-site
heterogeneity. Only children with $6 months of follow-up
after failure were included in the switch model. The following
variables were included a priori in multivariable models: age,
gender, and immune suppression at ART initiation (failure
model); age, gender and treatment duration at time of failure
(switch model). Thereafter, multivariable models retained
variables with adjusted P values ,0.1. In comparison to
known lack of PMTCT exposure, missing PMTCT exposure
information had no effect on failure, so these categories were
combined. Separate failure models were generated including
and excluding WAZ and stage, as missing data for these
variables and exclusion of children .10 years old due to lack
of WHO WAZ reference values substantially reduced the
number of children that could be included in the model. The
proportional hazards assumption was met for all models.
Statistical analyses were performed using Stata version 10
(STATA Corporation, College Station, TX).
RESULTS
Data from all South African IeDEA sites providing
pediatric ART were included (Table 1). This comprised 6266
children of whom 781 (12%) were excluded for the following
reasons: missing or inconsistent baseline data (n = 85), non-
naı̈ve (n = 39), mono/dual therapy (n = 64) and starting
regimen not recorded (n = 593). The final dataset comprised
5485 children (49% female) with median (IQR) follow-up of
16 (6–29) months. During follow-up, 344 (6%) children died,
411 (7%) were lost to follow-up and 885 (16%) were
transferred out after median durations of 1.5, 5.8, and 12.9
months, respectively. There were 13,877 viral load and 12,749
CD4 percent measurements during follow-up with median
(IQR) intervals between measurements of 168 (104–190) and
168 (126–197) days, respectively.
Most children were severely ill at ART start (Table 2).
The median (IQR) age of children commencing ART was 42
(15–82) months. The NRTI backbone was d4T/3TC for 89%
of children. The most common ‘‘third’’drugs were EFV (55%),
LPV/r (33%), RTV alone (7%), and NVP (5%).
Virologic Failure
The estimated probability of failure (second elevated
value $ 1,000 copies/mL) by 36 months was 19.3% [95%
confidence interval (CI): 17.6 to 21.1, Fig. 1]. Of the 523
children with VF, 311 (59%) had never been virologically
suppressed. Among these children whose viral load was never
,400 copies per milliliter, 217 had both baseline and
$1 subsequent viral load measurement performed between
6 and 15 months on ART, and 121 (55%) showed a virologic
response to therapy ($1 log10 reduction from baseline viral
load during the first year on ART). Using different thresholds
for the second unsuppressed viral load, the 36-month
estimated probability of failure ranged from 14.6%
(95% CI: 13.1 to 16.3) (cut-off = 10,000 copies/mL) to
21.1% (95% CI: 19.3 to 23.0) (cut-off = 400 copies/mL)
(Fig. 1). By 1 year and 3 years on ART, the estimated
probabilities of a single viral load measurement.1,000 copies
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*This is the PMTCT intervention available through the public health system within the province in which each site is located. It is not necessarily the intervention that each individual
child attending that facility received, as individual program PMTCT regimens varied and mothers may have accessed antenatal care in other provinces/programs.
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per milliliter were 16.9% (95% CI: 15.8 to 18.1) and 32.1%
(95% CI: 30.2 to 34.1), respectively. By 3 years, 384 children
had immunologic failure with an estimated cumulative
probability of 12.6% (95% CI: 11.3 to 13.0). The probability
of immunologic failure was lower than that for all definitions
of VF, except in the early months as the immunologic failure
definition did not require confirmation.
In the multivariable model of associations with VF, viral
load .1 million copies per milliliter at ART initiation was the
only disease characteristic that predicted failure (Table 3).
After adjustment for gender, age, baseline viral load, and
immune suppression, failure risk was increased with use of
either NVP [adjusted hazard ratio (aHR): 1.77; 95%CI: 1.11 to
2.83] or RTV alone (aHR: 2.39; 95% CI: 1.57 to 3.64)
compared with EFV in the initial regimen. Known PMTCT
exposure was also associated with failure (aHR: 1.40; 95%
CI: 1.02 to 1.92). Results were very similar using different
thresholds to define VF. Results were also similar if addi-
tionally adjusted for WHO stage and WAZ, neither of which
remained independently associated with failure. A further
model was developed excluding children with virologic non-
response, and results were similar except for an attenuated
effect of PMTCT. Results of all additional analyses are shown
in (see Table, Supplemental Digital Content 1,
http://links.lww.com/QAI/A146).
Switching to Second-Line
The estimated probability of switching to second-line
by 3 years after ART initiation for all children was 6.2%
(95% CI: 5.2 to 7.5, Fig. 1). Of the 153 children switched,






With VF, n = 523
Children With
VF Switched to
Second-Line, n = 145*
Female 2674 (49%) 235 (45%) 51 (35%)
Median (IQR) age (mo)
At ART start 42 (15–82) 37 (13–86) 60 (16–94)
At failure NA 51 (26–103) 74 (29–108)
,12 months of age at ART start 1158 (21%) 123 (23%) 26 (18%)
Severe immune suppression
At ART start 3690/4577 (81%) 384/447 (86%) 119/128 (93%)
At failure NA 184/493 (37%) 57/138 (41%)
Median (IQR) CD4 percent
At ART start, n 12 (7–17) 10 (5–15), 408 7 (3–12), 118
At failure, n NA 20 (14–26), 464 18 (12–25), 127
WHO stage 3 or 4 at ART start 2887/3832 (75%) 275/374 (74%) 88/116 (76%)
Viral load . 1 million copies/mL
At ART start 777/3745 (21%) 110/388 (28%) 29/111 (26%)
At failure NA 13/524 (2%) 4/145 (3%)
Median (IQR) log viral load
At ART start, n 5.3 (4.7–5.9) 5.6 (5.0–6.1), 388 5.6 (5.0–6.1), 111
At failure; n NA 4.2 (3.7–4.9), 524 4.4 (3.9–5.1), 145
Weight-for-age z score , 22
At ART start 1759/3646 (48%) 170/329 (52%) 46/89 (52%)
At failure NA 73/385 (19%) 22/103 (21%)
Median (IQR) weight-for-age z score
At ART start, n 21.93 (23.36 to 20.96), 3646 22.08 (23.43 to 21.07), 329 22.14 (23.31 to 20.96), 89
At failure, n NA 20.87 (21.74 to 20.12), 385 20.79 (21.74 to 20.13), 103
PMTCT exposure
Exposed 556 (10%) 67 (13%) 14 (10%)
Known unexposed 1644 (30%) 176 (34%) 61 (42%)
Exposure status unknown 3285 (60%) 280 (53%) 70 (48%)
First-line regimen
d4T and 3TC based 4857 (89%) 420 (80%) 103 (71%)
Nevirapine as third drug 254 (5%) 45 (9%) 20 (14%)
Efavirenz as third drug 3030 (55%) 251 (48%) 88 (61%)
LPV/r as third drug 1819 (33%) 140 (27%) 10 (7%)
Ritonavir alone as third drug 382 (7%) 88 (17%) 27 (19%)
*Eight children were switched to second-line who did not meet criteria for VF but had viral load.400 copies per milliliter preceding switch. These children are excluded from this
column.
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8 did not meet the VF criteria because there was only 1
unsuppressed viral load measurement (n = 7), or consecutive
measurements were both before 24 weeks on ART (n = 1).
Of 252 children with $1 year of follow-up after failure,
38% (95% CI: 32% to 45%) were switched. The median (IQR)
time to switch from failure was 5.7 (2.9–11.0) months and
from first unsuppressed viral load was 9.5 (5.5–14.6) months.
The median (IQR) interval between consecutive unsuppressed
viral load measurements was 3.2 (2.5–5.4) months.
Most second-line regimens included didanosine as one
of the NRTIs (108 of 153; 71%). Other NRTIs included ZDV
(66%), 3TC (25%); d4T (21%); abacavir (13%), and tenofovir
(1%). The ‘‘third drug’’ in the regimen was LPV/r for 74%
of children.
After adjustment for age at ART initiation, gender and
treatment duration, children with more severe or progressive
disease from the time of failure (higher viral load, CD4%,25
at switch, CD4% decline .1 percentage point per month
between switch date and preceding visit) were more likely
to be switched, while taking a PI-based initial regimen
was negatively associated with switch (aHR: 0.40; 95%
CI: 0.17 to 0.91) (Table 4). Failure to initially attain viral load
,400 copies per milliliter after starting ART was not
associated with switch in univariable or multivariable analysis.
(aHR: 1.02; 95% CI: 0.52 to 1.99).
DISCUSSION
Main Findings
This study reports in detail on confirmed VF and
switching in children on ART in a large African multicenter
FIGURE 1. Kaplan-Meier probability of virologic failure using
different viral load values (measured in copies/mL) to define
failure, and immunologic failure and switch. Solid lines indicate
VF defined as 2 consecutive unsuppressed viral loads with the
second viral load being above the threshold value indicated;
dashed line indicates immunologic failure; dash-dot line
indicates switch to second-line. Note: The numbers in
parentheses in the risk table refer to VF events defined as 2
consecutive viral load measurements .400 copies per milliliter
with second viral load .1,000 copies per milliliter, and this is
used as the definition of failure in analyses.
TABLE 3. Univariable and Multivariable Associations With Virologic Failure in All Children Commenced on ART (Cox-proportional
Hazards Model Stratified by Site)
Failure Definition
2 Consecutive Unsuppressed




(95% CI) n = 5485 P
Adjusted HR
(95% CI), n = 3605 P
Age
$2 yrs 1 ,0.001* 1 0.934*
1–2 yrs 1.37 (1.07 to 1.75) 1.02 (0.71 to 1.48)
,1 year 1.83 (1.47 to 2.28) 1.07 (0.74 to 1.56)
Female gender 0.88 (0.74 to 1.05) 0.16 0.92 (0.75 to 1.13) 0.442
Viral load . 1 million copies/mL 2.05 (1.63 to 2.58) ,0.001 1.67 (1.28 to 2.16) ,0.001
Severe immune suppression 1.48 (1.13 to 1.95) 0.004 1.25 (0.94 to 1.68) 0.131
WHO stage 3 or 4 (vs. 1 or 2)† 1.35 (1.06 to 1.73) 0.016 — —
Weight-for-age z score , 23† 1.34 (1.06 to 1.69) 0.014 — —
Third drug in regimen
Efavirenz 1 — 1 —
Nevirapine 1.96 (1.37 to 2.80) ,0.001 1.77 (1.11 to 2.83) 0.016
Lopinavir/ RTV 1.36 (1.10 to 1.67) 0.004 1.07 (0.76 to 1.51) 0.701
Ritonavir alone 3.06 (2.31 to 4.04) ,0.001 2.39 (1.57 to 3.64) ,0.001
PMTCT exposure
Unexposed/unknown 1 — 1 —
Exposed 1.64 (1.25 to 2.14) ,0.001 1.40 (1.02 to 1.92) 0.039
Year of ART initiation‡
.2005 1 — — —
#2005 0.83 (0.66 to 1.04) 0.1 — —
*The P value was derived from Wald’s test.
†Not included in multivariable model as missing information would have limited overall number of children that could be included.
‡Not included in multivariable model as P . 0.1 after adjustment for other variables in the model.
HR, hazard ratio.
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study where routine viral load monitoring was available. One
in 5 children had met the analysis definition of confirmed
VF by 3 years on ART. Baseline viral load .1 million copies
per milliliter, use of either NVP, or RTV as a sole PI, and
PMTCT exposure independently predicted failure. Less than
half of children with $1 year of follow-up after failure were
switched, with a median interval between failure and switch of
5.7 months. Across all sites, current poor immunologic and
virologic status together with being on an NNRTI-based
regimen favored switch.
Time to VF
Previous studies from Thaila d and Uganda with all
children on NNRTI-based regimens and failure defined using
a single viral load measurement, reported similar proportions
of children with VF at 12 months on ART as we report at
36 months using confirmed measurements.5,6 Similarly, a
recent cohort study found the frequency of consecutive viral
load measurements .400 copies per milliliter among 116
children with follow-up $6 months to be 17%.8 Nevertheless,
the cumulative probability of a single elevated viral load
measurement after 1 year on ART in our study (16%) is similar
to the Thai and Ugandan studies. In contrast, prevalence of
a single viral load measurement.400 copies per milliliter was
32% at a Tanzanian pediatric clinic, however, 12% of those
with VF were on second-line.9 Notwithstanding, our study
differs from these with use of PI-based first-line therapy and
possible differences in PMTCT exposure and adherence.
For those on NNRTI-based regimens, the confirmation
of VF following adherence optimization, as reported in this
study, is likely to identify patients who are truly failing with
resistance to $1 drug in the regimen. For example, an adult
study from South Africa showed that 86% of patients with
confirmed viral load .1,000 copies per milliliter had therapy-
limiting NNRTI mutations.27 Among children with VF in the
Thai study, 89% and 97% had major NRTI and NNRTI
resistance mutations, respectively. We had no access to resis-
tance testing for children failing therapy, and the prevalence of
resistance among children on PI-based regimens with con-
firmed VF in our context remains unknown.
Comparisons with rich countries are difficult due to
differences in age at ART commencement, previous mono-
therapy or dual therapy, follow-up duration, and first-line
regimens. The United Kingdom Collaborative HIV Pediatric
Study reported 32% of 595 children having VF after a median
follow-up of 3 years, whereas a Dutch cohort of 39 children
on nelfinavir-based ART reported 74% VF-free survival after
48 weeks.28,29
First-Line Regimen Choice
The association between NVP-containing regimens and
VF concurs with findings from previous pediatric and adult
studies.5,6,30,31 It has been suggested that NVP may be
underdosed in children taking split adult fixed-dose combi-
nation tablets, however, in South Africa, NVP is administered
to children as a single drug in syrup/tablet form.5,6 Children
may harbor resistance from unrecorded exposure to sdNVP,
and subsequent NVP-based ARTwould be expected to result
in poor virologic outcomes.32,33 Although the majority of
sdNVP-exposed children in this cohort would have com-
menced PI-based regimens, it is likely that some initiated
NNRTI-based regimens due to site variation in regimen use
TABLE 4. Univariable and Multivariable Associations With Switch to Second-Line Therapy in Children With at Least 6 Months
Follow-Up After a Second Consecutive Unsuppressed Viral Load, With the Second Viral Load Being .1,000 Copies Per Milliliter
(Cox-Proportional Hazards Model Stratified by Site)
Characteristic
Unadjusted HR
(95% CI) n = 367 P
Adjusted HR
(95% CI) n = 229 P
Age in years at ART initiation (per 1 year increase in age) 1.11 (1.05 to 1.16) ,0.001 1.03 (0.87 to 1.23) 0.698
Female gender 0.64 (0.44 to 0.92) 0.017 0.72 (0.42 to 1.25) 0.244
Years on treatment at time of failure (per 1 year duration on treatment) 1.38 (1.04 to 1.84) 0.025 1.37 (0.82 to 2.29) 0.229
Log10 viral load at failure (per 1 log increase) 1.43 (1.15 to 1.78) 0.002 1.55 (1.11 to 2.16) 0.01
Current* immunologic failure† 1.08 (0.67 to 1.75) 0.75 — —
Current* CD4% ,25 2.45 (1.56 to 3.84) ,0.001 1.94 (1.07 to 3.52) 0.029
Current CD4% decline . 1 unit/month‡ 4.37 (2.14 to 8.92) ,0.001 6.44 (2.15 to 19.25) 0.001
Current* weight-for-age z score (per 1 unit increase in z score) 0.94 (0.78 to 1.13) 0.521 1.14 (0.90 to 1.43) 0.281
Current weight-for-age z score decline . 0.1 units/month‡ 1.62 (0.64 to 4.11) 0.313 2.10 (0.58 to 7.58) 0.257
Viral load decline , 1 log10 since ART start† 0.88 (0.55 to 1.41) 0.596 — —
PI-containing regimen 0.39 (0.25 to 0.60) ,0.001 0.40 (0.17 to 0.91) 0.03
Year of ART initiation†
.2005 1 — — —
#2005 1.10 (0.52 to 2.32) 0.803 — —
Reasons for children having less than 6 months follow-up after failure (n = 156), were death (n = 5; 3%), loss to follow-up (n = 15; 10%), transfer out (n = 13; 8%) and failure
occurring less than 6 months before database closure (n = 123; 79%).
HR, hazard ratio.
*Measurement taken at time of switch.
†Not include in multivariable model.
‡Difference between measurement taken at time of switch and preceding visit.
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before national guidelines recommendations. This is sup-
ported by both the finding of an association between PMTCT
exposure and subsequent failure, despite PMTCT under-
ascertainment, and attenuation of this effect when those
without virologic response to ART were excluded. This
attenuation is expected as children with NVP resistance would
most likely be virologic nonresponders.
Despite our inability to adjust for potential confounding
by concomitant tuberculosis and other confounding by
indication, our findings suggest that RTV as the sole PI is
indeed associated with failure. RTV is unpleasant tasting,
associated with poor adherence, and results in a greater
accumulation of major PI resistance mutations in comparison
with LPV/r.34,35 However, as RTV use would have been more
common in children with tuberculosis, we cannot exclude that
worse outcomes may have been due to tuberculosis itself or the
increased medication burden of ART combined with
antituberculous therapy.
Switching to Second-Line
This study reflects clinical practice in a setting with viral
load monitoring but no supporting national or WHO guide-
lines regarding management of children with VF. This is
reflected in the low proportion of children switched after
failure, and the delay between VF and switch. Heterogeneity in
switching practice was also seen in the Collaborative HIV
Pediatric Study with nearly half of children with VF being
switched before the date of first viral load .1000 copies per
milliliter but an equal proportion on first line $6 months
thereafter.28 In our study, service factors may contribute to
the delay; clinical appointments are often 3-monthly with results
only available for decision-making at subsequent appointments.
Nevertheless, less than half of children with confirmed
VF for $1 year were switched, and those who were switched
were on a failing regimen for a median of 10 months after the
first elevated viral load measurement. In this study, factors
other than VF were associated with being switched, including
initial regimen, disease severity and progressive immunolog-
ical decline.
Reluctance to switch a young child failing therapy
without thorough assessment of adherence is reasonable in the
context of access only to unpleasant second-line regimens,
with no third-line/salvage therapy. In this respect, reduced
switching of children on PI-based regimens is consistent with
knowledge that viral escape is more likely due to poor adher-
ence than resistance.34 Nevertheless, poor access to a wider
range of second-line drugs, particularly for children failing
first-line PI-based regimens after sdNVP exposure, may result
in an understandable reluctance to switch children to a drug to
which their virus may be resistant.
If the intention of treatment guidelines is to avoid pro-
longed viremia, this study suggests the need for more intensive
monitoring and adherence interventions soon after a single
elevated viral load. The PENPACT1 trial recently reported
similar outcomes overall for children switched at viral load
measurements of 1000 or 30,000 copies per milliliter, however,
highlighted the importance of adherence interventions after
initial elevated viral load measures.36,37 In addition, children on
NNRTI-based therapy switched at 30,000 copies per milliliter
accumulated more NRTI-resistant mutations compared with
those switched at 1000 copies per milliliter, suggesting that
switching guidelines should be tailored according to regi-
men.36,37 In large programs, viral load monitoring could
additionally be used to manage patient load by stratifying
risk. More clinical and adherence input could be given to
unsuppressed patients although those with sustained virologic
suppression could be managed less intensively.7,38
Strengths and Limitations
This is a large combined cohort of children across many
sites providing different levels of care. In addition, viral load
measurements were available for .75% of children in care at
each 6-monthly duration, and it was possible to use as an
outcome confirmed VF rather than a single measure. The large
number of infants and inclusion of a PI in first line enabled us
to examine the effect on virologic outcome of RTVas the sole
PI and LPV/r in comparison to NVP or EFVas components of
first-line regimens.
The size of the cohort resulted in a relatively large
absolute number of failures and switches, permitting investiga-
tion of switching practice.
Despite the study size and the general application of the
public health approach to ART provision, the study cohorts,
being relatively well resourced and urban, may not be repre-
sentative of all sites across the region or even South Africa.
Data was collected in the context of routine care in busy
clinics. There is limited data on key possible predictors of VF
such as tuberculosis coinfection, adherence and PMTCT, and
on clinical events. Missing data on other variables limited the
range of variables and number of children that could be
included in multivariable models. Tuberculosis coinfection not
only affects first-line regimen choice, but may impact on
virologic outcomes directly or through drug–drug interactions
or reduced adherence. We could not explore the extent to
which our observed associations with failure were mediated
through poor adherence, due to limited data. PMTCT expo-
sure data was only recorded for 40% of children. Furthermore,
exact PMTCT regimens were not recorded, so the effect
of different regimens could not be examined. The effect of
severe clinical disease at ART initiation on VF may have
been reduced by combining stage 3 and 4 disease. Due to
lack of detailed clinical event data and confounding by
indication (with sicker children being preferentially switched),
we were unable to determine the clinical consequences of
delayed switching.
CONCLUSIONS
This study demonstrates the probability of VF in
children on ART in South Africa at 3 years to be nearly
20%. The time between failure and switch and low proportion
of children switched to second-line in this and other studies
supports use of clearer definitions of VF and clinical practice
guidelines for managing children with unsuppressed viral load
tailored to starting regimen. In addition, access to second-line
drugs for PMTCT exposed children failing PI-based ART is
important for better pediatric HIV care in the countries where
the majority of HIV-infected children reside.
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2.5 Accuracy of immunological criteria for identifying virological 
failure in children on antiretroviral therapy – The IeDEA Southern 
Africa Collaboration 
2.6 The role of targeted viral load testing in diagnosing virological 
failure in children on antiretroviral therapy with immunological 
failure 
 
Overview of papers 
These papers used data from South African IeDEA-SA sites that had access to both CD4 and 
virological monitoring at least six monthly for the duration of the period of analysis. The first 
paper describes the poor diagnostic accuracy of WHO and USA Department of Health and 
Human Services (DHHS) Guidelines immunological failure criteria for identifying children 
with confirmed VF. The second paper analyses the improvement in positive predictive value 
(PPV) when a single targeted viral load (TVL) measurement is performed in children 
identified as having immunological failure (IF).  
Contribution to the thesis and novelty 
Together these papers address the third objective of the thesis, examining the measurement of 
treatment success in settings without access to routine HIV-RNA monitoring. Both studies 
are the biggest to compare HIV-RNA and CD4 measures and the only studies to do this 
continuously for up to three years with failure diagnosis based on a confirmed viral load. The 
first paper demonstrates that all IF criteria have low sensitivity and PPV for identifying 
children with confirmed VF, supporting results of previously published smaller studies. The 
second paper is the only published study to evaluate TVL in children and shows that a TVL 
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Summary objectives To determine the diagnostic accuracy of World Health Organization (WHO) 2010 and
2006 as well as United States Department of Health and Human Services (DHHS) 2008 definitions of
immunological failure for identifying virological failure (VF) in children on antiretroviral therapy
(ART).
methods Analysis of data from children (<16 years at ART initiation) at South African ART sites at
which CD4 count ⁄ per cent and HIV-RNA monitoring are performed 6-monthly. Incomplete virological
suppression (IVS) was defined as failure to achieve ‡1 HIV-RNA £400 copies ⁄ ml between 6 and
15 months on ART and viral rebound (VR) as confirmed HIV-RNA ‡5000 copies ⁄ ml in a child on ART
for ‡18 months who had achieved suppression during the first year on treatment.
results Among 3115 children [median (interquartile range) age 48 (20–84) months at ART initiation]
on treatment for ‡1 year, sensitivity of immunological criteria for IVS was 10%, 6% and 26% for WHO
2006, WHO 2010 and DHHS 2008 criteria, respectively. The corresponding positive predictive values
(PPV) were 31%, 20% and 20%. Diagnostic accuracy for VR was determined in 2513 children with
‡18 months of follow-up and virological suppression during the first year on ART with sensitivity of 5%
(WHO 2006 ⁄ 2010) and 27% (DHHS 2008). PPV results were 42% (WHO 2010), 43% (WHO 2006)
and 20% (DHHS 2008).
conclusion Current immunological criteria are unable to correctly identify children failing ART
virologically. Improved access to viral load testing is needed to reliably identify VF in children.
keywords children, antiretroviral therapy, immunological criteria, sensitivity, specificity,
virological failure
Introduction
Poor access to viral load testing in resource-limited settings
results in reliance on immunological criteria to identify
treatment failure in patients on antiretroviral therapy
(ART). Studies in adults have shown limited value of
immunological criteria to detect virological failure (VF)
(Badri et al. 2008; Mee et al. 2008; Keiser et al. 2009).
While low sensitivity of immunological criteria for identi-
fying VF could result in delayed switching to second-line
treatment with accumulation of resistance mutations, low
positive predictive value (PPV) may incorrectly identify
patients as needing second-line treatment when they are
virologically suppressed. The few paediatric studies of
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diagnostic accuracy of immunological criteria for VF are
limited by small cohort size and ⁄ or VF definition based on
single elevated HIV-RNA measurements (Jittamala et al.
2009; Emmett et al. 2010; Ruel et al. 2010). We analysed
data from routine paediatric ART clinics to determine the
diagnostic accuracy of WHO (2006, 2010) and United
States Department of Health and Human Services (DHHS)
2008 (National Institutes of Health 2008) criteria for
immunological failure for identifying (i) incomplete
virological suppression (IVS) during the first year on ART,
and (ii) confirmed viral rebound (VR).
Methods
Data were collected prospectively from ART-naı̈ve chil-
dren (<16 years at ART start) initiating ‡3 antiretrovirals
at South African sites participating in IeDEA–Southern
Africa (IeDEA-SA, see http://www.iedea-sa.org), all of
which had CD4 and HIV-RNA measurements performed
6-monthly. The characteristics of these sites have been
described previously (Davies et al. 2009). Each site has
institutional ethical approval to contribute data to IeDEA
analyses.
HIV-RNA was measured using Amplicor 1.5 (Roche
Diagnostics) or NucliSens EasyQ assays (bioMerieux),
with good comparability (Stevens et al. 2005). CD4
measurements were performed using standard dual plat-
form flow cytometry or the single platform PanLeucogated
method (Glencross et al. 2008). We defined IVS as failure
to achieve ‡1 HIV-RNA £400 copies ⁄ ml between 6 and
15 months on ART and VR as confirmed HIV-RNA
‡5000 copies ⁄ ml in a child on ART for ‡18 months whose
HIV-RNA had suppressed during the first year on treat-
ment. We examined the following immunological criteria:
WHO 2010: No definition for children <2 years; CD4%
<10% or CD4 <200 cells ⁄ mm3 (age 2–4 years); CD4
<100 cells ⁄ mm3 (age ‡5 years) (WHO 2010). WHO 2006:
No definition for children <1 year; CD4% <15% (age
1–2 years); CD4% <10% (age 3–4 years); CD4
<100 cells ⁄ mm3 (age ‡5 years) (WHO 2006). DHHS:
During first year on ART: <5 percentage point CD4%
increase from baseline (CD4% <15 and age <5 years at
baseline) or <50 cells ⁄ mm3 CD4 increase from baseline
(CD4 <200 cells ⁄ mm3 and age ‡5 years at baseline);
decline of CD4% by 5 percentage points from previous
value, confirmed at subsequent measurement (<365 days
after first low value) (any age); return of CD4 count
£baseline value (age ‡5 years at baseline) (National Insti-
tutes of Health 2008).
For IVS, we assessed the diagnostic accuracy of never
achieving a CD4 above the immunological thresholds
between 6 and 15 months on ART for identifying a child
who never had HIV-RNA £400 copies ⁄ ml during the same
period. Only children followed up for ‡1 year with ‡1
HIV-RNA measurement between 6 and 15 months were
included. For VR, CD4 and HIV-RNA measurements were
carried forward for up to 3 months where tests were
performed asynchronously. For each unique paired CD4
and HIV-RNA measurement, we determined the diagnostic
value of CD4-based criteria for identifying VR, using
robust standard errors to account for multiple measures
per patient. Immunological results for which there was still
no concurrent virological diagnosis after carrying forward
results were not evaluated. Further, the last immunological
result before the end of follow-up ⁄ database closure was
excluded to ensure that there was sufficient follow-up for
a confirmatory low viral load measurement to have been
performed. Separate sensitivity analyses were performed
requiring either consecutive (within 365 days) CD4
measurements meeting immunological criteria or using an
HIV-RNA threshold of 1000 copies ⁄ ml to define
confirmed VR.
Results
Of 3640 children with ‡1 year of follow-up, 3115 (86%)
had ‡1 HIV-RNA measurement between 6 and 15 months
on ART. At ART initiation, median [interquartile range
(IQR)] age was 48 (20–84) months. Most children were
severely ill at ART initiation: WHO-defined severe immune
suppression was present in 81% of 2911 children with
baseline CD4 measures recorded, and 68% of 2294
children with WHO Clinical Stage data had Stage 3 ⁄ 4
disease (WHO 2006). In keeping with South African
guidelines recommending protease inhibitor- (PI-) based
first-line therapy in children <3 years old (National
Department of Health South Africa 2005), 35% of children
were on PI-based first-line treatment with non-nucleoside
reverse transcriptase-based therapy in the remainder. IVS
occurred in 12.6% of children and sensitivity of immuno-
logical criteria for identifying IVS ranged from 6% (WHO
2010) to 26% (DHHS) and PPV from 20% (WHO 2010
and DHHS) to 31% (WHO 2006) (Table 1a).
The accuracy of immunological criteria for identifying
VR was assessed in 2513 children with at least 18 months
follow-up on ART whose HIV-RNA had suppressed
during the first year on treatment. The cumulative prob-
ability of VR in the following 2 years (by 42 months since
ART start) was 5.5% [95% confidence interval (CI):
4.2–7.1]. Sensitivity of immunological criteria for identi-
fying VR ranged from 5% (WHO 2006 ⁄ 2010) to 27%
(DHHS) and PPV from 20% (DHHS) to 43% (WHO
2006) (Table 1b). For diagnosing both IVS and VR,
requiring consecutive CD4 counts to meet immunological
Tropical Medicine and International Health volume 16 no 11 pp 1367–1371 november 2011
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Table 1 Diagnostic value of immunological criteria for identifying children (a) with incomplete virological suppression during first year on
ART and (b) with viral rebound
(a)
Comparison of immunological failure diagnosis
(based on highest CD4 between 6 and 15 months on
ART) with failure of viral suppression in same period
Comparison of immunological failure diagnosis
(based on highest CD4 between 6 and 15 months
on ART and confirmed on a subsequent
measurement) with failure of viral suppression
in same period
WHO 2006* WHO 2010 USA WHO 2006* WHO 2010 USA
Number of children (%) 90 ⁄ 2714 (3.3) 61 ⁄ 2380 (2.6) 355 ⁄ 2585 (13.7) 13 ⁄ 2502 (0.5) 9 ⁄ 2217 (0.4) 72 ⁄ 2277 (3.2)
Number of children with
paired data
2581 2256 2470 2405 2126 2190
Sensitivity (%) 10 (7–14) 6 (3–10) 26 (21–31) 2 (0–4) 2 (0–4) 9 (5–12)
Specificity (%) 97 (97–98) 98 (97–98) 87 (86–89) 99 (99–100) 99 (99–100) 97 (97–98)
PPV (%) 31 (22–41) 20 (10–30) 20 (16–24) 38 (8–69) 33 (0–72) 27 (16–38)
NPV (%) 90 (89–91) 92 (91–93) 91 (89–92) 90 (89–91) 92 (91–93) 90 (89–92)
Number of true positives 28 12 69 5 3 19
Number of true negatives 2242 2017 1928 2151 1945 1916
Number of false negatives 250 179 197 241 172 204
Number of false positives 61 48 276 8 6 51
LR+ 3.80 2.70 2.07 5.49 5.57 3.29
LR) 0.92 0.95 0.85 0.98 0.99 0.94
Area under ROC curve 0.537 0.520 0.567 0.508 0.507 0.530
ART, antiretroviral therapy; PPV, positive predictive value; NPV, negative predictive value; LR+, likelihood ratio of a positive test; LR),
likelihood ratio of a negative test; ROC, receiver operating characteristic.
*Only determined for children >12 months of age.
Only determined for children >24 months of age.
Number of children with paired data (both CD4 and HIV-RNA measures available and CD4 criteria evaluable in terms of immunological
criteria) differs for different definitions because of different age and data requirements for each definition.
(b)
Comparison of immunological failure diagnosis (based
on single CD4 measure meeting criteria) with
confirmed HIV-RNA >5000 copies ⁄ ml
Comparison of immunological failure diagnosis
(based on consecutive CD4 measures meeting
criteria) with confirmed HIV-RNA >5000 copies ⁄ ml
WHO 2006 WHO 2010* USA WHO 2006 WHO 2010* USA
Cumulative probability
by 2 years
2.2% (1.5–3.2) 2.3% (1.5–3.3) 28.1% (25.2–31.3) 0.4% (0.2–1.0) 0.3% (0.1–0.9) 10.4% (8.6–12.6)
Number of evaluable
pairs of data
2499 2593 2191 2395 2507 2110
Sensitivity (%) 5 (2–9) 5 (2–9) 27 (19–35) 2 (0–5) 2 (0–4) 13 (6–21)
Specificity (%) 99 (99–100) 99 (99–100) 88 (86–90) 100 (99–100) 100 (99–100) 95 (94–96)
PPV (%) 43 (23–63) 42 (22–61) 20 (13–26) 50 (19–81) 44 (14–75) 21 (10–32)
NPV (%) 91 (89–93) 91 (89–93) 92 (90–94) 91 (89–93) 91 (89–93) 91 (89–93)
Number of true positives 13 13 58 5 4 26
Number of true negatives 2245 2327 1740 2168 2269 1816
Number of false negatives 224 235 157 217 229 172
Number of false positives 17 18 236 5 5 96
LR+ 7.30 6.83 2.26 9.79 7.81 2.62
LR) 0.95 0.95 0.83 0.98 0.98 0.91
Area under ROC curve 0.524 0.522 0.575 0.510 0.508 0.541
PPV, positive predictive value; NPV, negative predictive value; LR+, likelihood ratio of a positive test; LR), likelihood ratio of a negative
test; ROC, receiver operating characteristic.
*Only determined for children >24 months of age.
Paired data created from carrying forward asynchronously measured CD4 and HIV-RNA results for up to 3 months; Number of children
with paired data differs for different definitions because of different age and data requirements for each definition.
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criteria increased PPV only slightly at the expense of
sensitivity, without any improvement in the receiver
operating characteristic curve (Table 1). For VR, lowering
the VR threshold to 1000 copies ⁄ ml and using confirmed
CD4 values to define immunological criteria yielded
sensitivity (95% CI) of 2% (0–5%) (WHO 2006); 2%
(0–4%) (WHO 2010) and 14% (8–19%) (DHHS); and
PPV (95% CI) of 90% (72–100%) (WHO 2006); 89%
(68–100%) (WHO 2010) and 38% (26–50%) (DHHS).
Discussion
In this large longitudinal study, we found that sensitivity
and PPV were low for identifying VF using WHO and
DHHS immunological criteria. For example, using con-
firmed HIV-RNA ‡5000 copies ⁄ ml after initial virological
suppression to define VR, sensitivity was only 4% using
either WHO 2006 or 2010 criteria. Fewer than half of
children meeting WHO 2006 ⁄ 2010 criteria would have
HIV-RNA ‡5000 copies ⁄ ml.
These results concur with those of previous small studies
from resource-limited settings. Among 116 children in
Uganda, 20 (17%) had sustained viraemia (‡400 cop-
ies ⁄ ml) beyond 24 weeks on ART (Ruel et al. 2010). Only
two of these ever met WHO 2006 immunological criteria
and did so after >550 days of viraemia, while none met
WHO 2010 criteria (Ruel et al. 2010). Similarly, in a
cross-sectional study of 206 children in Tanzania on ART
for a median duration of 2.4 years, 32% had a single
HIV-RNA ‡400 copies ⁄ ml (Emmett et al. 2010). WHO
2006 clinical and immunological failure criteria combined
had a PPV of 100% but identified only 3.5% of children
with HIV-RNA ‡400 copies ⁄ ml (Emmett et al. 2010). In
Thailand, the sensitivity and PPV of DHHS immunological
criteria for identifying children with a single HIV-RNA
>1000 copies ⁄ ml were 15% and 16%, respectively
(Jittamala et al. 2009).
The poor sensitivity of immunological criteria for
identifying VF is disappointing; however, perhaps, an even
greater concern is preventing the incorrect diagnosis of
treatment failure in a virologically suppressed child, with
unnecessary switch to second-line treatment, hence the
importance of PPV. While PPV reached 89% for identify-
ing VR ‡1000 copies ⁄ ml using a confirmed CD4 value
meeting WHO 2010 criteria, given that the WHO 2010
guidelines HIV-RNA threshold for switching to second-line
is 5000 copies ⁄ ml, in most instances the number of false
positives using immunological criteria is unacceptably
high. Further, absence of immunological failure on ART
provides no assurance that a child is virologically sup-
pressed and not accumulating resistance mutations, and
even high CD4 thresholds (e.g. DHHS criteria) have low
sensitivity for VF (PENPACT1 Study Team 2011).
Improved access to HIV-RNA monitoring both to assess
adherence and identify VF is therefore needed (Wilson
et al. 2009; Ford & Calmy 2010).
There are several limitations to this analysis of routinely
collected data. Missing baseline CD4 values limited the
evaluation of DHHS criteria. Baseline CD4 values are
often unavailable to clinicians if children initiate ART on
clinical criteria, records are lost or a child changes
treatment site after ART initiation, highlighting the value
of simple criteria using current or recent measurements.
The accuracy of WHO 2006 and 2010 criteria could not
be evaluated in children <1 and <2 years old, respectively.
Work-up bias may occur if either the reference (HIV-
RNA) or index (CD4) tests are not applied consistently
(Whiting et al. 2004). In particular, rigorous confirmation
of low CD4 values is seldom performed in South Africa,
owing to access to HIV-RNA measurements to diagnose
treatment failure. Exclusion of intercurrent illness as a
cause of low CD4, as advised in WHO guidelines (WHO
2010), was not possible because of limited data on
episodes of clinical illness. Immunological criteria may
have performed better if only low CD4 counts not
explained by intercurrent illness had been considered. PPV
is dependent on the VF incidence in different programs;
however, the incidence in this cohort was similar to that of
other studies (Kamya et al. 2007; Jittamala et al. 2009;
Davies et al. 2011).
In summary, our results suggest that current immuno-
logical criteria are unable to correctly identify children
failing ART virologically. Improved access to viral load
testing appears to be the only feasible approach at this
stage for reliably identifying VF in children on ART.
There are several existing technologies for the measure-
ment of viral load (Stevens & Marshall 2010), and
expanded access should be supported by governments and
donors.
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Abstract objectives To determine the improvement in positive predictive value of immunological failure
criteria for identifying virological failure in HIV-infected children on antiretroviral therapy (ART) when
a single targeted viral load measurement is performed in children identified as having immunological
failure.
methods Analysis of data from children (<16 years at ART initiation) at South African ART sites
at which CD4 count ⁄ per cent and HIV-RNA monitoring are performed 6-monthly. Immunological
failure was defined according to both WHO 2010 and United States Department of Health and Human
Services (DHHS) 2008 criteria. Confirmed virological failure was defined as HIV-RNA >5000 copies ⁄ ml
on two consecutive occasions <365 days apart in a child on ART for ‡18 months.
results Among 2798 children on ART for ‡18 months [median (IQR) age 50 (21–84) months at ART
initiation], the cumulative probability of confirmed virological failure by 42 months on ART was 6.3%.
Using targeted viral load after meeting DHHS immunological failure criteria rather than DHHS
immunological failure criteria alone increased positive predictive value from 28% to 82%. Targeted
viral load improved the positive predictive value of WHO 2010 criteria for identifying confirmed
virological failure from 49% to 82%.
conclusion The addition of a single viral load measurement in children identified as failing immu-
nologically will prevent most switches to second-line treatment in virologically suppressed children.
keywords HIV, virological failure, children, antiretroviral therapy, monitoring, immunological failure
Introduction
In many resource-limited settings, access to HIV-RNA
measurement is limited and clinicians rely on clinical and
immunological criteria to identify children failing first-line
antiretroviral therapy (ART). These criteria have poor
diagnostic accuracy for virological failure, with both low
sensitivity and positive predictive value (PPV; Jittamala
et al. 2009; Ruel et al. 2010; Davies et al. 2011). Low PPV
means that children may be inappropriately switched to
limited and expensive second-line ART, when they are still
virologically suppressed. Confirming treatment failure
with a single elevated targeted HIV-RNA measurement
once immunological failure criteria are met [targeted viral
load (TVL) approach], together with a thorough
*The members of IeDEA Southern Africa Collaboration are given
in Appendix.
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assessment of adherence, may prevent switches to second-
line when the virus is likely to still be sensitive to the first-
line regimen. This approach is recommended in WHO
2010 pediatric treatment guidelines (Rewari et al. 2010,
WHO 2010). For example, inappropriate switches to
second-line of adults who had TVL performed were far less
common than of those with CD4 monitoring only (12.4%
vs. 46.9%; Sigaloff et al. 2011).
Different CD4 thresholds have been used to define
immunological failure (IF). For example, the United States
Department of Health and Human Services (DHHS) 2008
guidelines defined children as failing immunologically if
they experienced any of: a confirmed decline of CD4% by
five percentage points from the previous value or a
return of CD4 count to below the baseline value in child
aged at least 5 years at baseline (National Institutes of
Health, 2008). The WHO 2010 guidelines consider a child
to be failing immunologically if CD4% or CD4 count
declines to <10% or 200 cells ⁄ mm3, respectively (children
aged 2–4 years), or CD4 count declines to <100 cells ⁄ mm3
(children aged ‡5 years). No definition of IF is provided for
children <2 years of age (WHO 2010). We have previously
shown that the sensitivity of the DHHS 2008 IF definition
[27%; 95% confidence interval (CI): 19–35%] was greater
than that of WHO 2010 definition (5%; 95% CI: 2–9%)
for identifying children with confirmed virological rebound
(Davies et al. 2011; Note: Confirmed virological rebound
was defined as HIV-RNA >5000 copies ⁄ ml on two con-
secutive occasions <365 days apart in a child on ART for
‡18 months who achieved suppression during the first year
on ART). However, PPV was low for both DHHS (20%;
95% CI: 13–26%) and WHO 2010 (42%; 95% CI: 22–
62%) criteria. While these results underline the value of
routine HIV-RNA monitoring, access is lik ly to remain
limited in the short term in many settings because of
financial and logistical constraints (Sigaloff et al. 2011).
Therefore, we aimed to use data from children receiving
ART at South African IeDEA-Southern Africa (IeDEA-SA)
sites, all of which had access to at least 6-monthly CD4 and
HIV-RNA monitoring, to determine to what extent PPV
for identifying virological failure improves when adding
TVL to either DHHS or WHO 2010 IF criteria.
Methods
Data were collected prospectively from ART-naı̈ve chil-
dren (<16 years at ART start) initiating ‡3 antiretroviral
drugs at South African sites participating in IeDEA-SA
(http://www.iedea-sa.org). Site characteristics have been
described previously (Davies et al. 2009). Each site has
institutional ethical approval to contribute data to IeDEA
analyses. HIV-RNA was measured using Amplicor 1.5
(Roche Diagnostics) or NucliSens EasyQ assays (bio-
Merieux), with good comparability (Stevens et al. 2005).
CD4 measurements were performed using standard dual
platform flow cytometry or the single platform PanLeuc-
ogated method (Glencross et al. 2008).
Confirmed virological failure (CVF) was defined as HIV-
RNA >5000 copies ⁄ ml on two consecutive occasions
<365 days apart in a child who had been on treatment for
at least 18 months irrespective of whether suppression to
<400 copies ⁄ ml was achieved in the first year on treatment.
IF criteria were as follows: DHHS: a decline of CD4% by
five percentage points from the previous value, confirmed
at a subsequent measurement within 365 days after the
first low value (applicable to a child of any age) or a return
of CD4 count to below the baseline value in child aged at
least 5 years at baseline (National Institutes of Health,
2008). WHO (2010): no definition for children <2 years;
CD4% <10% or CD4 <200 cells ⁄ mm3 (age 2–4 years);
CD4 <100 cells ⁄ mm3 (age ‡5 years). For each of these IF
criteria, children were further considered to meet TVL
failure criteria if they met the respective IF criteria and the
next HIV-RNA measurement (within 4 months of meeting
IF criteria) was >5000 copies ⁄ ml. CD4 results for which
there was no available HIV-RNA measurement within
4 months, which was required to assess TVL, were
excluded from the analysis (1% and <1% of measurements
for DHHS 2008 and WHO 2010 criteria, respectively).
For all failure diagnoses (IF, TVL or CVF), measure-
ments had to be taken during a period when the child was
on treatment and not during a treatment interruption.
Where tests were performed asynchronously, IF, TVL and
CVF diagnoses were carried forward for up to 3 months.
We compared each unique paired TVL and CVF diagnosis
to determine diagnostic accuracy, using robust standard
errors to account for multiple measures per patient. TVL
results for which there was no concurrent CVF diagnosis
after carrying forward results were not evaluated. The last
TVL result before the end of follow-up was excluded to
ensure that sufficient follow-up for a confirmatory low
viral load measurement had been performed. All analyses
were performed using stata 11 (Stata Corporation,
College Station, TX, USA).
Results
Data from 2798 children on ART for ‡18 months were
included. Characteristics at ART initiation were as follows:
median (interquartile range) age 50 (21–84) months; 48%
female; 64% WHO Clinical Stage 3 or 4 and 79% WHO-
defined severe immune suppression. One-third of children
started a protease inhibitor-based first-line regimen. The
cumulative probability of CVF by 42 months on ART was
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6.3%. Using TVL after meeting DHHS IF criteria rather
than DHHS IF criteria alone increased PPV from 28% to
82% and the likelihood ratio of a positive test from 2.08
to 23.89, respectively (Table 1). Among the 19 TVL-
diagnosed false positive cases, 8 (42%) had two HIV-RNA
measurements >400 copies ⁄ ml but only one >5000 cop-
ies ⁄ ml, and 11 (58%) had a single elevated HIV-RNA with
resuppression at subsequent measurement.
Using TVL after meeting WHO IF criteria rather than
WHO IF criteria alone increased PPV from 49% to 82%
and the likelihood ratio of a positive test from 5.41 to
25.98, respectively (Table 1). Among the four TVL-
diagnosed false positive cases, three (75%) had two
HIV-RNA measurements >400 copies ⁄ ml but only one
>5000 copies ⁄ ml, and one (25%) had a single elevated
HIV-RNA with resuppression at subsequent measure-
ment.
Discussion
These results illustrate that although even the most
sensitive immunological criteria detect only a quarter of
cases of virological failure, the addition of TVL to these
criteria raises PPV and could reduce the number of
switches to second-line treatment in virologically sup-
pressed children. More than 80% of children considered to
be failing therapy according to either DHHS or WHO IF
criteria together with TVL would also meet the criteria for
CVF.
Nevertheless, TVL results in a small but important
number of false positive diagnoses as a proportion of
children resuppress after a single elevated HIV-RNA
measurement. Although children were not considered to be
failing therapy according to any definition if measurements
were taken during a documented treatment interruption,
we did not have detailed adherence data. It is possible that
these measurements may have been taken during adherence
lapses. Because these data come from programs with
routine HIV-RNA monitoring, the elevated HIV-RNA
measurement may have actually facilitated identification of
poor adherence, prompting counselling and intervention
with subsequent resuppression (Wilson et al. 2009). This
adds to the evidence in adults supporting HIV-RNA
measurement as a tool to discriminate between poor
adherence and therapeutic failure (Calmy et al. 2007;
Orrell et al. 2007). Routine HIV-RNA monitoring also
allows early accurate identification of virological failure
and consequent switching to second-line, thus preventing
accumulation of resistance mutations, which is not possible
with a more limited TVL approach (Wilson et al. 2009;
Sigaloff et al. 2011). Indeed, modelling studies in children
suggest that annual HIV-RNA monitoring after an ini-
tial screen 6 months after ART start would result in a
77% reduction in time spent with virological failure
compared with no HIV-RNA monitoring (Schneider et al.
2011).
Strengths of this study include the large cohort across
many sites in South Africa with routine access to both CD4
Table 1 Diagnostic accuracy of DHHS and WHO immunological failure (IF) criteria alone and DHHS and WHO IF criteria with targeted
viral load monitoring (TVL) for identifying children with confirmed virological failure (CVF)
DHHS IF
criteria met
DHHS IF criteria met
and next HIV-RNA
‡5000 copies ⁄ ml
WHO IF
criteria met




by 2 years (95% CI)
28.8% (26.0–31.8) 5.8% (4.6–7.3) 2.4% (1.7–3.4) 1.2% (0.8–2.0)
Number of evaluable pairs
of data*
2524 2480 2945 2906
Sensitivity (%) (95% CI) 24 (19–29) 22 (17–27) 4 (2–6) 4 (2–6)
Specificity (%) (95% CI) 88 (87–90) 99 (99–100) 99 (99–100) 100 (100–100)
PPV (%) (95% CI) 28 (22–35) 82 (74–90) 49 (31–66) 82 (65–99)
NPV (%) (95% CI) 86 (84–88) 87 (85–89) 86 (83–88) 86 (84–88)
Number true positives 98 86 18 18
Number true negatives 1873 2066 2487 2473
Number false negatives 306 309 421 411
Number false positives 247 19 19 4
LR+ 2.08 23.89 5.41 25.98
LR) 0.85 0.79 0.97 0.96
Area under ROC curve 0.563 0.604 0.517 0.520
*Evaluable pairs refers to each unique occasion where a diagnosis according to either IF or IF + TVL criteria can be compared with the
CVF diagnosis. Number of evaluable pairs differs for different definitions because of different data requirements for each definition.
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and HIV-RNA measurement, hence the large number of
TVL and CVF results available for comparison. Limita-
tions of these routinely collected data include missing
baseline CD4 values in some children, which limited
evaluation of DHHS criteria, work-up bias that may
occur if either the reference (HIV-RNA) or index (CD4
with single HIV-RNA) tests are not applied consistently
(Whiting et al. 2004) or when people switch to a second-
line regimen before immunological failure occurs. The
study was further limited by lack of data with respect to
intercurrent illnesses that should be excluded before
considering a low CD4 count to be indicative of immu-
nological failure (WHO 2010).
We conclude that the addition of targeted viral load to
CD4 monitoring will prevent most switches to second-line
therapy in virologically suppressed children. This is
particularly important to avoid exhausting the limited drug
options for children facing lifelong therapy. Our previous
study demonstrated the low sensitivity of immunological
criteria for identifying virological failure (Davies et al.
2011), and TVL should not replace routine HIV-RNA
monitoring in settings such as South Africa where it is
available or easily achievable. Rather, the introduction of
TVL may be a first step towards increasing access to
routine viral load monitoring where this is currently
unavailable.
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2.7 Temporal trends in the characteristics of children at 
antiretroviral therapy initiation in Southern Africa: The International 




This paper describes temporal trends in the number and characteristics of >30,000 children 
that initiated ART from 2005-2010 at all IeDEA-SA sites.  
Contribution to the thesis and novelty 
This paper addresses the fourth objective of the thesis. It is the largest analysis of temporal 
trends in patient characteristics at ART initiation based on individualized data. It is the only 
study including a range of settings in more than one country. The number of children 
included is nearly 10% of all children estimated to have been receiving ART in eastern and 
southern Africa by the end of 2010. The study demonstrates that there have been significant 
increases in the number of children starting treatment and improvement in disease severity of 
patients at ART initiation. There have been increases in the proportion of both infants and 
older children (≥ 10 years of age) in later years. The study found that even by the end of 
2010, most children still initiate ART with severe disease.  
Role of the candidate 
The candidate was responsible for all data management to generate the IeDEA paediatric data 
sets for these analyses. She was solely responsible for the analysis. The candidate drafted the 
manuscript, incorporated input from co-authors and was responsible for finalising and 
submitting the final version of the manuscript for publication. 
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Background: Since 2005, increasing numbers of children have started antiretroviral therapy (ART) in sub-
Saharan Africa and, in recent years, WHO and country guidelines for ART initiation have recommended ART 
initiation for all infants and very young children, and at higher CD4 thresholds for older children. We examined 
temporal changes in patient and regimen characteristics at ART start using data from 12 cohorts in 4 countries 
participating in the IeDEA-SA collaboration.  
Methods: Data from 30,300 ART-naïve children aged <16 years at ART initiation who started therapy between 
2005 and 2010 were analysed. We examined changes in median values (continuous variables) using the 
Cuzick’s test for trend over time. We also examined changes in the proportions of patients with particular 
disease severity (expressed as a binary variable e.g. WHO Stage III/IV vs I/II) using logistic regression.  
Results: Between 2005 and 2010 the number of children starting ART each year increased and median age 
declined from 63 months (2006) to 56 months (2010). Both the proportion of children <1 year and ≥10 years of 
age increased from 12-19% and 18-22% respectively. Children had less severe disease at ART initiation in later 
years with significant declines in the percentage with severe immunosuppression (81–63%), WHO Stage III/IV 
disease (75-62%), severe anemia (12-7%) and weight-for-age z-score <-3 (31-28%). Similar results were seen 
when restricting to infants with significant declines in the proportion with severe immunodeficiency (98-82%) 
and Stage III/IV disease (81-63%). First-line regimen use followed country guidelines. 
Conclusion: Between 2005 and 2010 increasing numbers of children have initiated ART with a decline in 
disease severity at start of therapy. However, even in 2010, a substantial number of infants and children started 













The estimated number of children receiving antiretroviral therapy (ART) in southern and eastern Africa has 
increased several-fold from <50,000 in 2005 to 337,200 by the end of December 2010, corresponding to a 
coverage of 26% of those eligible for ART.[1] In addition, WHO 2010 guidelines advocate immediate ART for 
infected children <2 years of age irrespective of disease severity, and ART at much higher CD4 thresholds than 
before in older children.[2] This means that more children are starting therapy and increasingly those initiating 
treatment should have less advanced disease. Furthermore, although drug development, availability and 
accessibility for children lags behind that of adults,[3,4] there have been moves towards less toxic and more 
effective first-line ART.[2] 
Timely ART initiation is important especially in infants and young children where pre-ART disease progression 
is rapid and mortality is high.[5,6] Even after ART initiation, early mortality remains very high in children with 
advanced disease, whereas starting ART with less advanced disease is associated with a good prognosis in 
terms of mortality, immunological, growth and neurodevelopmental outcomes.[7,8,9,10,11,12] There have been 
few articles published examining temporal trends in children initiating ART in sub-Saharan 
Africa.[13,14,15,16] During the early years of pediatric ART availability in South Africa between 2003 and 
2007, ART initiation at 7 pediatric sites increased 3-fold and median baseline CD4% among children <5 years 
of age increased.[17] A later South African study (2005-2009) found that in later years children had less severe 
disease and there were increasing proportions both of very young (<18 months) and older (≥10 years) children 
initiating therapy.[13] Comparison of secular trends in a study of 565 children initiating ART at urban and rural 
clinics in Zambia showed trends towards decreasing age and increasing CD4% with later years, however the 
study was small and changes were not all significant.[14]  
The International epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) collaboration now 
includes individualized data on >35,000 children ever started on ART across 12 sites in southern Africa. This 
provides an opportunity to examine temporal trends in baseline characteristics and regimen use in a very large 
cohort across a range of settings in 4 countries (Malawi, South Africa, Zambia and Zimbabwe). This is 












ART initiation has improved in recent years, especially in relation to WHO and country guideline changes, as 
well as for program planning. In addition to examining characteristics across the cohort as a whole, we 
particularly aimed to focus on changes in infants starting therapy as the Children with HIV Early Antiretroviral 
Therapy (CHER) trial has shown that ART initiation in infants before disease progression substantially reduces 
mortality and morbidity.[2,12,18,19]  
 
Methods 
The IeDEA-SA collaboration has been described previously and currently includes 12 HIV care and treatment 
programs for children in 4 southern African countries (www.iedea-sa.org).[9,20] Data are collected 
prospectively at each site at ART initiation (baseline) and follow-up visits, using standardized definitions. 
Anonymized data are transferred to data centers at the Universities of Cape Town, South Africa, or Bern, 
Switzerland, in a standardized format and merged at regular intervals. All sites have institutional ethics 
approval for their local research ethics committee to contribute data to IeDEA-SA analyses. The IeDEA-SA 
Collaboration has been approved by the human research ethics committees of the Universities of Cape Town 
and Bern. We included all ART-naïve children (except for exposure to antiretrovirals to prevent mother to child 
transmission [PMTCT]) starting therapy at age <16 years between 1 January 2005 and 31 December 2010. 
Children starting before 2005 were excluded to limit the analysis to children likely to have presented after ART 
roll-out began. Children starting after 2010 were excluded as most cohorts transferred data during 2011 and so 
full data for that year is not available. The Hlabisa (South Africa) and Newlands (Zimbabwe) cohorts 
transferred data during 2010, and so did not contribute a full year of data for 2010. Children with a documented 
HIV-RNA measurement <400 copies/ml at baseline were excluded as they were unlikely to be ART-naïve. 
Laboratory and anthropometric disease severity characteristics at ART start were the characteristics measured 
at the date closest to ART initiation within a window of -6 months to +7 days for CD4%/count, HIV-RNA and 
hemoglobin and a window of -1 month to +2 weeks for weight, height and body mass index (BMI). Weight-for-












standards.[21] BAZ was used rather than weight-for-height z-scores as these can be calculated for all ages, 
whereas weight-for-height standards are only available for children <5 years of age. Severe immune 
suppression was defined using the worst of CD4% and count, or whichever measure was available, using age-
specific thresholds according to WHO guidelines.[22] Severe anemia was defined according to both 
hemoglobin and age using Division of AIDS criteria for grading of adverse events.[23] 
We examined changes over the duration of the programme in continuous variables (using medians and 
interquartile ranges [IQR]) and in categorical variables (using proportions) for all children, and separately for 
those <1 year old at ART start. Changes in median values were assessed using the Cuzick’s test for trend over 
the ordered groups of programme year. Changes in the proportion of patients with a particular disease severity 
characteristic (expressed as a binary variable e.g. WHO Stage III/IV vs I/II) over the duration of the programme 
were tested using logistic regression with the disease severity characteristic as the dependent variable and 
examining the linear trend over programme years as the independent variable. All analyses were done using 
STATA 12.0 (College Station, Texas, USA).  
 
Results 
Characteristics of all children starting therapy 
Between 2005 and 2010, 30,300 ART-naïve children initiated ART at 12 IeDEA-SA treatment programs in 4 
countries and were included in the analysis. There was considerable heterogeneity in program characteristics 
and the number (median 1,178; range across sites: 402-12,378), and characteristics of children initiating 
treatment at each program (Table 1; Figure 1; Supplementary Table S1). Programs ranged from single hospital 
facilities providing pediatric tertiary care to a number of clinics and hospitals providing all levels of care for 
adults and children across a health district or province. Median (IQR) age at ART initiation was 58 (20-109) 
months; range across sites 8-113. As expected with such heterogeneity in age, there was variability in CD4 
count with median (IQR) of 381 (180-734) cells/mm3; range across sites: 193-647. CD4% was less variable 
with median (IQR) of 14.0% (8.9-20.0); range across sites: 12.0-17.0. Overall, 70% of children were severely 












respectively. Median (IQR) WAZ was -2.01 (-3.23 to -0.97) and 29% of children <10 years old had WAZ<-3 
(range across sites 13-40%). Variables were frequently not available for all children. Overall the proportions of 
missing data for WHO Stage, CD4 %/count, haemoglobin and weight were 19%, 34%, 47% and 22%. The 
median (IQR) number of days between variable measurement and ART start date was -21 (-44 to -9) (CD4 
count), -23 (-46 to -12) (CD4%), -20 (-45 to 0) (HIV-RNA) -16 (-34 to -6) (haemoglobin) and 0 (0 to 0) for 
WAZ. 
 Changes in guidelines and temporal trends in child characteristics 
Most programs followed national guidelines for ART initiation and first-line regimen choice which were based 
on WHO guidelines (Table 2).[24,25,26,27,28,29] There were sometimes lags or minor discrepancies between 
WHO recommendations and national guidelines. For example, while the WHO 2010 guidelines recommend 
ART initiation for all children <24 months old irrespective of disease severity, this was implemented in Zambia 
in 2011 and, until recently, South Africa had only implemented ART irrespective of disease severity for infants 
<12 months.   
The number of children starting therapy increased each year from 3,849 in 2005 to 6,368 in 2009 (Figure 2). 
There was a slight decline in 2010, however 2 programs transferred data before the year ended. The median age 
dropped from a peak of 63 months in 2006 to 56 months in 2010 (p<0.001). Both the proportion of children <1 
year and ≥10 years increased over time from 12 to 19% (p<0.001) and 18 to 22% (p<0.001) respectively. 
Children had less severe disease at ART initiation in later years for almost all markers – baseline CD4%/count 
increased and there were significant declines in the proportions with severe immunosuppression (81 to 63%; 
p<0.001), WHO Stage III/IV disease (75 to 62%; p<0.001) and severe anemia (12 to 7%; p<0.001) (Figure 2; 
Supplementary Table S3). Nutritional status improved slightly e.g. the proportion with WAZ <-3 decreased 
from 31 to 28% (p<0.001) and other nutritional indices showed similar trends. Completeness of data for most 
variables increased over time e.g. the proportion with missing data on weight and hemoglobin dropped from 30 
to 18% and 60 to 41%. Notable exceptions were CD4%/count where the proportion of missing data was 
constant and HIV-RNA where it increased from 43% to 61%. Median HIV-RNA and proportion with >5 log10 












trend to lower values in the later years. The increased values in 2010 may be due to both the younger age of 
infants starting ART and increasing coverage and effectiveness of PMTCT, with high HIV-RNA values in 
young infants infected despite PMTCT exposure.[30]  
Temporal trends in characteristics of children <1 year of age 
The number of children <1 year old at ART initiation more than doubled from 475 in 2005 to a peak of 1114 in 
2009, with a slight drop in 2010. Median age at ART start in children <1 year dropped from 6.9 to 5.6 months. 
Children <1 year at ART start in later years had less severe disease. Median CD4%/count increased (p<0.001) 
and the proportion with severe immunodeficiency dropped from 98 to 82% and with WHO Stage III/IV disease 
from 81 to 63%. In 2005 nearly 60% of infants were severely underweight at ART start and this declined to 
35% in 2010, with similar improvements in HAZ and BAZ. 
First-line regimen 
Almost all first-line regimens were an option selected from nucleosid /nucleotide reverse transcriptase inhibitor 
(NRTI)1 (stavudine [d4T] / zidovudine [AZT] / abacavir [ABC] / tenofovir [TDF]) + NRTI2 (lamivudine 
[3TC] / emtricitabine [FTC]) + protease inhibitor (PI) / non-nucleoside reverse transcriptase inhibitor (NNRTI). 
First-line regimen differed for sites from within and outside South Africa and for children younger and older 
than 3 years. This is in keeping with national guidelines and drug prescribing information – dosing for efavirenz 
(EFV) is not established for children <3years/10kg; outside South Africa nevirapine (NVP) was recommended 
as the “third drug” for all children, while South African guidelines recommended PIs for children <3 
years/10kg, and EFV in older children. Across all age groups, 3TC predominated as NRTI2.  
NRTI1: Outside South Africa d4T use predominated and increased over time from 61% to 81% (p<0.001) and 
66% to 71% (p<0.001) in children below and above 3 years of age, with corresponding declines in AZT use. 
There were also small increases over time in ABC use for all children and TDF for children >3 years. Within 
South Africa d4T use increased slightly in children <3years from 2005 to 2009 (83 to 89%) with corresponding 
declines in AZT, but was constant at 96-97% in older children. In both age groups a change was seen in 2010 
with proportion starting d4T dropping to 41% and 60% in children younger and older than 3 years, with ABC 












NNRTI/PI: Outside South Africa NVP use predominated in both age groups: 97 and 87% of children younger 
and older than 3 years. Almost all of the remainder of children initiated EFV, use of which increased over time 
in older children from 8 to 16% (p<0.001). There was negligible use of PIs. Inside South Africa in children <3 
years, NVP use declined from 9% in 2005 to <1% in 2010 (p<0.001) with corresponding increases in lopinavir-
ritonavir (LPV/r) use. In 2005 and 2006, 11% of children <3 years initiated therapy with ritonavir alone as the 
third drug, but this was almost completely eliminated from 2007 onwards when LPV/r dosing recommendations 
for children <6 months of age were introduced and double dose LPV/r or ritonavir-boosted LPV/r were used 




This analysis of >30,000 children who started ART across Southern Africa between 2005 and 2010 
demonstrates that not only is the number of children starting thera y increasing, but also that in recent years 
children are younger and less severely ill at ART start. Nevertheless, even in 2010 many children were still 
initiating therapy with advanced disease – 62% with WHO Stage III/IV disease, 29% with WAZ<-3 and 63% 
were severely immunosuppressed.  
Similar temporal trends in disease severity characteristics were noted in a South African study of 3,000 children 
initiating therapy at 30 health facilities between 2005 to 2009 [13], as well as in Zambia[14]. Initiating therapy 
earlier in the course of disease is important as children with less severe disease experience better outcomes on 
ART and, in particular, the high early mortality seen in children starting therapy in resource-limited settings 
may be attenuated.[7,31,32,33,34,35,36] Early ART also improves neurodevelopmental outcomes in 
infants.[12] Indeed both the South African and Zambian studies showed temporal improvements in 
mortality.[13,14] As has been found in adult studies, however, in Zambia there was also increasing loss to 
follow-up over time which may include unascertained mortality.[14,37,38] Encouragingly in the South African 












It appears there is a mixed pattern of temporal trends in age with increasing proportions of infants as well as 
older children and adolescents initiating therapy.[13] Despite temporal increases, the proportion of infants 
initiating therapy in our study was still low reaching 19% in 2010. Nevertheless this is substantially higher than 
in previously published studies and may be due to the inclusion of data from 2010 after most countries had 
adopted universal ART for children <1 year, as well as inclusion of 2 sites providing exclusive tertiary care in 
South Africa where >50% of children were infants. The proportion of children starting therapy at <1 year of age 
is complex as it is a composite result of the ability of health care services to promptly diagnose and initiate 
infants on therapy, the coverage and effectiveness of PMTCT programs in reducing numbers of newly infected 
infants, as well as the backlog of older children not yet initiated on therapy. The latter may be substantial and is 
an important consideration in designing pediatric HIV care and ART programs as the needs and disease 
spectrum in these children are different from infants and toddlers.[39,40,41] In our study 1,151 children ≥10 
years of age (22% of all children) initiated therapy, however these were not all confirmed to be infected 
perinatally, rather than through sexual transmission. Other studies have found considerable numbers of 
perinatally infected children being diagnosed with HIV in late childhood or adolescence.[39,42,43] 
Despite temporal improvements across all ages in disease severity at ART start, the proportion of children 
initiating therapy with severe disease even at the end of the analysis period is a concern. Even in 2010, the 
median CD4%, WAZ and log10 HIV-RNA in our study indicated markedly more severe disease than those from  
a review of studies from developed countries.[8] This is particularly the case for infants where early ART 
initiation before disease progression substantially reduces mortality and morbidity.[18] In our study in 2010, 
>60% of infants started therapy with WHO Stage III/IV disease and >80% with severe immune suppression. 
The median age of infants starting ART in 2010 was 5.6 months which is well above the median age of <2 
months in the immediate arm of the CHER Study. There are a number of barriers to early ART initiation 
including lack of access to HIV-DNA PCR testing for diagnosis,[24,44,45,46] poor integration of antenatal, 
PMTCT, maternal and child health (MCH) and HIV services with poor infant HIV testing even among those 
whose mothers enrolled in PMTCT care,[47] lack of expertise, experience and confidence with initiating and 












to improve ART access for infants such as integration of PMTCT, MCH and HIV services and provider 
initiated testing at vaccination and other health visits[49,50,51,52] need to be developed and expanded. In 
Zambia, the median age of children enrolling in HIV care declined in settings where there was close 
collaboration between the MCH service and the ART clinic.[14] Notwithstanding these measures, disease 
progression in infants, especially those infected in utero, is extremely rapid – 25% of 560 HIV-infected infants 
identified at <12 weeks old as potential participants in the CHER study were ineligible as they already had 
CD4%<25, symptomatic disease or had died before screening/enrolment.[18] Currently infant diagnostic 
testing is recommended at 6 weeks of age, with ART initiation in infected infants at 10-14 weeks of age. 
However, in a study to determine optimal timing of infant diagnostic testing, it was found that 45% of in utero-
infected and 22% of intrapartum-infected infants had died or were lost to follow-up by 14 weeks of age.[53] 
The role of earlier PCR testing in infants needs to be explored. 
First-line regimen use closely followed national guidelines. PI use was almost completely absent outside of 
South Africa, but this is likely to change following the results of the P1060 trial that demonstrated better 
survival and virological outcomes in children <3 years old initiating PI based compared to NNRTI-based 
therapy, irrespective of prior PMTCT exposure.[54] Similarly while TDF use was very limited, this is likely to 
increase with the WHO/UNAIDS Treatment 2.0 strategy that aims to harmonize guidelines across ages and 
may advise TDF use in children >5 years of age. The feasibility, cost and long term outcomes of these changes 
will need to be examined. 
To our knowledge this is the largest study of temporal trends in child characteristics at the start of ART in sub-
Saharan Africa and the only study including a range of settings in more than one country to date. The number 
of children in our study is nearly 10% of the 337,200 children estimated to be receiving ART in eastern and 
southern Africa by the end of 2010.[1] Inclusion of data from 3 different periods of WHO guidelines enabled us 
to comment on how patient characteristics at ART start have changed as a result of WHO and national 
guideline changes. Representativeness of all children initiating ART in the region may however be limited as 
cohorts contributing to IeDEA-SA must have electronic patient databases and so are likely to be better 












this analysis, rather than dedicated research databases, enhances representativeness. There was substantial 
missing data on a number of variables, but this is true of routine monitoring data from many settings, and it is 
encouraging that the proportion of missing data for most variables decreased in later years.[13,34] Data on key 
variables of interest such as PMTCT exposure and tuberculosis infection at ART start were too sparse to 
include in the analysis.  
In conclusion, over time increasing numbers of children are initiating ART at younger ages and with less severe 
disease in these programs. However the proportion of infants remains low and proportion of children across all 
ages initiating ART with severe disease remains high. It is important to continue to develop strategies for earlier 
diagnosis and treatment of infants as well as to examine long term outcomes in the era of expanding coverage 
of pediatric HIV and more effective PMTCT.  
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Table 1: Characteristics of cohorts 
 
  




Type of clinic and payment Target population
Number of children ever 
started on ART since 
program start
Number of children 
included in the analysis 
(started ART between 1 Jan 
2005 and 31 Dec 2010)
Zambian MOH-CIDRZ, Lusaka, Zambia Primary Yes Public, Free ART Adults and children, 
combined clinics
14,500 12,378
Free State Province, South Africa All levels Yes Public and research, Free ART Adults and children, 
combined clinics
4,629 4,579
Gugulethu Community Health Centre,  
Cape Town, South Africa
Primary No Public and research, Free ART Adults and children, 
separate clinics
483 402
Hlabisa HIV Care and Treatment 
Programme, Kwazulu-Natal, South Africa
Primary Yes Public, Free ART Adults and children, 
combined clinics
1,141 1,134
Harriet Shezi, Chris Hani Baragwanath 
Hospital, Soweto, South Africa
All levels No Public and research, Free ART Children only 4,629 3,996
Khayelitsha Community Health Centre, 
Cape Town, South Africa
Primary Yes Public, Free ART Adults and children, 
separate clinics
1,191 919
Lighthouse Clinic, Kamuzu Central 
Hospital, Lilongwe, Malawi
All levels No Public, Free ART Adults and children, 
combined clinics
1,416 1,221
McCord Hospital, Durban, South Africa Secondary No Private not-for-profit; Small co-
payment
Adults and children, 
separate clinics
804 735
Newlands Clinic, Harare, Zimbabwe Secondary No Public, Free ART Adults and children, 
separate clinics
874 829
Red Cross Children’s Hospital, Cape 
Town, South Africa
Tertiary No Public and research; Free ART Children only 1,873 1,360
Rahima Moosa Mother and Child 
Hospital, Johannesburg, South Africa
All levels No Public, Free ART Children and 
pregnant women
2,198 1,854
Tygerberg Hospital, Cape Town, South 
Africa




















2004 - 2005 2006 - 2007 2008 -2009 2010 onwards 2006 - 2007 2008 - 2010 2011 onwards 2004-2009 2010 onwards 2004-2005 2006-2008 2009 and 2010 2011 onwards 2005-2006 2007-2009 2010 onwards
<18 mos, presumptive HIV diagnosis: 
WHO Stage IV  
>18 mos, definite HIV  diagnosis:    
WHO Stage III/IV disease
<18 mos:  
CD4% <20 
≤11 mos:                 
CD4 <1500 or 
25%
 ≤11 mos: all
Recurrent (>2/yr) or prolonged 
(>4 wks)  hospitalizations  for HIV-
related illness
 ≤11 mos: all
<18 mos:  
CD4% <25 
 ≤11 mos: all
<18 mos: CD4% <20 
≥5 years: CD4 
≤350
≥5 years: CD4  
<350
≥5 years: CD4 
<200 
≥5 years: CD4 
<350 
GUIDELINE
2004 - 2005 2006 - 2007 2008 -2009 2010 onwards 2006 - 2007 2008 - 2010 2011 onwards 2004-2009 2010 onwards 2004-2005 2006-2008 2009 and 2010 2011 onwards 2005-2006 2007-2009 2010 onwards
NRTI 1 AZT/d4T AZT d4T ABC AZT AZT/d4T AZT
NRTI 2
<24 mos; no 
prior NVP 
exposure: NVP 
6mos - 3 yrs: LPV/r                                        
(ritonvair alone for children < 6 









<24 mos; prior 
NVP exposure: 
LPV/r 







WHO Stage III or IV WHO Stage III/IV disease
WHO
12 to 35 mos: CD4 <750  or 
20% 
12 - 18 mos: CD4 <20%
Malawi
24 - 59 mos: 
CD4 ≤750  or 
≤25%  
36 to 59 mos: CD4 <350 or 15%
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Figure 1: Short title: Characteristics of children at ART start in the different cohorts 
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Figure 2: Short title: Characteristics of children at ART start by programme year  
Figure 2: Legend: Characteristics of children at ART start by programme year summarized as medians for continuous variables 
and proportions for categorical variables. p <0.001 for changes over programme year for all variables (Cuzick’s test for trend 
for continuous variables and logistic regression for categorical variables). (Note: Only children <10 years of age included in 















Figure 3: Short title: Characteristics of children <1 year of age at ART start by programme year. 
Figure 3: Legend: Characteristics of children <1 year of age at ART start by programme year summarized as medians for 
continuous variables and proportions for categorical variables. p<0.001 for changes over programme year for all variables 















Appendix Table S1: Characteristics of children at ART initiation in each cohort for (a) continuous variables and (b) categorical variables 
a) 
b) 
Cohort N median IQR N median IQR N median IQR N median IQR N median IQR N median IQR N median IQR N median IQR
CIDRZ 12378 66 24 to 120 7623 14.0 9.1 to 20.2 9753 381 187 to 733 9569 10.0 8.8 to 11.2 8729 -2.17 -3.39 to -1.11 8970 -2.59 -3.75 to -1.48 8978 -0.80 -2.06 to 0.37
Free State 4579 63 28 to 105 360 193 23 to 455 292 11.0 9.0 to 12.0 273 5.00 4.53 to 5.6 1721 -2.08 -3.18 to -1.08
Gugulethu 402 42 14 to 88 183 12.0 8.6 to 18.0 199 312 187 to 564 183 10.5 9.7 to 11.1 194 4.93 4.55 to 5.45
Hlabisa 1134 64 25 to 112 951 13.0 9.0 to 19.0 967 359 159 to 655 885 10.1 9.2 to 11.1 540 4.45 3.86 to 5.20 828 -1.29 -2.39 to -0.41 96 -2.00 -2.95 to -0.82 98 -0.66 -2.29 to 0.27
Harriet Shezi 3996 53 16 to 99 3000 13.1 8.0 to 19.0 2975 407 192 to 726 1385 10.5 9.5 to 11.6 2788 5.15 4.49 to 5.80 3092 -1.94 -3.20 to -0.96 3555 -2.42 -3.41 to -1.50 3552 -0.55 -1.75 to 0.36
Khayelitsha 919 36 14 to 79 423 16.0 11.0 to 22.0 543 520 241 to 907 20 10.0 9.0 to 11.0 344 5.19 4.45 to 5.85 764 -1.00 -2.04 to -0.10 104 -1.98 -3.05 to -0.84 103 -0.18 -1.38 to 1.21
Ligthouse 1221 90 45 to 140 614 13.4 8.4 to 19.9 688 346 178 to 623 211 10.4 9.1 to 11.2 649 -1.68 -2.85 to -0.74 761 -2.42 -3.42 to -1.50 762 -0.42 -1.40 to 0.37
McCord 735 75 34 to 120 616 12.0 6.1 to 15.5 626 254 106 to 485 483 10.2 9.2 to 11.1 36 5.51 4.80 to 6.26 192 -1.46 -2.68 to -0.61 172 -2.07 -3.00 to -1.29 172 -0.17 -1.37 to 0.70
Newlands 829 113 68 to 150 26 12.0 9.5 to 15.8 741 227 96 to 411 743 10.8 9.8 to 11.9 423 -1.80 -2.79 to -0.95 740 -2.48 -3.36 to -1.59 740 -0.75 -1.72 to 0.11
Red Cross 1360 8 3 to 35 847 16.1 9.3 to 24.1 834 416 162 to 932 843 9.8 8.6 to 11.0 749 5.84 5.15 to 6.36 941 -2.56 -3.88 to -1.51 740 -2.45 -3.60 to -1.40 748 -1.70 -3.3 to -0.63
Rahima Moosa 1854 33 10 to 79 1247 14.4 9.0 to 20.3 1241 495 237 to 877 632 10.5 9.4 to 11.5 1123 5.36 4.69 to 6.00 1192 -1.99 -3.11 to -1.01 1304 -2.13 -3.16 to -1.15 1308 -0.90 -2.22 to 0.16
Tygerberg 893 14 6 to 53 746 17.0 11.2 to 24.5 782 647 295 to 1197 750 10.0 8.8 to 11.0 620 5.58 4.92 to 6.20 534 -1.75 -3.34 to -0.67 537 -2.16 -3.13 to -1.11 536 -0.60 -2.20 to 0.44
All 30300 58 20 to 109 16276 14.0 8.9 to 20.0 19709 381 180 to 734 15996 10.1 9.0 to 11.3 6848 5.23 4.53 to 5.89 19065 -2.01 -3.23 to -0.97 16979 -2.46 -3.56 to -1.45 16997 -0.75 -2.03 to 0.32
*Chi ldren < 10 years  of age
$South African s i tes  only
Height-for-age z-score BMI-for-age z-score Age in months CD4 percent CD4 absolute count (cells/mm3) Haemoglobin (g/dl) Log10 HIV-RNA
$ Weight-for-age z-score*
Cohort Yes NR Yes NR Yes NR Yes NR Yes NR Yes NR Yes NR
n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n %
CIDRZ 1,230 10 3,095 25 7,989 67 459 4 6,511 66 2579 21 883 9 2809 23 2836 33 623 7 3587 40 3408 28 1,233 14 3400 27
Free State 499 11 804 18 551 28 2592 57 234 65 4219 92 20 7 4287 94 137 50 4,306 94 481 28 2063 55 4579 100 4579 100
Gugulethu 93 23 48 12 285 72 8 2 146 74 203 51 8 4 219 54 91 47 208 52 354 100 402 100 402 100
Hlabisa 105 9 237 21 830 81 111 10 718 74 159 14 42 5 249 22 166 31 594 52 117 14 72 8 22 23 1038 92 16 16 1036 91
Harriet Shezi 797 20 600 15 3307 95 519 13 2282 75 973 24 61 4 2611 65 1,552 56 1,208 30 849 28 322 9 1214 34 441 11 427 12 444 11
Khayelitsha 208 23 92 10 679 75 11 1 398 67 322 35 1 5 899 98 191 56 575 63 97 13 67 8 27 26 815 89 7 7 816 89
Lighthouse 44 4 427 35 1028 93 117 10 460 67 532 44 10 5 1,010 83 136 21 154 19 264 35 460 38 47 6 459 38
McCord 76 10 183 25 735 100 524 84 108 15 21 4 252 35 25 69 699 95 40 21 364 66 43 25 563 76 14 8 563 77
Newlands 19 2 364 44 89 72 706 85 397 54 88 11 19 3 86 10 92 22 49 11 260 35 89 11 80 11 89 11
Red Cross 789 58 65 5 1149 86 22 2 691 81 509 37 85 10 517 38 586 78 611 45 373 40 357 28 274 37 620 46 222 30 612 45
Rahima Moosa 541 29 172 9 1002 68 373 20 958 77 605 33 36 6 1222 66 727 65 731 39 332 28 497 29 366 28 550 30 210 16 546 29
Tygerberg 417 47 54 6 639 88 167 19 574 73 107 12 58 8 143 16 447 72 273 31 162 30 307 37 149 28 356 40 73 14 357 40
Total 4,818 16 6141 20 17,776 72 5,915 19 13893 70 10404 34 1244 8 14304 47 3,922 59 9,205 58 5515 29 5229 22 6,259 36 13321 44 2329 14 13303 44
NR = Not recorded
*South African s i tes  only
#Chi ldren < 10 years  of age













Appendix table S2 (a): Median (IQR) values of characteristics at antiretroviral therapy initiation for children by 





2005 2006 2007 2008 2009 2010 p-value#
age
n 3849 4360 4791 5732 6368 5200
median 60 63 59 56 55 56 <0.001
IQR 24 to 103 24 to 107 22 to 108 18 to 110 18 to 111 18 to 113
CD4 percent
n 2270 2355 2431 2883 3404 2933
median 11.3 12.2 13.6 15.0 15.0 16.0 <0.001
IQR 7 to 15.7 7.5 to 17.8 8.9 to 19.3 9.8 to 21.7 9.8 to 21.2 10.4 to 22.5
CD4 count
n 2681 2884 3082 3559 4113 3390
median 320 334 376 405 405 469 <0.001
IQR 140 to 575 150 to 624 174 to 710 198 to 765 196 to 789 217 to 885
Log10 HIV-RNA
*
n 1264 1195 991 1178 1102 937
median 5.36 5.28 5.41 4.94 4.92 5.32 <0.001
IQR 4.81 to 5.94 4.69 to 5.89 4.74 to 6.15 4.26 to 5.74 4.20 to 5.72 4.61 to 6.06
WAZ
n 2225 2574 2982 3679 4267 3338
median -2.10 -2.03 -2.06 -1.97 -1.97 -1.97 <0.001
IQR -3.35 to -1.05 -3.26 to -1.03 -3.35 to -0.98 -3.22 to -0.97 -3.17 to -0.92 -3.15 to -0.94
HAZ
n 1812 2207 2687 3463 3695 3115
median -2.69 -2.52 -2.46 -2.41 -2.46 -2.32 <0.001
IQR -3.7 to -1.67 -3.57 to -1.51 -3.59 to -1.44 -3.52 to -1.39 -3.64 to -1.43 -3.37 to -1.31
BAZ
n 1815 2208 2704 3450 3696 3124
median -0.74 -0.81 -0.82 -0.76 -0.71 -0.69 0.01
IQR -2.11 to 0.38 -2.08 to 0.28 -2.11 to 0.28 -1.97 to 0.26 -1.94 to 0.38 -2.01 to 0.38
Haemoglobin
n 1536 1957 2444 3101 3873 3085
median 10.0 10.0 10.1 10.1 10.2 10.2 <0.001
IQR 8.6 to 11.1 8.9 to 11.3 8.9 to 11.2 9 to 11.2 9.1 to 11.3 9.1 to 11.3
#Cuzick's  test for trend over ordered groups












Appendix table S2(b): Proportion of children in each age group and with particular disease severity characteristics or 





2005 2006 2007 2008 2009 2010 p-value#
Age category
   <1 year n 475 565 691 1,000 1,114 973
12.3 13.0 14.4 17.5 17.5 18.7
   1 year n 475 540 621 801 867 725
12.3 12.4 13.0 14.0 13.6 13.9
   2 - 4 years n 981 1,013 1,094 1,182 1,331 990
25.5 23.2 22.8 20.6 20.9 19.0
   5-9 yrs n 1,238 1,431 1,417 1,561 1,713 1,361
32.2 32.8 29.6 27.2 26.9 26.2
   ≥10 years n 680 811 968 1,188 1,343 1,151
17.7 18.6 20.2 20.7 21.1 22.1
WHO Stage III/IV n 2,247 2,715 3,003 3,430 3,455 2,698
75.0 81.3 78.6 73.5 65.0 62.1
   NR n 852 1,021 971 1,066 1,056 854
22.1 23.4 20.3 18.6 16.6 16.4
WAZ < -3 n 689 770 926 1,058 1,182 923
31.0 29.9 31.1 28.8 27.7 27.7
   NR n 970 1,001 869 887 786 741
30.4 28.1 22.6 19.4 15.6 18.2
HAZ < -3 n 744 809 973 1,242 1,395 1,043
41.1 36.7 36.2 35.9 37.8 33.5
   NR n 2,037 2,153 2,104 2,269 2,673 2,085
52.9 49.4 43.9 39.6 42.0 40.1
BAZ < -3 n 278 308 383 453 501 406
15.3 14.0 14.2 13.1 13.6 13.0
   NR n 2,034 2,152 2,087 2,282 2,672 2,076
52.8 49.4 43.6 39.8 42.0 39.9
Severe anaemia n 183 168 192 210 274 217
11.9 8.6 7.8 6.8 7.1 6.9
   NR n 2,313 2,403 2,347 2,631 2,495 2,115
60.1 55.1 49.0 45.9 39.2 40.7
HIV-RNA >5 log10
* n 842 740 662 576 522 580
66.6 61.9 66.8 48.9 47.4 61.9
   NR n 946 1,307 1,525 1,871 2,085 1,471
42.8 52.2 60.6 61.4 65.4 61.1
n 2,187 2,179 2,177 2,396 2,792 2,162
% of ava i lable data 80.8 74.7 70.1 66.6 67.4 63.1
   NR n 1,142 1,443 1,685 2,135 2,225 1,774
29.7 33.1 35.2 37.3 34.9 34.1
NR = not reported
*South African s i tes  only
#p-va lues  derived from logis tic regress ion of binary dependent variable with programme year as  an independent variable 
Programme Year
% of a l l  chi ldren
% of a l l  chi ldren
% of a l l  chi ldren
% of a l l  chi ldren




% of ava i lable data
% of a l l  chi ldren
<0.001
% of ava i lable data
% of a l l  chi ldren
<0.001
% of ava i lable data
% of a l l  chi ldren
0.025
% of ava i lable data
% of a l l  chi ldren
<0.001
% of a l l  chi ldren
<0.001
% of ava i lable data
% of a l l  chi ldren
<0.001
% of ava i lable data














Appendix Table S3 (a): Median (IQR) values of characteristics at ART initiation for children <1 year of age at ART start 







2005 2006 2007 2008 2009 2010 p-value#
Age in months n 475 565 691 1000 1114 973
median 6.9 6.0 6.0 6.2 6.1 5.6 <0.001
IQR 4.5 to 9.4 4 to 8.7 3.5 to 8.9 3.9 to 9 3.8 to 8.8 3.4 to 8.7
CD4 percent n 307 347 404 574 678 567
median 13.7 17.0 17.7 19.2 19.4 20.4 <0.001
IQR 8.9 to 20 10.7 to 24.9 11.9 to 24 13 to 26.5 13.4 to 26.4 13.2 to 28
CD4 count n 317 363 422 615 722 610
median 509 658 717 767 893 873 <0.001
IQR 197 to 1013 299 to 1202 347 to 1222 364 to 1274 388 to 1511 429 to 1477
Log10 HIV-RNA* n 250 287 275 368 363 280
median 6.00 6.01 6.30 5.83 5.82 6.06 0.06
IQR 5.53 to 6.32 5.46 to 6.48 5.79 to 6.48 5.20 to 6.30 5.15 to 6.30 5.36 to 6.51
WAZ n 319 351 503 776 900 742
median -3.45 -3.29 -2.90 -2.49 -2.28 -2.20 <0.001
IQR -4.61 to -2.21 -4.37 to -1.82 -4.17 to -1.52 -3.8 to -1.15 -3.79 to -0.93 -3.49 to -0.83
HAZ n 251 285 390 559 596 507
median -3.03 -3.14 -2.68 -2.43 -2.19 -2.17 <0.001
IQR -4.23 to -1.58 -4.15 to -1.81 -4.06 to -1.14 -3.73 to -1.07 -3.82 to -0.98 -3.54 to -0.9
BMI-age z n 259 287 401 558 602 519
median -2.74 -2.08 -1.83 -1.65 -1.43 -1.44 <0.001
IQR -4.01 to -1.07 -3.44 to -0.91 -3.26 to -0.35 -3.16 to -0.4 -3.23 to 0.04 -3.09 to 0.13
Haemoglobin n 155 223 333 541 670 561
median 9.9 9.8 9.5 9.6 9.8 9.8 0.08
IQR 8.3 to 10.8 8.5 to 11 8.5 to 10.8 8.7 to 10.8 8.8 to 10.9 8.7 to 10.8
*South African sites only













Appendix Table S3 (b): Proportion of children <1 year of age at ART start with particular disease severity 
characteristics or missing data by programme year from 2005 to 2010. 
 
 
2005 2006 2007 2008 2009 2010 p-value#
n 308 400 492 662 656 519
% of available data 81.1 87.7 85.4 78.3 67.1 62.5 <0.001
NR n 95 109 115 154 137 143
% of all children 20.0 19.3 16.6 15.4 12.3 14.7
WAZ <-3 n 184 189 242 305 341 262
% of available data 57.7 53.9 48.1 39.3 37.9 35.3 <0.001
NR n 156 214 188 224 214 231
% of all children 32.8 37.9 27.2 22.4 19.2 23.7
HAZ <-3 n 127 149 163 221 228 171
% of available data 50.6 52.3 41.8 39.5 38.3 33.7 <0.001
NR n 224 280 301 441 518 466
% of all children 47.2 49.6 43.6 44.1 46.5 47.9
BAZ <-3 n 115 87 118 148 172 131
% of available data 44.4 30.3 29.4 26.5 28.6 25.2 <0.001
NR n 216 278 290 442 512 454
% of all children 45.5 49.2 42.0 44.2 46.0 46.7
Severe anaemia n 22 23 34 35 54 46
% of available data 14.2 10.3 10.2 6.5 8.1 8.2 0.022
NR n 320 342 358 459 444 412
% of all children 67.4 60.5 51.8 45.9 39.9 42.3
n 318 329 383 556 620 515
% of available data 97.6 88.4 88.5 87.7 83.8 81.8 <0.001
NR n 149 193 258 366 374 343
% of all children 31.4 34.2 37.3 36.6 33.6 35.3
HIV-RNA >5log10* n 223 255 257 294 288 231
% of available data 89.2 88.9 93.5 79.9 79.3 82.5 <0.001
NR n 167 215 252 367 363 338
% of all children 40.1 42.8 47.8 49.9 50 54.7
*Only s i tes  in South Africa
NR = not recorded
#p-va lues  derived from logis tic regress ion of binary dependent variable with programme year as  an independent variable 















CHAPTER 3: SYNOPSIS 
 
3.1 Introduction 
The papers included in this dissertation include data from children initiating ART over a 
period of more than ten years (1999 – 2010). This has been a time of rapid expansion and 
change not only of HIV care and treatment programmes for children, but also PMTCT 
programmes, which impact on the burden and nature of paediatric HIV. Programmes have 
had to adapt rapidly and frequently both to increase their capacity as well as to incorporate 
guideline changes in response to new and emerging evidence of more effective and safer 
treatment strategies.20-22,33,129,153 The papers included in this dissertation reflect this evolution 
in and relationship between WHO and country level guidelines, HIV care and treatment 
programmes for children, and characteristics and outcomes of children enrolled in these 
programmes. The literature review paper and two of the analyses are focused on evaluating 
the outcomes and effectiveness of ART programmes in South Africa in order to inform future 
programme and guideline development and compare outcomes across different settings. 
Three analyses focus on strategies for monitoring treatment effectiveness and associations 
with treatment failure. The last analysis examines ART scale-up for children in terms of 
changes in characteristics of children at ART initiation in responses to guideline changes. 
In order to avoid repetition, comments from the discussion sections of the published papers 
will not be repeated in this synopsis. Rather, the synopsis will focus on issues raised when 
considering the papers as a combined body of work in relation to the objectives of the 
dissertation and in the context of other relevant publications in the field of paediatric ART in 












3.2 Survival and related outcomes and their determinants. 
 
Mortality and retention in care reported from paediatric ART cohorts 
There are now many paediatric ART cohort studies from a range of settings across Africa that 
have found good outcomes on ART as demonstrated in the published literature review and in 
the literature review section of this dissertation.13,154 However, the collaborative South 
African cohort study included in this thesis remains one of the largest cohorts published from 
a single country setting representing a substantial percentage of all children in the national 
programme at the time.12,155 Uniquely the Malawi national programme has recently reported 
mortality and LTFU outcomes at 12 months on ART for all of the nearly 10,000 children 
started on ART between 2004 and 2007 using routine monitoring data.155 
We reported on outcomes for up to three years after ART initiation which, in contrast to adult 
studies,156,157 is still unusual for any paediatric cohort analysis from a developing country 
setting.8,12 The finding of mortality at three years of 7.7% and retention in care of 81.4% 
compares favourably with other studies of pediatric ART from resource-limited settings, but 
is substantially higher than mortality reported from developed country settings.12,13,18,27 The 
large Malawi national cohort reported a mortality rate during the first three months on ART 
of 24.3 per 100 child years and 5.9 per 100 child years during months four to twelve on 
ART.155  
Generalizability of paediatric ART outcomes and their determinants across 
different resource-limited settings 
The South African data reported in the paper describing outcomes of the national programme 
was included in a multiregional IeDEA analysis of 13,611 children that also included data 
from Asia, West and East Africa as well as other Southern African countries.158 By 18 












8.6% had transferred to another clinic.158 Mortality in Asia, Southern and East Africa was 
similar and lower than in West Africa after adjusting for patient age and disease severity as 
well as programme characteristics.158 Probability of LTFU was similar in Asia and Southern 
Africa and lower than for children in East and West Africa.158  
A large number of paediatric cohort analyses, including analyses of data from more than one 
region like the multiregional IeDEA analysis, describe associations of patient characteristics 
at ART initiation with subsequent mortality.7,8,10-13,16,18,24,49,155,158 The multiregional IeDEA 
analysis found that individual child characteristics of age <24 months, WHO Stage IV 
disease and CD4% <10 were independently associated with poorer survival. In the study of 
ART outcomes in South Africa, young age, all markers of disease severity (low weight-for-
age z-score, high viral load, severe immune suppression, WHO Stage III/IV disease and 
anaemia) were all independently associated with mortality.145 Across studies, reported 
associations are similar, but not exactly the same due to differences in the patient 
characteristics and settings of each study. This limits comparability of outcomes across 
programmes. The prognostic model of mortality on ART, however, uses cross-validation 
across the different regions to identify a model of associations of baseline characteristics with 
mortality that is generalizable. It also provides absolute predictions of mortality associated 
with particular child characteristics as has been done in adults.142,159,160 The finding that most 
children fall into the group with the good prognosis concurs with the South African paediatric 
ART outcomes paper as well as other studies from resource-limited settings that show low 
mortality on ART.145 
The absolute predictions of mortality that are generalizable across settings are useful for 
prognosis both at individual level and for programme planning, as well as for comparing 
outcomes of different programmes. Using a previously collected dataset from many of the 












attenuates the between-programme heterogeneity in mortality outcomes, however the choice 
of characteristics adjusted for in this analysis were not based on a generalizable model.24 The 
large differences in child characteristics of different programmes reported in the literature 
review and the prognostic model paper highlights the need for a robust generalizable model 
of mortality. 
Association between age and mortality 
A striking finding of the paediatric prognostic model was that it compared so well with the 
adult model for resource-limited settings and actually had higher R2 and C-statistics.142 Most 
studies, including the Southern African outcomes studies included in this thesis, have 
identified young age at ART initiation as strongly predicting mortality in children.145,148 The 
good discrimination and agreement of predicted and observed outcomes in the paediatric 
prognostic model are ascribed to this powerful prognostic value of age in a setting where 
children have to “wait” from time of infection (usually perinatally) until particular disease 
severity criteria are met, before they become eligible for ART.20 In this context, the age at 
which a child starts therapy is a proxy for the severity of disease and speed of progression, 
and may be a more accurate measure of disease progression than other laboratory or clinical 
measures. The equivalent measure of disease progression in adults is frequently not possible 
to measure as the timing of infection is often unknown.  
With universal ART for all children less than two years of age, and even less than five years 
of age as currently recommended in South Africa161,162 and contemplated for WHO 2013 
guidelines, assessment of disease severity is not required to determine eligibility. For 
prognostic purposes, programme planning and comparing the outcomes of different 
programmes, it may be useful to continue to record and measure a child’s age and low cost 












paper, new models will need to be developed for children starting ART before the onset of 
severe disease, as there were insufficient children in our dataset without severe disease to 
determine meaningful differences in mortality associated with different disease 
characteristics within the less severe disease spectrum.  
Outcome ascertainment 
As highlighted in the literature review, however, interpretation and comparison of mortality 
estimates across settings even after adjustment for patient characteristics at ART initiation, 
may be difficult due to differences in the accuracy of outcome ascertainment when LTFU is 
high. In the multiregional IeDEA analysis the crude estimate of LTFU by 18 months after 
ART initiation was >15% in two regions.158 As mentioned in the literature review, the few 
tracing studies in children show that mortality among children on ART who become LTFU 
may be up to 50%.116,117 Possible under-ascertainment of mortality in those LTFU/transferred 
was highlighted as a limitation in the prognostic model study – children transferred/LTFU 
within six months of ART start were excluded as early mortality on ART is high12,155 and the 
risk of outcome misclassification was likely to be highest in this group.118 The sensitivity 
analyses demonstrated that mortality at the programme level was indeed affected by 
assumptions about mortality in this group. A further limitation of the prognostic model is that 
it is restricted to predictions during the first year on ART. As patients remain on therapy for 
longer, it will be important to develop models that predict longer term outcomes.160 For this, 
good outcome ascertainment in those LTFU/transferred will continue to be important in order 
to get accurate predictions of mortality. This will enable calculating more accurate 
predictions of mortality as well as calculating the life expectancy on ART in children as has 












Improving estimates of mortality in cohort studies 
In South Africa, linkage of HIV cohort patient data to the death registry using the national 
identification number to improve mortality ascertainment has been done in adults with high 
sensitivity and specificity for known deaths.156,164 Using this data in the Khayelitsha adult 
cohort, about one third of patients LTFU were found to have died, and mortality estimates at 
five years increased from 15.5% based on facility-level data to 23.4% when correcting for 
under-ascertained mortality.156 This approach has been shown to be feasible for children with 
results very similar to those of adults. In a study of approximately 3,000 children initiating 
ART in four provinces in South Africa, nearly 50% of children LTFU had a valid national 
identification number, and one third of these had died according to the national registry.165 
While mortality probability by two years based on deaths recorded in facility-level data was 
3.9%, this increased to 6.1% when correcting for the unascertained deaths.165  
Data from linkage to death registries or tracing studies is, however, frequently unavailable in 
resource-limited settings. Nevertheless, it may be possible to adjust estimates of mortality at 
the programme level using a nomogram method based on results of tracing studies.24,110,111 
Although only adult tracing studies were used in developing the nomogram, the finding of 
similar mortality in adult and paediatric patients LTFU when linking to the South African 
death registry, supports its applicability to paediatric programmes. The nomogram approach 
to adjusting mortality estimates has been applied in an analysis of 8,225 children that 
included the South African data from this thesis as well as data from other Southern African 
countries. Estimated probability of dying by one year was 4.5% in children remaining in care, 












Temporal trends in mortality, LTFU and retention in care 
In the South African programme outcomes paper LTFU increased from 2.2% in those 
commencing ART prior to 2006 to 8.2% for those commencing in later years.145 Under-
ascertainment of mortality with increasing LTFU in later programme years has been seen in 
adult studies from South African cohorts43,156,166 and in our study is one possible contributory 
explanation for the apparent protective effect on mortality of starting ART in later years. The 
major reason postulated for increasing LTFU is increasing patient numbers putting pressure 
on services at the same facility and limiting ability to trace patients after missed 
appointments.46,166 Encouragingly, in an analysis combining data from a number of facilities 
in four provinces in South Africa Fatti et al.165 showed no difference in corrected mortality 
and true LTFU between annual enrolment cohorts after adjusting for patient characteristics at 
ART initiation and correcting mortality for unascertained deaths. This may be because, in the 
study by Fatti et al.,165 the increasing numbers of children starting ART in later programme 
years came from increasing numbers of new facilities starting children on ART, rather than 
the increasing cohort size at the same clinics in our and other studies, supporting 
decentralization of care.145 
Impact of transfers and decentralization of care on outcomes of pediatric 
ART  
Both the prognostic model and South African outcomes papers reported very high rates of 
transfer out from tertiary care sites in the Western cape Province of South Africa, with nearly 
50% of the cohort being transferred to primary care within two years of ART initiation.145 At 
the time, this practice was fairly unique to the Western Cape paediatric ART program4 but 
has now become much more widespread in both adult and pediatric programs.157,167 Recently, 
pediatric programs in other provinces have started decentralizing care to facilities closest to 












hospitals have transferred patients to primary health care facilities due to reductions in 
external funding streams for hospital-based care.168 There has been little research in children 
or adults on whether patients successfully transfer to their new treatment site and the 
outcomes of patients transferred.169,170 In Malawi, 92% of patients transferred from Mzuzu 
Central Hospital to health facilities nearer their homes were traced as having successfully 
enrolled at the new facility at a median of 1.3 months after transferring out.169 Survival 
probability was reported to be higher in patients transferred, supporting decentralization, 
however this was not adjusted for the less severe clinical disease in the transferring 
patients.169 
Similarly, comparisons of children receiving ART at different level of care facilities have 
yielded conflicting results due to the difficulty of adequately adjusting for disease severity 
characteristics and differential LTFU. In the Western Cape province retention in care was 
lower in children treated at academic and regional hospitals compared to district hospitals and 
primary care facilities, however this difference was ascribed to unmeasured/unrecorded 
differences in patient characteristics for which adjustment could not be done.45 In Malawi, 
patients treated at either central or rural hospitals had lower mortality but higher LTFU than 
those treated at district hospitals, while those treated at health centres experienced both lower 
mortality and lower LTFU compared to those treated at central and district hospitals.155 When 
comparing outcomes between urban and rural children and rural children accessing care at 
urban facilities (rural/urban), mortality was found to be highest in rural children, but LTFU 
was greatest in rural/urban children who also experienced the poorest virological suppression, 
suggesting that there are adherence and retention challenges when children receive treatment 
far from their home.59,92,171,172 These results support decentralization of paediatric ART to 
primary care facilities near the patients home, however research on the outcomes of children 












Effectiveness of ART 
Despite concerns regarding outcome ascertainment and notwithstanding the impact of level 
of care on ART outcomes, the South African outcomes and prognostic model papers both 
highlight good survival on ART especially when compared with expected outcomes based on 
data from the pre-ART era.70 Like other studies, the South African outcomes paper also 
showed good retention in care, immunological, virological and growth response, although 
anthropometric and laboratory measures only in patients remaining in care are affected by 
selection bias.127,152,173-183 However, we did not analyse pre-ART data, compare pre-ART and 
on-ART outcomes or attempt to demonstrate a causal link between ART a d the positive 
outcomes reported. A recent analysis of 790 HIV-infected children in the Democratic 
Republic of the Congo (DRC) used marginal structural models to estimate the effect of ART 
on survival, adjusting for time-dependent confounders (e.g. CD4) that influence both whether 
patients received the exposure (ART), and experience the outcome (death), and are 
themselves affected by the exposure.123,184,185 This analysis found a 75% reduction in 
mortality (95% CI: 0.06 – 0.95) when comparing ART with no ART.185 
Timing of ART initiation in children greater than one year of age  
As the study period for DRC analysis ended in August 2010, most data would have been 
collected prior to the WHO 2010 guidelines, so the effect estimate of ART reflects the 
mortality benefit when starting ART in children with severe clinical or immunological 
disease, but does not address the optimal timing of ART initiation in terms of the mortality 
benefit associated with starting ART at higher CD4 thresholds. A causal modelling analysis 
of the effect of ART on CD4 recovery using the same data, however, found that recovery was 
slower in children with lower baseline CD4 percentages supporting earlier initiation of 
paediatric ART.186 The CHER trial33 established the substantial mortality benefit of early 












optimal timing of ART initiation in older children remains unclear.187-189 The Pediatric 
Randomised Early versus Deferred Initiation in Cambodia and Thailand (PREDICT) RCT 
found no difference in AIDS-free survival, Centre for Disease Control (CDC) Stage B or C 
events, rate of immune response or neurodevelopmental outcomes when starting children 
aged 1-12 years on ART immediately compared to deferring until WHO 2006 treatment 
initiation criteria were met.190-192 However the study was underpowered to detect a mortality 
difference due to the lower than expected mortality and occurrence of new AIDS events in 
the study.189 In addition, it only included a small number of children in the 1-5 year age group 
in whom disease progression would be expected to be most rapid and the benefits of early 
ART are likely to be greatest.188,192 There may be a role to use cohort data to examine the 
mortality benefit of starting ART at different CD4 thresholds in this age group as has been 
done for adults.193-195  
 
3.3 Measuring treatment success in patients retained in care and 
determinants of virological failure 
 
Optimal monitoring of children on ART 
There has been much debate on optimal monitoring strategies for resource-limited settings 
and a number of RCTs and cost effectiveness analyses have examined different strategies for 
measuring treatment success in patients on ART.37,135,196,197 This is especially important for 
children where treatment options are limited.36 Children should remain on first-line for as 
long as it is effective, but accumulation of resistance mutations that might limit the success of 












Diagnostic accuracy of immunological criteria for identifying confirmed 
virological failure 
In a setting with access to 6-monthly HIV-RNA monitoring, we found that one in five 
children would meet virological failure (VF) criteria by three years on ART.146 However, 
routine HIV-RNA measurement is expensive and remains inaccessible in many settings. A 
key question is therefore whether it is possible to identify these children without routine HIV-
RNA monitoring. A number of studies have now reported similar results to our studies of 
diagnostic accuracy regarding the poor ability of both clinical and immunological criteria to 
diagnose VF.67,144,147,152,180,198 Both of our studies on diagnostic accuracy are the biggest to 
compare HIV-RNA and CD4 measures and the only studies to do this continuously for up to 
three years with failure diagnosis based on a confirmed elevated viral load.144,147 Comparison 
of immunological criteria with a VF diagnosis based on a single elevated HIV-RNA 
measurement over-estimates PPV as a substantial proportion of patients resuppress on 
subsequent measurement.199 In our paper on TVL, even among children meeting 
immunological failure (IF) definitions, a small but important number resuppress after a single 
elevated viral load.147  
Effectiveness and cost-effectiveness of CD4 and HIV-RNA monitoring in 
reducing mortality 
While clinical and immunological criteria are poor at identifying VF, the impact of this on 
mortality may be limited. The Antiretroviral Research for Watoto (ARROW) trial in children 
on NNRTI-based first-line recently reported similar results to the Development of 
AntiRetroviral Therapy in Africa (DART) trial in adults showing a small risk difference in 
mortality of patients randomized to laboratory monitoring (CD4 measurements but not HIV-
RNA) compared to clinically driven monitoring.200,201 However the cost-effectiveness of 












monitoring.202,203 There has been limited RCT evaluation of HIV-RNA monitoring; lower 
mortality/new AIDS events were found in adults randomized to either clinical+CD4 or 
clinical+CD4+HIV-RNA monitoring, compared to those monitored clinically only, but there 
was no difference in the first two monitoring arms.204  
Cost effectiveness analyses of different monitoring strategies have mostly focused on adults 
and have yielded conflicting results due to differences in the strategies evaluated and 
modelling scenarios.197,205-211 The only analysis in children based on a cohort on NNRTI-
based first line reported the optimal frequency of HIV-RNA monitoring to be annual, after a 
single screen at 6 months.210 Compared with no HIV-RNA monitoring, the optimal strategy 
reduced total person-years of VF by 77%.210 However the costs of such monitoring and 
second-line ART when needed would approximately triple current treatment costs.210 The 
incremental cost per quality adjusted life year gained using optimal monitoring was estimated 
as US$ 68,084 when including costs of ART and US$ 7,224 without ART costs.210 The 
estimated cost attributed to preventing one year of VF was US$ 3393 and US$ 359 with and 
without ART costs respectively.210 
Modest mortality benefits associated with HIV-RNA monitoring in comparison to expanding 
ART coverage are perhaps not surprising. While remaining on a failing NNRTI-based first-
line regimen is associated with rapid and early accumulation of NNRTI-resistance mutations 
as well as TAMS,152,173,212 there is limited evidence in children that early switching to 
second-line confers mortality or morbidity benefit.212 More than 80% of Ugandan children 
suppressed on LPV/r-based second-line after failing first-line NNRTI-based therapy with 
extensive resistance.213 A systematic review found that in adult patients on NNRTI-based 
therapy, HIV-RNA needs to be measured three-monthly to avoid the development of 
resistance mutations.214 This may not currently be a realistic in resource-limited settings, and 












monitoring requirements and first and second-line regimens with non-overlapping resistance 
profiles. Wider availability of integrase inhibitors for children could ensure less overlap of 
resistance profiles.  
Other roles of HIV-RNA monitoring 
HIV-RNA monitoring may nevertheless be valuable where it can be made available, 
irrespective of whether it confers mortality benefit. Our finding that one in five patients still 
in care by three years of therapy would fulfil the criteria for a diagnosis of VF according to 
WHO 2010 criteria22 is extremely useful for programme planning and identifying children 
needing more intensive review of their treatment, even though not all of these children may 
require or benefit from second-line therapy. We did not do resistance testing in children with 
VF, however it is likely that not all of these children have resistance and need second-line 
ART, especially in the context of LPV/r-based first line therapy where development of 
resistance is unusual.141,216,217 Further, the finding that a notable proportion of those with VF 
showed no virological response to treatment may indicate ongoing poor adherence, rather 
than true treatment failure, and highlights the difficulty of distinguishing between non-
adherence and failure in children on LPV/r-based ART.  
Despite these differences in interpreting a VF diagnosis depending on the first-line therapy 
used, the paper highlights that by three years, 20% of children will need some sort of 
intervention, whether adherence support, regimen simplification to more adherence-friendly 
drugs or change to second-line therapy, while the remaining children experience a relatively 
uncomplicated course in terms of virologic response to treatment. Indeed, in adults on  
NNRTI-based therapy, it has been argued that at the 6-12 months frequency that HIV-RNA 
monitoring is currently implemented when available in resource-limiting settings, its major 












of viraemia has been shown to indicate whether the patient is likely to be non-adherent or 
truly failing therapy.135,136,218,219 Given that resistance to LPV/r is rare, the major role of HIV-
RNA monitoring in children, especially those on PI-based therapy as included in our studies, 
may also be as an “adherence test”. Despite its current cost, such an “adherence test” is very 
useful in children where the best self-report measure of adherence is by proxy of the 
caregiver and has been shown to correlate poorly with virological outcomes. Volumetric 
measurement of returned syrups is cumbersome and may be difficult to interpret due to 
spitting, spillage and vomiting of medication.172,220,221 Using HIV-RNA monitoring to 
identify the 80% of children without VF may also be useful in determining the level of care 
needed and facilitating decentralization to primary care. A further benefit of HIV-RNA 
monitoring in resource-limited settings is reducing transmission of resistant virus.222 This is 
an important consideration in perinatally infected adolescents who may have been exposed to 
many years of ART by the time they become sexually active. 
Strategies for HIV-RNA monitoring in resource limited settings 
Given these non-mortality benefits of HIV-RNA monitoring, there may be a role for 
innovative monitoring approaches in resource-limited settings that are less costly. These 
include pooled HIV-RNA measurements on pre-selected patients with a low pre-test 
probability of having an unsuppressed HIV-RNA measurement, different monitoring 
frequencies, qualitative point of care tests based on different HIV-RNA thresholds shown to 
be associated with poor adherence or true VF and TVL strategies.197,223-227 For instance, a 
strategy of pooled HIV-RNA measurement on patients with a low pre-test probability of VF 
resulted in 30-60% fewer tests, thus lowering the cost of HIV-RNA monitoring.223 This 
approach may be more difficult to implement in children where the probability of an 
unsuppressed HIV-RNA measurement is higher than in adults. Indeed, there has been limited 












TVL monitoring strategy has only been evaluated in adults, but was found to be the most 
cost-effective monitoring strategy, with an incremental cost-effectiveness ratio similar to that 
of ART initiation at higher CD4 thresholds.207 The analysis of TVL included in this thesis 
shows substantial improvement in PPV for diagnosing VF compared to immunological 
criteria alone, suggesting that this may also be a useful strategy in children in settings where 
access to HIV-RNA monitoring remains restricted. 
Guidelines for management of patients with VF 
To be beneficial, any monitoring strategy needs to be supported by clear guidelines regarding 
how to manage patients identified as potentially failing therapy. We found considerable 
between-site heterogeneity in switching practices, with a large proportion of children not 
switched to second-line therapy or switched only after a long period.146 South African 2010 
and 2013 draft paediatric HIV guidelines162,228 are much clearer regarding management of a 
child with unsuppressed HIV-RNA. Recommendations include earlier repeat testing 
following HIV-RNA >1000 copies/ml, and lower thresholds for switching in children on 
NNRTI-based regimens or previously exposed to unboosted RTV, where resistance testing is 
recommended.141,217,229 
Strategies for optimising the durability of first-line ART and possible 
alternative approaches in children meeting VF criteria. 
Given the large number of children that may need some sort of treatment intervention, and 
the few alternative drugs, especially for PMTCT-exposed children initiating LPV/r-based 
first-line therapy, evaluating strategies that may delay the development of treatment failure, 
such as temporary treatment interruptions, is warranted. Results regarding treatment 
interruptions are conflicting: The CHER study found that in children who received ART from 
early infancy and then interrupted at two years of age, one-third of children had no clinical 












seemed less successful in a smaller study where ART was started later in infancy.231 The 
Paediatric European Network for Treatment of AIDS (PENTA) trial of planned treatment 
interruptions in older children (median age of nine years and duration on ART of six years 
when randomized to interrupt or continue therapy) showed no serious adverse clinical 
outcomes in children that interrupted therapy.232,233 This is in contrast to findings from adult 
studies.234 The PENTA study found that treatment interruptions were acceptable to patients 
and carers, however some considered the need for more clinic visits during the interruption to 
be a problem.235 Indeed, the need for more intensive clinical and laboratory monitoring of 
children during interruptions may be a barrier to implementing this strategy in resource-
limited settings where facilities are already overburdened and access to laboratory testing is 
poor. 
Monotherapy with 3TC in children with the M184V mutation during periods where there are 
barriers to adherence may also be a reasonable approach.236 In a longitudinal US-based cohort 
it was recently reported that by 12 months after a VF diagnosis (confirmed HIV-RNA >1000 
copies/ml), 73% of children remained on their failing first-line regimen, and 5% were 
changed to mono- or dual therapy regimens such as 3TC monotherapy.236 The outcomes of 
this strategy still need to be evaluated, however. 
Higher risk of VF associated with NVP-based regimens 
We found that NVP was associated with an increased risk of VF in comparison to EFV- or 
LPV/r-based regimens and this effect was independent of PMTCT exposure.146 Worse 
virological outcomes on NVP compared to LPV/r or EFV have been reported from other 
paediatric ART cohorts63,131,180 as well as from adult studies.237 The finding of better 
virological response to LPV/r compared to NVP irrespective of prior exposure to NVP for 












was more common with NVP than LPV/r (hazard ratio: 3.00; 95% CI, 1.06 to 8.21) and 
similar findings have been reported by an analysis of treatment-limiting toxicity of the 
IeDEA-SA data.238 Poorer NVP efficacy may be due to the very high viral loads in infants 
and young children. Agents against which single gene mutations confer resistance such as 
NVP may be suboptimal in the presence of high viral replication and prolonged time to 
suppression.239 In our study of VF, 21% of children had baseline HIV-RNA >1 million 
copies/ml.146 While we did not have resistance data in our study, the high frequency of NVP 
resistance in the NVP arm of P1060, and the rapid accumulation of resistance mutations in 
children treated with NNRTIs in the PENPACT trial and other cohort studies support this 
hypothesis.130,176,212 It has also been postulated that underdosing of NVP may occur during 
the ramp-up of dosing in the first two weeks of therapy when viral loads in infants are 
especially high.130 For this reason as well as simplification of drug administration, ART 
initiation with full dose NVP has been compared with the ramp-up strategy, but was 
associated with higher risk of rash.240 However the authors considered that this may be 
manageable without interrupting treatment.240 The baby “cocktail” using a four-drug NVP-
containing regimen in infants initiating ART may be another strategy for improving the 
outcomes in children initiating therapy on NVP-based regimens.241 A collaborative European 
cohort study found  virological and immunological responses at 12 months after ART 
initiation in infants on four-drug NNRTI-based regimens to be superior to both three-drug 
NNRTI-based and PI-based regimens.241 
Implications for recommended first-line treatment in infants and young 
children 
It is likely that WHO 2013 guidelines will now recommend LPV/r-based first-line ART for 
all children less than three years old if feasible. However there are a number of challenges to 












difficulty of co-treatment for tuberculosis and unpleasant taste which makes adherence 
challenging.187,188 We did not measure adherence in our study, but the high rate of virological 
non-response may indicate non-adherence in some children. There may be a role for 
treatment simplification or induction-maintenance strategies in children initiating LPV/r-
based therapy such as treatment interruptions described above or changing to NNRTI-based 
therapy in virologically suppressed children, especially those not previously exposed to 
PMTCT NVP.242 The NEVEREST trial examined substitution of NVP for LPV/r in the first-
line regimen of virologically suppressed children previously exposed to sdNVP.243 However, 
this strategy requires HIV-RNA monitoring both before and after changing therapy which is 
still not available in most resource-limited settings. In addition, the widespread use of 
extended NVP prophylaxis in infants for PMTCT, limits the applicability of the NEVEREST 
findings.  
While LPV/r is now available in tablet formulation, tablets are large and cannot be crushed 
making their administration difficult.244 There are, however, promising results of a new 
generic LPV/r sprinkle formulation that has recently been evaluated in Uganda in children 
aged one to four years.245 Pharmacokinetic parameters were similar to those of LPV/r syrup 
with neither formulation resulting in subtherapeutic concentrations.245 Nevertheless, while 
carers preferred the sprinkle for storage and transport reasons, nearly 70% rated both syrup 
and sprinkle formulations as unpleasant, and nearly 20% of carers reported child refusal of 
the drug in sprinkle formulation.245 
Limitations: effect of PMTCT exposure and tuberculosis on risk of VF 
Like many cohort studies, our study did not have sufficient data to look in detail at the effect 
of prior PMTCT exposure on VF.63 However, it is well known that prior exposure to sdNVP 












as well as the P1060 cohort trial have demonstrated an increased risk of VF.129,252,253 
Resistance has also been reported in children infected despite maternal triple ART for 
PMTCT,254,255 however the impact of this on subsequent virological response to treatment is 
unknown.  
We also had insufficient data on co-treatment for tuberculosis to determine its effect on VF. 
Other studies have reported lower probability of virological suppression and higher risk of 
rebound only among children on PI-based first-line regimens co-treated for tuberculosis or 
experiencing incident IRIS.41,98,256,257 Frohoff et al. 257 found that amongst children on PI-
based first-line, virological suppression in children co-treated for tuberculosis was only lower 
than for children without tuberculosis among those treated with double-dose LPV/r or RTV 
alone, but not among those treated with RTV-boosted LPV/r. In contrast, Reitz et al.41 found 
poorer virological outcomes in co-treated children on PI-based therapy irrespective of the 
treatment modification used. Poorer virological outcomes in children treated with RTV were 
also found in our study and it was not possible to determine whether this was due to RTV 
itself or tuberculosis.146 However, the development of resistance mutations in children treated 
with unboosted RTV, in contrast to the rarity of resistance in children treated with LPV/r, has 
been established.141,216,217,229  
Role of cohort studies in monitoring the safety and effectives of ART 
The finding of increased risk of VF in children treated with NVP compared to LPV/r in our 
and other cohort studies, highlights the important role for well conducted and appropriately 
analysed cohort studies in rapidly generating effectiveness and safety data. Due to the large 
size and lack of exclusion criteria of cohort studies, in some circumstances their results may 
be more generalizable and more applicable to routine care settings than that of RCTs. It has 












field of comparative effectiveness research that do not lend themselves to assessment in 
standard analyses of RCTs.258-260 Comparative effectiveness research (CER) is the generation 
and synthesis of evidence that compares the benefits and harms of alternative methods to 
prevent, diagnose, treat, and monitor a clinical condition or improve the delivery of care.261 
When applied to a chronic condition such as HIV, RCTs have been very successful in 
showing that ART is beneficial, however a number of key questions such as what to start, 
when to start, when and how to monitor and when to switch remain unanswered.22 For each 
of these questions there are a range of possible strategies with potentially very wide variation 
in effectiveness and safety. While RCTs are the best method of assessing the effectiveness of 
one-time treatments, they are a less well suited to examining the effectiveness and safety of 
long term clinical strategies.123,260 
Cohort studies may be especially important in the rapidly changing field of CER to inform 
HIV care and treatment guidelines and there are a number of examples where evidence has 
emerged from cohort studies rather than RCTs, leading to guideline changes. For example, 
stavudine-associated lactic acidosis was identified by cohort studies262-264 and not in the 
initial RCTs of the drug which were mainly conducted in North America in populations 
where the prevalence of risk factors associated with developing this condition (female sex, 
overweight) were low.260,262 One of the IeDEA-SA paediatric cohorts has recently 
demonstrated a decline in probability of virological suppression at 6 and 12 months co-
incident with the change from d4T to ABC based first-line therapy.265 While secular trends 
cannot be excluded as the cause of this finding, it is plausible that it may be due to lower 
efficacy of ABC especially in patients with higher viral loads.266,267 Cohort studies may be 
particularly important for children where conducting RCTs is more challenging and many 












be particularly useful in monitoring safety and effectiveness after guideline changes as 
illustrated by these two examples.  
 
3.4 Monitoring the scale up of ART for children through temporal 
trends in characteristics at ART initiation 
 
Improvement in disease severity characteristics at ART initiation 
The paper on temporal trends at ART initiation demonstrates successful scale up of ART in 
that in recent years increasing numbers of children have started therapy, children are 
initiating ART with less severe disease and the proportion of infants starting ART is 
increasing. However, even during 2010, a substantial number of children still initiated ART 
with advanced disease. One of the reasons for slow improvements in characteristics at ART 
start may in fact reflect successful expansion of access to ART as there may be a reduction 
over time in the survival bias when examining patients initiating therapy. In later years, as 
experience with paediatric ART increased and time from diagnosis to ART initiation 
decreased, children may have been initiated on ART who previously would have died before 
ART start. This hypothesis is supported by an analysis of adults from first HIV visit to ART 
initiation in the Free State province of South Africa, with the two competing outcomes of 
time to ART initiation or death prior to ART start. Compared to patients with CD4 of 100-
200 cells/mm3, those in the lowest CD4 category (<25 cells/mm3) were 35% less likely to 
start ART because they were three times more likely to die before ART initiation.268 The risk 
of dying before ART initiation may be even higher for infants and young children where 
disease progression is very rapid and barriers to ART initiation may be greater than in 
adults.5,36,37,70,71,82 Two years after eligibility in the Free State pre-ART mortality was 26% in 












South Africa, between 1997 and 2002 before widespread availability of PMTCT or paediatric 
ART, an increasing peak in infant mortality was noted at two to three months of age, which 
was most likely due to HIV, highlighting the rapid disease progression and high early 
mortality associated with paediatric HIV infection.269 Consequently, one of the major barriers 
to early infant ART even where PCR testing is widely available and implemented at six 
weeks of age, is the optimal timing of testing. A two-stage testing approach at birth and 10-14 
weeks of age could avert rapid disease progression and early mortality in perinatally infected 
infants.270 
Temporal trends in age at ART initiation 
As was found by a previous South African analysis of temporal trends in characteristics at 
ART start, there were growing numbers of both infants and older children at ART 
initiation.165 These results concur with predictions from a South African model of paediatric 
HIV. By 2020, with more effective and better coverage of PMTCT resulting in fewer new 
infant infections and hence a shift to more ART initiation in older long-term survivors, as 
well as children living longer on ART, the burden of paediatric HIV disease is predicted to 
shift towards older children.271 The mean age of children either on ART or ART-eligible 
(based on WHO 2006 criteria) was estimated to have increased from 3.3 years in 2000 to 7.2 
years in 2010, and is predicted to increase further to 8.1 years by 2020.271 In contrast, in our 
analysis the median age declined as we only looked at characteristics at ART start, and ART 
initiation in most of the IeDEA-SA cohorts by the end of 2010 included universal ART for all 
infants less than one year of age, rather than the more restrictive WHO 2006 guidelines used 
in the model-based analysis. Like our analysis, most papers only report on characteristics at 
ART start, however examining the changing age structure and disease characteristics in 
children remaining in care is also important to ensure that programmes continue to be focused 












Diagnosis and linkage to care of HIV-infected infants 
Our analysis comments on the importance of early diagnosis and linkage to care in ensuring 
that infants start ART before disease progression, but does not actually include data from the 
pre-ART period. In a meta-analysis of retention in care between HIV diagnosis and starting 
ART, including mostly older children, 63-89% of children identified as HIV-infected were 
assessed for ART eligibility and 39-99% of eligible children started ART.273 Estimates of 
pre-ART mortality and LTFU ranged from 3-46% and 0-37%, but were only reported by a 
few studies.48,53,58,69,116,185 None of the studies reviewed examined retention in care in those 
known to be HIV-exposed from birth through diagnosis to ART initiation in the era of 
universal ART, where there is no eligibility assessment step. However a high proportion of 
known HIV-exposed infants do not return for PCR testing,274-276 and we know that disease 
progression and mortality in this period is rapid especially in infants infected in utero.33,72,270  
 
Measuring paediatric ART coverage 
Our analysis demonstrates increasing numbers of children on ART that match the findings of 
increased ART coverage.2,32 Johnson and Boulle277 highlight the difficulties in interpreting 
coverage statistics that are highly sensitive to changes in eligibility criteria235 as well as 
programme duration, whereby longer running programmes will have an increasing number of 
patients contributing to both the numerator and denominator of the coverage metric, with 
little influence of recent programme performance.277 They propose an additional measure of 
recent programme performance, the enrolment ratio, which is the ratio between the number of 
children initiating ART in a particular time period and the number of new infections in 
children <24 months of age in the same period.277 The enrolment ratio needs to be considered 
alongside coverage figures, as, if there is a large coverage backlog, the enrolment ratio may 












many countries are large.1 Even using coverage and enrolment ratio, poor programme 
performance in terms of rapidly initiating ART in infants where mortality benefit is the 
greatest can easily be missed as enrolment ratios may be much greater than one due to the 
backlog of older children not yet on ART. Expansion of universal ART to all children less 
than five years of age as has been adopted in South Africa161,162 and is likely to be 
recommended in WHO 2013 guidelines will simplify programmes and may therefore 
accelerate early ART initiation in younger children as well. This is one of the reasons 
provided for the change in South African guidelines.161,162 However it may muddy the waters 
when interpreting coverage statistics even further. Coverage may improve as programmes 
initiate ART in children already in HIV care now eligible for treatment under new guidelines, 
without any increase in diagnosis and early ART initiation in infants. Aiming for higher 
coverage of all children under five years may even occur at the expense of investing 
resources in ensuring early diagnosis and treatment in infants where there is a known 
mortality benefit. In Uganda, the main ART eligibility criterion that did not lead to ART 
initiation was being <12 months of age.235 For the most part, expansion of ART initiation to 
patients without immune suppression is associated with modest mortality benefits193,278,279 
and the rationale for extending universal ART to all children less than five years of age is 
based on programmatic simplification, with no proven mortality reduction.191 In contrast, 
universal ART for all infants less than one year of age has large proven mortality benefit33 
and it is important to directly monitor the extent to which this goal is being achieved. 
Other areas of observational HIV cohort research important for 
understanding and improving paediatric ART scale-up 
This thesis has used analyses of the IeDEA-SA combined dataset from paediatric 
observational cohorts to reflect on a number of areas critical to understanding and improving 












particularly mortality and its determinants, the measurement of treatment effectiveness in 
children in resource-limited settings, determinants of treatment failure, the role of HIV cohort 
research in monitoring the safety and effectiveness of different ART regimens as well as 
initiation and monitoring strategies, and the extent of successful expansion of access to ART, 
especially in response to revision of treatment guidelines.  
There are, however, a number of other key areas of cohort research not addressed by this 
thesis that are important for informing successful paediatric ART programmes. These include 
studies of comorbidities such as IRIS, malignancy,280 opportunistic infections and 
prophylaxis94,98,99,121,122,256,281-288 as well as adherence to therapy and retention in 
care,92,115,117,172,289,290 and the impact of different models of care on these outcomes. In 
particular, with the increasing age of children in care in ART programmes, it is important to 
understand the effect of HIV disclosure, as well as different models of transition from 
paediatric to adolescent and ultimately adult care on adherence and retention in care.291,292 
Ways of successfully integrating such models of care into existing health services in a context 
of limited resource need to be examined. For example, while task-shifting has been widely 
proposed as a means to expand access to ART and nurse initiation and management of ART 
in adults has been shown to be non-inferior to that of doctors, these approaches have not been 
extensively studied in children.293-298 Similarly, there may be a role for adherence clubs or 
community-based care in children and adolescents, but these have not been evaluated in this 
population.299-302 Paediatric ART cohorts may be well positioned to implement and evaluate 















This thesis has analysed outcomes on ART both within South Africa and across the Southern 
African region, with a focus on mortality and VF. It has reviewed monitoring strategies for 
identifying children with VF needing adherence interventions or second line therapy in the 
absence of access to routine HIV-RNA monitoring. Lastly it has reviewed the evolution in 
HIV programmes in relation to changing WHO and national guidelines by examining 
changes in child characteristics at ART start since initiation through three iterations of WHO 
guidelines. 
The first major contribution of the thesis is to demonstrate the good outcomes for up to three 
years on ART in cohorts representing a substantial proportion of the South African national 
ART programme, supported by good compliance with monitoring guidelines. The prognostic 
model extends the finding of good survival outcomes on ART to programmes across the 
region and provides estimates of absolute mortality risk based on a generalizable model that 
is reasonably robust to programme heterogeneity.  
A second major contribution is to provide estimates for up to three years on ART of 
confirmed VF in children on both PI- and NNRTI-based therapy, and to demonstrate the poor 
diagnostic accuracy of non-routine HIV-RNA monitoring strategies for identifying these 
children. While sensitivity for VF is low, a TVL strategy can reduce switches to second-line 
therapy in virologically suppressed children with immunological failure.  
Thirdly, we demonstrated inferior virological outcomes in children treated with NVP-based 
compared to LPV/r based first-line therapy, irrespective of PMTCT exposure, a finding 
which has now been confirmed from RCT data. 
Finally, changes in number and characteristics of children at ART initiation from 2005-2010 












programmes that are tailored to the children being treated. The improvements in ensuring 
earlier access to ART at less severe disease are, however, modest. Future extensions of 
eligibility will make it increasingly difficult to monitor that very young infants who are at 
greatest risk of mortality in the absence of ART are prioritised for rapid initiation. This 
analysis thus highlights the need for integration of services for PMTCT, maternal and child 
health and paediatric HIV care in order to ensure early diagnosis and ART initiation. As 
PMTCT coverage and effectiveness increase, it will be important to also integrate research in 
these areas so that the impact of PMTCT exposure on the outcomes of HIV-infected and the 
large numbers of HIV exposed uninfected children can be studied, and the interface and 
pathway between PMTCT, early infant diagnosis and HIV care can be understood and 
optimized.  
The thesis also emphasizes the role of paediatric HIV cohort research in order to answer 
clinical questions related to treatment strategies and models of care for children on lifelong 
ART that may be difficult to answer in RCTs. With increasing numbers of adolescents 
surviving with HIV and exposed to ART for long periods of time, the interaction between 
pubertal development, the effects of HIV and its treatment needs to be understood.292 Cohort 
studies may be well positioned to assess this. It is also important that cohort studies continue 
to evaluate the effect of guideline changes in eligibility, monitoring and regimen use and 
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1 Introduction  
1.1 General remarks 
 
• This document provides guidance on the preparation of data tables for the transfer of data 
for the IeDEA Southern Africa Collaboration. 
• It is requested that each clinic prepares ten separate tables with the new data, as described 
in detail below. While 6 of these tables should be submitted by all sites, tables 7 -10 will 
only be applicable to certain sites (see below).  
• The tables can be sent in the format that is most convenient for the site, including MS Excel, 
MS Access, ASCII etc. Please contact the IeDEA data manager if you have any queries.  
• It is appreciated that for some clinics it may be easier to send their data as they stand 
(for example in Excel) and to leave the data management and preparation of the ten 
tables to the data centre. This is not a problem, but it is requested that a separate 
document be included with a list of the variables in the dataset and brief 
descriptions/definitions.  
• It is accepted that there will be missing data for some patients, and even entire missing 
tables from some sites who simply do not have that data in electronic format.  
• It is requested that for security purposes, data tables be encrypted and compressed with 
WinZip 9 or higher using the AES encryption algorithm prior to sending.  The encryption 
password (minimum of 10 characters long, including upper/lower case, numbers and special 
characters) should be communicated to the relevant data centre contact person by fax or by 
telephone.   
• Please ensure that the dataset has been stripped of personal identifying information prior to 
sending. 
• Please include a unique anonymous identifier for each patient (PATIENT) for cross-
reference with your own database. It can be the identifier you are using or a special 
identifier you create for IeDEA Southern Africa. This anonymization key must be 
maintained by the site under secure conditions.  
• Sites treating children should please send the date at which they changed from using the 
WHO 3-stage clinical staging system to the 4-stage clinical staging system. 
• Thank you very much for your contribution to this collaborative project! 
 
1.2 Inclusion criteria for patients 
 
Please include all patients with the following characteristics:  
 
• Documented HIV-1 infection  
• Patients in care at the facility for whom the date of first visit at the facility is known exactly.  
Notes: 
• Where possible, it is intended that data be transferred on HIV-infected patients followed-up 
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• When transferring data just on patients who received HAART, it is preferable to include 
patients irrespective of whether or not they were exposed to antiretrovirals before the 
recorded HAART start date. In other words treatment-naïve and treatment-experienced 
patients are included.  
• Sites should send all information on all patients (adults and/or children) in a single dataset. 
For adult patients (those whose first visit at your facility was after their 16th birthday) the 
paediatric specific fields (highlighted in blue) do not need to be completed (i.e. enter code 
88 – not applicable). Paediatric specific fields must be entered as completely as possible for 
all patients whose first visit at your facility is before their 16th birthday even if their 
follow-up extends beyond the age of 16 years.  
• Some patients will have been in care at another facility prior to commencing care at your 
facility. These patients should be included in the dataset, noting against the relevant field 
that they have been transferred in. All treatment and opportunistic infection (OI) history 
prior to commencing care at the facility should be reconstructed as far as possible and 
entered in the appropriate tables, with unknown codes for dates of start and end date of 




• The term baseline will not be used as this creates confusion. We will rather make use of a 
set of key dates that will be entered into the first table, the PATIENT table. These are: 
 
Variable name Definition of key date 
FRSVIS_DMY Date of first visit at your facility 
HIVP_DMY  
(HIVP_Y (year) and HIVP_M (month) if 
exact date unknown) 
Date of first positive HIV-1 test 
HAART_DMY Date of HAART initiation 
 
• For all fields that require a date, the precise date should be entered in the format  
dd-mm-yyyy if it is known. If the precise date is not known, the month and year should be 
entered separately as far as possible in the separate dedicated fields provided for these, and 
the precise date field should be left blank.  
• If month or both the year and month are unknown, the precise date field should be left blank 
and unknown codes should be entered into the year field (9999) and the month field (99) as 
appopriate.   
• For certain date fields a precise date is obligatory e.g date of first visit at your facility 
(FRSVIS_DMY) and date of HAART initiation (HAART_DMY). In patients who 
commenced HAART at another facility, if the precise date of start of HAART cannot be 
estimated reasonably accurately, the patient should be entered as treatment experienced and 
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1.4 Definitions  
 
• HAART is defined as treatment with a combination of at least three drugs from any class or 
classes.  
• “Treatment experienced” is defined as previous exposure to any antiretroviral drug for at 
least 30 days, excluding exposure for prevention of mother to child transmission (PMTCT) 
or post-exposure prophylaxis (PEP).  
 
1.5 Standard codes 
 
Certain codes will appear repeatedly in a number of lists for coded fields. In this instance, the same 






95 Not ascertained/Not collected at this facility 
99 Unknown despite attempting ascertainment  
88 Not applicable 
 
1.6 Data tables 
 
For each clinic, the following five to ten data tables or files should be prepared, depending on data 
availability.  
 
• Tables 1 to 5 are required by all sites.  
• Table 6 (LINKAGE DATA) is required only for sites that record information on families 
• Table 7 (PREGNANCY) is required only for sites that record information on pregnancy 
electronically.  
• Table 8 (PAR HEALTH) is required only for patients who commence care before their 16th 
birthday.  
• Table 9 (TB) is required only from sites that record detailed information on episodes of 
tuberculosis electronically.  
• Table 10 (TRIAL) is required only for sites where patients may be enrolled on clinical trials 
or research studies apart from cohort analyses of routinely collected data.  
• In addition, a table summarising with information on the overall cohort or “meta-data” for 
the transfer, should be included with all transfers. 
  
1. PAT (Patient data): A table containing socio-demographic data on patients, clinical 
characteristics at start of HAART in HAART-treated patients, as well as information on the 
outcomes of patients. One line will correspond to one patient. In other words, each patient 
will appear only once in this table. We propose that this table is called PAT.   
2. LAB (Laboratory data at baseline and follow-up): This is a single table containing all 
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correspond to one laboratory result. In other words, most patient will have multiple records 
in this table. We propose that this table is called LAB.  
3. ART (Antiretroviral treatments): A table with the data on all antiretroviral drugs that a 
patient has received or been exposed to including PMTCT (both exposure to mother as well 
as infant peri- or post-natal) or post-exposure prophylaxis. This includes treatment received 
at your facility and at other facilities.  The table will contain one line for each separate drug, 
with different fields for the drug name (code), the prescription start dates and stop dates.  
Most patients will have numerous records in this table.  The drug history of patients who 
commence care at your facility but have previously been treated at another facility should be 
reconstructed and entered into this table as far as possible. We propose that this table be 
called ART. 
4. OI (Opportunistic Events): A table with the information on all opportunistic infections or 
incident HIV-associated diagnoses. One line will correspond to one clinical event with 
different fields for the event type (code), the start dates and stop dates. It is anticipated that 
stop dates will often not be known. In other words, some patients will have more than one 
record in this table and some may have no records in this table. History of opportunistic 
events occurring prior to commencing care at your facility should be reconstructed as far as 
possible.  We propose that this table be called OI. 
5. VIS (Visit data): A table containing information on all clinical visits (including the first 
visit at your facility). One line will correspond to one visit.  Most patients will have more 
than one record in this table. We propose that this table be called VIS. 
6. LINK (Linkage data): A table containing information on family members (partners, 
children and siblings) also receiving HIV care either within your cohort or at another site. 
All family members receiving HIV care should be included whether they are receiving care 
at an IeDEA collaborative site or at a non-IeDEA site. One line will correspond to one 
family member receiving HIV care. In other words, some patients will have more than one 
record in this table and some may have no records in this table. We propose that this table is 
called LINK.  
7. PREGNANCY (Pregnancy data): A table containing information on all pregnancies, 
including spontaneous abortions/miscarriages and terminated pregnancies, and their 
outcomes. One line will correspond to one pregnancy. Multiple pregnancies will each have a 
record in the table, with the outcome of the relevant foetus recorded. Some patients will 
have more than one record in this table, while others (including all males and children less 
than 10 years) will have no records in this table. We propose that this table be called 
PREGNANCY. 
8. PAR_HEALTH (Parental health): A table with information on parental health status. This 
table is only required for sites sending data on patients 15 years old and younger at their first 
visit to the facility.  This table is linked to the visit table, so ideally there is an update on 
parental health status at every visit. Alternatively, this table should be filled in at least once, 
either for the first visit at your facility or the date of start of HAART.  
9. TUBERCULOSIS (Tuberculosis data): A table with information on all episodes of 
tuberculosis (TB). This table is only for sites that record detailed information on TB 
episodes. Sites that do not collect detailed information on TB episodes should enter the TB 
episodes in the OI table. One line will correspond to one TB episode. In other words, some 
patients will have more than one record in this table and some may have no records in this 
table. We propose that this table be called TB. 
10. TRIAL (Enrolment in trials): A table with information on any trial or research study 
(apart from cohort analysis of routinely collected data) on which a patient is enrolled.  This 
table is only for sites running trials or research studies. One line will correspond to one 
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more than one record in this table and some may have no records in this table. We propose 
that this table be called TRIAL. 
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2 Variables to be included in core tables 
2.1 Socio-demographic characteristics and outcomes (PAT table) 
 
Table 1 below details the data that should be included in PAT table.  
 
The patient identification variable (PATIENT) must be unique, and it cannot be missing in 
any of the tables. This field must contain a unique and anonymous patient identifier; the field 
must NOT contain their name or any other identifying information. It is up to the local 
collaborator to maintain the key for linking the unique patient identifier with the patient. 
 
Table 1 – Variables to be included in PAT table 
Name Format and definitions Description 
PATIENT Free (numerical or alphanumerical) Unique, anonymous, patient identifier 
COHORT Text Text field identifying the cohort 
FACILITY Text Text field identifying particular clinic within cohort, if more than facility within the cohort 
BIRTH_DMY DATE (dd-mm-yyyy) 
Date of birth  
Enter exact date in this field if known. 
 If unknown leave blank and enter month and 
year as far as possible in fields below. 
BIRTH_Y 
Numeric (for example 1960) 
 
9995 = Not ascertained 
9999 = Unknown despite attempting 
ascertainment 
Year of birth 
BIRTH_M 
Numeric (for example 8) 
 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Month of birth 
GENDER 
Numeric with codes: 
 
1 = Male 
2 = Female 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Sex / gender of patient 
FRSVIS_DMY DATE (dd-mm-yyyy) Date of first visit at facility  (Note: This date must be entered exactly) 
ENTRY Numeric with codes (see List 1) Mode of entry to your facility 
ENTRY_OTHER Text Details of other mode of entry not listed in List 1 
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HIV_TYPE 
Numeric (for example 1) 
 
1 = HIV-1 
2 = HIV-2 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Field to distinguish HIV-1 from HIV-2 
HIVP_DMY DATE (dd-mm-yyyy) 
Date of first positive HIV test 
Enter exact date in this field if known. 
 If unknown leave blank and enter month and 
year as far as possible in fields below. 
HIVP_Y 
Numeric (for example 2001) 
 
9995 = Not ascertained 
9999 = Unknown despite attempting 
ascertainment 
Year of first positive HIV-1 test 
HIVP_M 
Numeric (for example 8) 
 
95 = Not ascertained  
99 = Unknown despite attempting 
ascertainment 
Month of first positive HIV-1 test 
HIV_TEST 
Numeric with codes (IeDEA SA codes) 
 
1 = Presumptive diagnosis 
2 = Serology 
3 = PCR 
4 = P24 
5 = Rapid test 
90 = Other 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 




0 =  Never started HAART 
1 =  Started HAART  
Conditional: 







Date of HAART initiation  
(minimum 3 drugs together) 
Note: This date must be entered exactly. If patient 
commenced HAART at another facility and the exact date is 
not known, the patient should be entered as “Treatment 
experienced” in the EXP_Y field below and the first visit at 
your facility will be used as the start of HAART date.  
FHV_STAGE_WHO 
Numeric with codes: 
 
1 = Stage I 
2 = Stage II 
3 = Stage III 
4 = Stage IV 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Clinical WHO stage (I to IV) at time of starting 
HAART 
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FHV_SDI_1 
Text (for example PCP - see List 3) 
 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Stage defining illness-1 at time of starting 
HAART. 
(Enter 88 patients who have not commenced 
HAART) 
Note: At least FHV_S_SDI_1 should be 
completed in patients commencing HAART; A 
maximum of 4 stage defining illness can be 
entered in the 4 fields provided. There is no 
specific ordering to the entering of stage defining 
illnesses.  
FHV_SDI_2 
Text (for example PCP - see List 3) 
 
0 = No further stage defining illness 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Stage defining illness-2 at time of starting 
HAART. 




Text (for example PCP - see List 3)  
 
0 = No further stage defining illness 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Stage defining illness-3 at time of starting 
HAART. 




Text (for example PCP - see List 3)  
 
0 = No further stage defining illness 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Stage defining illness-4 at time of starting 
HAART. 




Numeric with codes: 
 
0 = No (No previous ARV experience ) 
1 = Yes (Treatment experienced, drug 
history known and recorded in ART 
table) 
2 = Yes (Treatment experienced, drug 
history not known)  
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Patient is treatment experienced prior to starting 
HAART (HAART_DMY) ?   
Experienced = Any ARV drug for at least 30 
days before starting HAART (PMTCT regimen 
and PEP excluded)  
This should be entered for all patients even those 
who have not commenced HAART.  
MTCT_Y 
Numeric with codes: 
 
0 = No (No MTCT exposure ) 
1 = Yes (MTCT exposed, drug history 
reconstructed  and recorded in ART 
table) 
2 = Yes (MTCT exposed, drug history 
not reconstructable)   
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Patient exposed to MTCT drugs (either mother 
during pregnancy or infant peri- or post-natally) 
prior to start of HAART (HAART_DMY)? 
This should be entered for all patients even those 
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PEP_Y 
Numeric with codes: 
 
0 = No (No PEP exposure) 
1 = Yes (PEP exposed, drug history 
reconstructed  and recorded in ART 
table) 
2 =Yes (PEP exposed, drug history not 
reconstructable)   
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Patient exposed to post-exposure prophylaxis 
(PEP) drugs prior to start of HAART 
(HAART_DMY)? 
This should be entered for all patients even those 
who have not commenced HAART. 
TB_FHV 
Numeric with codes 
 
0 = No 
1 = Yes 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Patient was on treatment for TB at start of 
HAART (HAART_DMY) 
(Enter 88 patients who have not commenced 
HAART) 
WKS_TB_FHV 
Numeric (for example 8) 
 
88=Not applicable 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment  
Duration in weeks since start of TB treatment 
when HAART was commenced in  patients with 
TB at start of HAART  
(Enter 88 for patients who have not commenced 
HAART or who did not have TB at start of 
HAART) 
PREG_FHV 
Numeric with codes  
 
0 = No 
1 = Yes 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Pregnant at start of HAART 
(Enter 88 for men and children <10 years old 
AND all patients who have not commenced 
HAART) 
LAST_CONTACT_DMY DATE (dd-mm-yyyy) 
Date of last contact 
Note: This date must be entered exactly. 
LAST_CONTACT_T Numeric with codes (See List 4) Type of last contact 
OUTCOME Numeric with codes (See List 5) Outcome including death and loss to follow-up 
OUTCOME_DMY DATE (dd-mm-yyyy) 
Date of outcome  
(Leave blank if outcome is Alive [in care] or  
Alive [not in care])  
OUTCOME_Y 
Numeric (e.g. 2004) 
 
8888 = Not applicable or exact date of 
outcome entered above 
9995 = Not ascertained  
9999 = Unknown despite attempting 
ascertainment 
Year of outcome 
Enter 8888 for patients who have not died, or if 
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88 = Not applicable or exact date of 
outcome entered above 
 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
 
Month of outcome 
Enter 88 for patients who have not died, or if 
exact date of outcome entered above. 
 
 
DEATH_C1 Numeric with codes (see List 6)   
Cause of death : 
Enter 88 for patients who have not died 
Note : There are 3 fields for 3 causes of death to 
be entered in no specific order. If an HIV-related 
cause of death is recorded, please ensure that the 
condition is recorded appropriately in the OI 
table.   
 
Nature of contribution of cause: 
For each cause of death, please characterise the 
contribution of the specific cause. 
 
DEATH_N1 
Text with following codes: 
I = Immediate cause 
U = Underlying cause/condition 
C = Contributing cause 
N = Not available 
DEATH_C2 Numeric with codes (see List 6) 
DEATH_N2 
Text with following codes: 
I = Immediate cause 
U = Underlying cause/condition 
C = Contributing cause 
N = Not available 
DEATH_C3 Numeric with codes (see List 6) 
DEATH_N3 
Text with following codes: 
I = Immediate cause 
U = Underlying cause/condition 
C = Contributing cause 
N = Not available 
CAREG Numeric with codes (see List 7) 
Primary caregiver at start of HAART 
(HAART_DMY) 
(paediatric patients only – enter 88 for adult 
patients) 
DISCL_CG Numeric with codes (see List 8) 
Person informed of the HIV status of the child 
(paediatric patients only – enter 88 for adult 
patients) 
DISCL_CHILD 
Numeric with codes 
 
0 = No 
1 = Yes 
2 = In process 
88 = Not applicable (adult patient) 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Was the child informed of his/her status at 
HAART_DMY? 
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Numeric with codes 
 
10 = Vaginal, spontaneous 
11 = Vaginal, forceps 
12 = Vaginal, vacuum 
20 = Caesarean section – 
primary/elective (before onset of labour 
and rupture of membranes) 
21 = Caesarean section – emergency 
22 = Caesarean section – type unknown 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Mode of delivery  
(paediatric patients only - enter 88 for adult 
patients) 
WEIGHT_BIRTH 
Numeric (e.g 3.20) 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Weight at birth in kg  
(paediatric patients only - enter 88 for adult 
patients) 
BRSTFD 
Numeric with codes 
 
10 = breastfeeding, exclusive 
11 = breast-feeding, exclusivity 
unknown  
12 = mixed feeding 
20 = Formula feeding 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown, despite attempting 
ascertainment 
Main infant feeding option after birth 
(paediatric patients only - enter 88 for adult 
patients) 
BRSTFD_ED DATE (dd-mm-yy)  
Date of cessation of breast feeding if applicable 
Leave blank if not applicable, child still being 
breastfed, date not known, or child not breastfed 
at all. 
BRSTFD_EST_DUR 
Numeric (e.g. 2) 
 
77 = still breast-feeding, ED unknown 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Estimated duration of breastfeeding in months in 
children who are exclusively breastfed or mixed 
fed. 
(paediatric patients only - enter 88 for adult 
patients) 
Enter 88 if child still being breastfed or child not 
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List 1 - Codes for mode of entry (ENTRY)  
Code source: IeDEA SA codes 
Table name: LU :PAT :ENTRY 
 
Codes Mode of entry 
1 PMTCT program 
2 Diagnosis testing during hospitalization 
3 Diagnosis testing during consultation 
4 Orphans programs 
5 Family diagnosis 
6 TB program 
7 General HIV service clinic 
8 Self-referral with known diagnosis 
90 Other 
95  Not ascertained 
99 Unknown despite attempting ascertainment 
 
List 2 - Codes for mode of infection (MODE) 
Code source: Based on HICDEP codes; new codes denoted by * 
Table name: LU_mode 
 
Codes Mode of infection 
1 Homo/bisexual man  
2 Injecting drug user 
3 Homo/bisexual man + injecting drug user (1 + 2) 
4 Haemophiliac 
5 Transfusion, non-haemophilia related 
6 Heterosexual contact 
7 Heterosexual contact + Injecting drug user (6 + 2) 
8 Perinatal 
90 Other 
95*  Not ascertained 
99 Unknown despite attempting ascertainment 
 
List 3 - Disease codes for FHV_SDI (PAT table) and OI_ID (OI table)  
Code source: Based on HICDEP codes; new codes denoted by * 
Table name: LU:DIS 
 
Note that this is a common list of HIV-associated conditions for capturing incident opportunistic infections and HIV-associated 
conditions, as well as stage-defining conditions in adults and children.  Where duration or recurrence is required for a condition to be 
stage defining, the event columns have a zero to exclude them from lookups of incident conditions. Where conditions are not stage 
defining, the stage-defining columns for children and adults have zeros to exclude them from lookups of stage-defining conditions. 
 














ANGC* Angular cheilitis 2 2 1 1 1 1 
BCGD BCG disease – disseminated 4 4 1 1 1 1 
BCGL* BCG Lymphadenitis (localised to R axilla) 88 88 1 1 0 0 
BCGP* BCG Pulmonary 88 88 1 1 0 0 
BCIR* Recurrent severe presumed bacterial infection 
(excluding pneumonia)  
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BCIS* Severe presumed bacterial infection – single 
episode (excluding pneumonia) 
88 88 1 1 0 0 
BCNE Bacterial pneumonia, recurrent (>2 episodes 
within 1 year) 
4 3 0 0 1 1 
BCNS* Severe presumed bacterial pneumonia (single 
episode) 
88 88 1 1 0 0 
BLD* Unexplained anaemia (<8g/dl), and or 
neutropaenia (<500/mm3 – 2; <1000/mm3 - 
children), and or thrombocytopaenia 
(<50000/mm3) > 1 month 
3 3 0 0 1 1 
CANM* Candidiasis (oral) (outside neonatal period)  3 3 1 1 1 1 
CANO Candidiasis oesophogeal 4 4 1 1 1 1 
CANT* Candidiasis (trachea, bronchi or lungs) 4 4 1 1 1 1 
CLD* Chronic HIV-associated lung disease 88 3 0 1 0 1 
CMO* HIV-associated cardiomyopathy 88 4 1 1 0 1 
CMVO Cytomegalovirus other location (site other than 
liver, spleen or lymph nodes) (onset at 
age>1month) 
4 4 1 1 1 1 
CMVR Cytomegalovirus (CMV) chorioretinitis (onset at 
age>1month) 
4 4 1 1 1 1 
CRCO Cryptococcosis extrapulmonary 4 4 1 1 1 1 
CRSP Cryptosporidiosis (duration > 1 month) 4 4 0 0 1 1 
CRSPS* Cryptosporidiosis ? 88 88 1 1 0 0 
CRVC Cervical cancer (invasive) 4 88 1 1 1 0 
DEM AIDS dementia complex 4 88 1 0 1 0 
DIAC* Unexplained chronic diarrhoea (> 1month for 
adults; >14 days for children) 
3 3 0 0 1 1 
DIAS Diarrhoea (duration <1 month - adults; <14 days 
- children) 
88 88 1 1 0 0 
ENC* HIV encephalopathy 4 4 1 1 1 1 
FBLS Focal brain lesion 88 88 1 1 0 0 
FEVC* Unexplained persistent fever (> 1 month) 3 3 0 0 1 1 
FNID* Fungal nail infections (fingers or toes) 88 2 0 1 0 1 
FNIF* Fungal nail infections of fingers 2 88 1 0 1 0 
HERP Herpes simplex virus ulcers (duration > 1 month)  4 4 0 0 1 1 
HERPS* Herpes simplex virus ulcers 88 88 1 1 0 0 
HERPV* Visceral herpes simplex infection 4 4 1 1 1 1 
HG Hodgkins Lymphoma 88 88 1 1 0 0 
HIST Histoplasmosis extrapulm. 4 4 1 1 1 1 
HPVE* Extensive human papilloma virus infection  88 2 1 1 0 1 
HSM* Hepatosplenomegaly 88 2 0 0 0 1 
HZM* Herpes zoster (more than one dermatome) 88 88 1 1 0 0 
HZS* Herpes zoster (single dermatome)  2 2 1 1 1 1 
ISDI Isosporiasis diarrhoea (duration > 1 month) 4 4 0 0 1 1 
ISDS* Isosporiasis diarrhoea 88 88 1 1 0 0 
KS Kaposi Sarcoma 4 4 1 1 1 1 
LEIS Leishmaniasis visceral 4 88 1 1 1 0 
LEU Progressive multifocal leucoencephalopathy 4 4 1 1 1 1 
LGE* Lineal gingival erythema 88 2 1 1 0 1 
LIP* Lymphoid interstitial pneumonitis 88 3 0 1 0 1 
MC Mycobacterium avium complex (MAC) or 
Kanasii extrapulm. 
4 4 1 1 1 1 
MCDI Microsporidosis diarrhoea (duration > 1 month) 4 4 0 0 1 1 
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MCI* Mycobacterium Immune reconstitution syndrome 88 88 1 1 0 0 
MCP Mycobacterium tuberculosis pulmonary 3 3 1 1 1 1 
MCPO Mycobacterium pulmonary other (excluding 
BCG in children) 
88 88 1 1 0 0 
MCX Mycobacterium tuberculosis extrapulmonary 4 4 1 1 1 1 
MCXO Mycobacterium extrapulm. other (excluding 
BCG in children) 
4 4 1 1 1 1 
MNUM* Moderate unexplained malnutrition (60-80% 
EWFA) 
88 3 0 1 0 1 
MNUS* Unexplained severe wasting or malnutrition 
(<60% EWFA) 
88 4 0 1 0 1 
MOLC* Extensive molluscum contagiosum 88 2 1 1 0 1 
MYCD* Any disseminated mycosis 4 4 1 1 1 1 
NHG Non-Hodgkin Lymphoma, not specified 88 88 1 1 0 0 
NHGB Non-Hodgkin Lymphoma, Burkitt (classical or 
atypical) 
88 88 1 1 0 0 
NHGI Non-Hodgkin Lymphoma, diffuse large B-cell 
lymphoma (immunoblasti or centroblastic) 
4 4 1 1 1 1 
NHGP Non-Hodgkin Lymphoma primary brain 
lymphoma 
4 4 1 1 1 1 
NHGU Non-Hodgkin Lymphoma unknown/other 
histology 
88 88 1 1 0 0 
NPO* HIV-associated nephropathy 88 4 1 1 0 1 
NUS* Acute necrotising ulcerative stomatitis, gingivitis 
or periodontitis 
3 3 1 1 1 1 
OHLP* Oral hairy leukoplakia 3 3 1 1 1 1 
ORUL* Recurrent oral ulcerations 2 2 0 0 1 1 
PARE* Parotid enlargement 88 2 1 1 0 1 
PCP Pneumocystis carinii pneumonia  4 4 1 1 1 1 
PGL* Persistent Generalized Lymphadenopathy 1 1 0 0 1 1 
PPE* Papular pruritic eruptions 2 2 1 1 1 1 
RTIL* Lower respiratory tract infection (other than 
presumed pneumonia) ? 
88 88 1 1 0 0 
RTIR* Recurrent or chronic respiratory tract infection 
(RTIs, sinusitis, bronchitis, otitis media, otorrhea, 
pharyngitis) 
2 2 0 0 1 1 
RTIU* Upper respiratory tract infection 88 88 1 1 0 0 
RVF* Acquired HIV-associated recto-vaginal fistula 88 4 1 1 0 1 
SAME Salmonella bacteraemia (non-typhoid) (single 
episode) 
88 88 1 1 0 0 
SAM Salmonella bacteraemia (non-typhoid) recurrent 4 88 0 0 1 0 
SEBD* Seborrheic dermatitis 2 2 1 1 1 1 
TOX Toxoplasmosis brain (outside neonatal period) 4 4 1 1 1 1 
WAST HIV Wasting Syndrome 4 88 1 0 1 0 
WTLM* Moderate unexplained weight loss (<10% of 
body weight) 
2 88 1 0 1 0 
WTLS* Severe unexplained weight loss (>10% of body 
weight) 
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List 4 - Codes for last contact (LAST_CONTACT_T) 
Code source: IeDEA SA codes 
Table name: LU :PAT :LAST_CONTACT_T 
 
Codes Last contact type 
1 Visit in the facility 
2 Phone call 
3 Home visit 
4 Hospitalisation 
5 Drug pick-up only 
6 Visit in another facility 
7 Laboratory test received 
90 Other 
95  Not ascertained 
99 Unknown despite attempting ascertainment 
 
List 5 - Codes for outcome (OUTCOME) 
 Code source: IeDEA SA codes 
Table name: LU :PAT :OUTCOME 
 
Codes Mode of infection 
10 Death (HIV-related) 
11 Death (HIV relationship unknown) 
12 Death (not HIV-related) 
20 Alive and in care at your facility 
21 Known to be alive and in care at another facility  
22 Known to be alive and patient is not in care  
23 Known to be alive but not known whether patient is in care 
30 Transfer out within the same service, vital status after transfer out unknown 
31 Transfer out to a different service, vital status after transfer out unknown 
40 Loss to follow-up despite active tracing attempted 
41 Loss to follow-up (not actively traced) 
90 Other 
95 Not ascertained 
 
List 6 - Codes for cause of death (DEATH_C1 – 3) 
Code source: HICDEP codes; new codes denoted by * 
Table name: LU :PAT :DEATH_C 
 
For HIV-related and Aids defining events (8.*), it is expected that the associated event will be 
recorded in the OI table. 
 
Codes  Cause of Death  
1  Myocardial Infarction  
2  Stroke  
3  Other cardiovascular diseases  
4  Symptoms caused by mitochondrial toxicity  
4.1  Lactic acidosis  
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6  Pancreatitis  
7  Complications due to hepatitis  
7.1  Hepatitis related  
7.2  Liver failure not related to hepatitis or mitochondrial toxicity  
8  HIV-related  
8.1  AIDS defining event  
8.2  Invasive bacterial infection  
9  Renal failure  
10  Bleeding (haemophilia) 
20  Non AIDS defining cancer  
88* Not applicable 
90  Other  
91  Suicide 
92  Drug Overdose  
93 Accident 
95* Not ascertained 
99 Unknown, Fatal case with no information 
 
List 7 - Codes for primary caregiver (CAREG)  
Code source: IeDEA SA codes 
Table name: LU :PAT :CAREG 
 








88 Not applicable 
95  Not ascertained 
99 Unknown despite attempting ascertainment 
 
List 8 - Codes for person informed of the HIV status of the child (DISCL_CG)  
Code source: IeDEA SA codes 
Table name: LU :PAT :DISCL_CG 
 
Codes Disclosure to caregiver 
1 Mother 
2 Father 
12 Both parents 
3 Grandmother 
4 Other primary caregiver 
90 Other 
88 Not applicable  
95 Not ascertained 
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2.2  Laboratory data (LAB table) 
Table 2 details the laboratory data that should be included in the LAB table.  All available data from 
the date of first visit should be included.   
 
Notes: 
• Results of laboratory tests must be provided in the units specified 
• Results of laboratory tests can be entered in one of two fields – a numeric field (LAB_V) 
and a coded text field (LAB_T) (for very high and/or undetectable viral loads, and for TB 
microscopy and culture results). 
• TB microscopy and culture results should only be entered in the coded result field (LAB_T) 
as follows, and not in the numeric field (LAB_V): 
• For viral loads, there is an additional field to indicate the lower limit of detection of the 
assay used. This field should be entered as not-applicable (Code = -88) for other laboratory 
results.  
• For TB sensitivity results, there are 2 additional fields. The first (TB_DRUG) where the 
drug to which sensitivity testing has been done is entered, and the second (SENS), where the 
sensitivity is recorded using the standard yes/no format. These fields should be entered as 
not-applicable (Code = 88) for other laboratory results.  
• Both CD4 percentage and absolute count should be included on paediatric patients until they 
are 16 years old. 
• There is no code for unknown values of for laboratory test results as tests of which the result 
is unknown should not be included in the dataset.  
• Only dates in the DMY format are permissible in this table 
 
Table 2 – Variables to be included in the table LAB 
Name Format Description 
PATIENT Free (numerical or alphanumerical) Unique patient identifier 
LAB_DMY Date (for example dd/mm/yy) Date when specimen was taken 
LAB_ID Text (see List 9) Code representing the measurement 
LAB_V Numeric (for example 44) 
Numeric value of measurement 
Leave blank if result entered as code (LAB_C) 
LAB_T 
Text  
Lower than limit of detection for viral loads 
should be entered as “LDL” 
TB microscopy and culture results should be 








 eg. “> 6 000 000” or “P+++” 
Leave blank if result entered as number (LAB_V) 
RNA_L 
Numeric 
-88 = Not applicable 
-99 = Unknown 
Lower limit of detection of RNA assay 










IeDEA Southern Africa Standard Procedures for Data Transfer 




Text with codes: 
 
INH_L = Isoniazid low dose 
INH_H = Isoniazid high dose 
INH_U = Isoniazid – dose unspecified 
PZA = Pyrazinamide 
RIF = Rifampicin 
ETN = Ethionamide 
ETB = Ethambutol 
STREP = Streptomycin 
QUI = Quinolone 
88 = Not applicable 
TB Drug against which sensitivity has been tested.  
(Enter 88 for laboratory tests other than viral load) 
DRUG_RES 
Numeric with codes: 
0 = No (Sensitive) 
1 = Yes (Resistant) 
88 = Not applicable 
 
Is Mycobacterium TB cultured RESISTANT to drug in 
TB-DRUG field? 
(Enter 88 for laboratory tests other than viral load)  
 
List 9: Codes for measurement type (LAB_ID) 
Code source: HICDEP codes; new codes denoted by * 
Table name: LU :LAB :LAB_ID 
 
Codes Measurement 
ALB Albumin (g/L) 
ALT Alanine-Aminotransferase (UI/L) 
AST Aspartate aminotransferase (UI/L) 
CD4A* CD4 absolute cell count (cells/μl) 
CD4P* CD4 percentage (%) 
CHOL Cholesterol (mmol/L) 
CRE Creatinine (μmol/L) 
HAEM Haemoglobin (g/dl) 
LACT Lactate (mmol/L) 
LYMP Total lymphocyte count (cells/µl) 
NEUT Neutrophil count (x1000/mm3) 
PLT Platelets (cells/μl) 
RNA* HIV-RNA measurement value (copies/ml) 
TBC* TB culture 
TBM* TB microscopy 
TBS* TB sensitivity 
TG Triglycerides (mmol/L) 
URE Urea (mmol/L) 
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2.3 Antiretroviral drug variables (ART table) 
 
Table 3 details the data on antiretroviral treatment that should be included in the ART table. As 
previously mentioned, preferably we will receive one line per drug, each with its prescription, start 
and stop date.   
 
Notes: 
• All antiretroviral drugs to which a patient has been exposed (including PMTCT exposure of 
both pregnant women and infants peri-  or postnatally) and PEP should be included with 
either the dates of starting and stopping the individual drugs, OR the number of doses OR 
the duration of treatment.  
• History of exposure to antiretroviral drugs prior to commencing care at the reporting facility 
should be reconstructed as far as possible and included in this table, making use of 
appropriate drug codes for unknown regimens and date/time codes for unknown start and 
stop dates or unknown durations.  
 
Table 3 – Variables to be included in ART table 
Name Format Description 
PATIENT Free (numerical or alphanumerical) Unique patient identifier 
ART_ID ATC (for example NVP – see List 10) Type of antiretroviral drug 
ART_SD_DMY Date(dd-mm-yyyy) Date of starting each antiretroviral drug (start date). 
Enter exact date in this field if known. 
 If unknown leave blank and enter month and year as far as 
possible in fields below. 
ART_SD_Y Numeric (e.g. 2003) 
 
8888 = Exact start date entered in 
appropriate field 
9999 = Unknown despite at empting 
ascertainment 
9995 = Not ascertained 
Year of starting drug 
ART_SD_M Numeric (e.g. 7) 
 
88 = Exact start date entered in 
appropriate field 
99 = Unknown despite attempting 
ascertainment 
95 = Not ascertained 
Month of starting drug 
ART_RS Numeric with codes  
(See List 11) 
Reason for receiving ART  
ART_FORM Numeric with codes  
 
1 = Tablet/capsule 
2 = Syrup/Suspension 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
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ART_COMB Numeric with codes  
 
1 = Individual drug 
2 = Part of a fixed dose combination  
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Is drug part of a fixed dose combination? 
ART_ED_DMY Date(dd-mm-yyyy) Date of stopping each antiretroviral drug (end date) 
Enter exact date in this field if known. 
 If unknown leave blank and enter EITHER month and year 
as far as possible in fields below OR number of doses OR 
duration in weeks in the appropriate fields.  
ART_ED_Y Numeric (e.g. 2004) 
 
8888 = exact end date or number of 
doses or duration in weeks entered in 
appropriate fields 
9999 = Unknown despite attempting 
ascertainment 
9995 = Not ascertained 
Year of stopping drug 
ART_ED_M Numeric (e.g. 7) 
 
88 = exact end date or number of 
doses or duration in weeks entered in 
appropriate fields 
99 = Unknown despite attempting 
ascertainment 
95 = Not ascertained 
Month of stopping drug 
NO_DOSES Numeric (e.g. 1) 
 
888 = end date or duration in weeks 
entered in appropriate fields 
999 = Unknown despite attempting 
ascertainment 
995 = Not ascertained 
Number of doses of drug e.g. 1 for single dose Nevirapine 
NO_WEEKS Numeric (e.g. 12) 
 
888 = end date or number of doses 
entered in appropriate fields 
999 = Unknown despite attempting 
ascertainment 
995 = Not ascertained 
Number of weeks of receiving drug  
e.g. 12 for AZT from 28 weeks of pregnancy delivering at 
term 
ART_END_RS Numeric with codes  
(See List 12) 
Reason for stopping antiretroviral drug 
INFO_SOURCE Numeric with codes  
 
1 = Clinical records at this facility 
2 = Clinical records/letter from 
      another facility 
3 = Patient/caregiver report 
4 = Likely protocol in use 
90 = Other 
99 = Unknown 
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List 10: Anti-retroviral drugs :  (ART_ID) 
Code source: ATC classification: Anatomical Therapeutic Chemical 
Table name: LU :ART :ART_ID 
 
ATC codes Antiretroviral treatment 
J05A  Drug unspecified (i.e. single drug, totally unknown) 
J05AE  PI unspecified  
J05AE01  Saquinavir (gel, not specified)  
J05AE01-SQH  Saquinavir hard gel (INVIRASE)  
J05AE01-SQS  Saquinavir soft gel (FORTOVASE)  
J05AE02  Indinavir (CRIXIVAN)  
J05AE03  Ritonavir (NORVIR) 
J05AE03-H  Ritonavir high dose (NORVIR)  
J05AE03-L  Ritonavir low dose (NORVIR)  
J05AE04  Nelfinavir(VIRACEPT) 
J05AE05  Amprenavir (141W94) (AGENERASE)  
J05AE06  Lopinavir/Ritonavir (ABT-378/r, Kaletra)  
J05AE07  Fosamprenavir  
J05AE-ATV  Atazanavir (ZRIVADA) 
J05AE-GW4  GW433908/VX-275 (Drug phase III) (PROGENERASE)  
J05AE-TMC  TMC 114 (Tibotec)  
J05AE-TPR  Tipranavir (trial drug)  
J05AF  NRTI unspecified 
J05AF01  Zidovudine (AZT, RETROVIR)  
J05AF02  Didanosine (ddI) (VIDEX)  
J05AF03  Zalcitabine (ddC) (HIVID)  
J05AF04  Stavudine (d4T) (ZERIT)  
J05AF05  Lamivudine (3TC, EPIVIR)  
J05AF06  Abacavir (1592U89) (ZIAGEN)  
J05AF07  Tenofovir (TDF, VIREAD)  
J05AF08  Adefovir (PREVEON)  
J05AF09  Emtricitabine (FTC, EMTRIVA)  
J05AF10  Entecavir  
J05AF30-KIV  Kivexa  
J05AF30-TZV  Trizivir  
J05AF-FOZ  Fozivudinetidoxi 
J05AF-LDN  Lodenosine (trialdrug)  
J05AG  NNRTIunspecified  
J05AG01  Nevirapine (VIRAMUNE)  
J05AG01-SD  Nevirapine (VIRAMUNE) single dose 
J05AG02  Delavirdine (U-90152) (RESCRIPTOR)  
J05AG03  Efavirenz (DMP-266) (STOCRIN, SUSTIVA)  
J05AG-LOV  Loviride  
J05AG-TMC  TMC 125 (Tibotec)  
J05A-PBT  Participant in Blinded Trial  
J05AR*  ART regimen and drug unspecified (i.e. both number and names of 
drugs totally unknown) 
J05AX07  Enfurvirtide (FUZEON, T-20/Ro 29-9800)  
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List 11: Codes for reason for receiving ART (ART_RS)  
Code source: IeDEA SA codes  
Table name: LU :ART :ART_RS 
 
Codes Reason 
10 MTCT – antenatal (mother) 
11 MTCT – peripartum (mother) 
12 MTCT – postpartum (mother) 
13 MTCT – timing unknown (mother) 
20 MTCT – peripartum (infant) 
21 MTCT – postpartum (infant) 
22 MTCT – timing unknown (infant) 
30 ARV as treatment 
 40 PEP 
95 Not ascertained 
99 Unknown despite attempting ascertainment 
 
List 12: Reason for treatment discontinuation (ART_END_RS)  
Code source: HICDEP codes; new codes denoted by * 
Table name: LU :ART :ART_END_RS 
Codes Reason for treatment discontinuation AE CI FL Other 
1 Treatment failure (i.e. virological, immunological, and /or clinical 
 
  1  
1.1 Virological failure   1  
1.2 Partial virological failure   1  
1.3 Immunological failure – CD4 drop   1  
1.4 Clinical progression   1  
10 Hyperlactataemie/lactic acidosis 1    
2 Abnormal fat redistribution 1    
3 Concern of cardiovascular disease 1    
3.1 Dyslipidaemia 1    
3.2 Cardiovascular disease 1    
4 Hypersensitivity reaction 1    
5 Toxicity, predominantly from abdomen/G-I tract 1    
5.1 Toxicity – GI tract 1    
5.2 Toxicity – Liver 1    
5.3 Toxicity – Pancreas 1    
6 Toxicity, predominantly from nervous system 1    
6.1 peripheral neuropathy 1    
7 Toxicity, predominantly from kidneys 1    
8 Toxicity, predominantly from endocrine system 1    
8.1 Diabetes 1    
88 Death (note overlap with N/A in other lists)    1 
9 Haematological toxicity (anemia …etc.) 1    
90 Side effects – any of the above but unspecified 1    
90.1 Comorbidity  1   
91 Toxicity, not mentioned above 1    
92 Availability of more effective treatment (not specifically failure or 
side effect related) 
   1 
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92.2 Treatment too complex    1 
92.3 Drug interaction  1   
92.4 Drug interaction - commencing TB treatment  1   
92.5 Drug interaction ended - stopping TB treatment    1 
93 Structured Treatment Interruption (STI)    1 
93.1 Structured Treatment Interruption (STI) – at high CD4    1 
94 Patient's wish/ decision, not specified above    1 
94.1 Non-compliance    1 
95 Physician’s decision, not specified above (note overlap with 
standard code 
   1 
95.1* Contra-indication expired    1 
96 Pregnancy  1   
96.1* MTCT regimen completed    1 
96.2* Pregnancy ended    1 
97 Study treatment    1 
98 Other causes, not specified above    1 
99 Unknown despite attempting ascertainment    1 
99.5 Not ascertained    1 
2.4 Opportunistic events (OI table) 
Table 4 below details the data on opportunistic events or HIV associated conditions diagnosed 
during follow up that should be included in table OI. 
 
History of opportunistic events prior to commencing care at the reporting facility should be 
reconstructed as far as possible and included in this table, making use of appropriate date/time 
codes for unknown start and end dates. It is anticipated that the end date of OIs will frequently be 
unknown.  
 
Table 4 – Variables to be included in OI table 
Name Format Description 
PATIENT Free (numerical or alphanumerical) Unique patient identifier 
OI_ID Text (for example PCP - see List 3 – Disease codes – under PAT table)  Type of opportunistic event 
OI_SD_DMY Date(dd-mm-yyyy) 
Date of start of each opportunistic event. 
Enter exact date in this field if known. 
 If unknown leave blank and enter month and 
year as far as possible in fields below. 
OI_SD_Y 
Numeric (e.g. 2001) 
 
8888 = Not applicable 
(Exact date entered in field above) 
9995 = Not ascertained 
9999 = Unknown despite attempting 
ascertainment 
Year of start of event 
OI_SD_M 
Numeric (e.g. 11) 
 
88 = Not applicable  
(Exact date entered in field above) 
95 = Not ascertained 
99 = Unknown despite attempting ascertainment 
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Date of end of each opportunistic event. 
Enter exact date in this field if known. 
 If unknown leave blank and enter month and 
year as far as possible in fields below 
If OI is ongoing (has not yet ended) leave blank 
and enter appropriate code in field below 
OI_ED_Y 
Numeric (e.g. 2001) 
 
8885 = Ongoing 
8888 = Not applicable 
(Exact date entered in field above) 
9995 = Not ascertained 
9999 = Unknown despite attempting 
ascertainment 
Year of end of event 
OI_ED_M 
Numeric (e.g. 11) 
 
85 = Ongoing 
88 = Not applicable  
(Exact date entered in field above) 
95 = Not ascertained 
99 = Unknown despite attempting ascertainment 
Month of end of event 
DIAG_METH Numeric (see List 13 ) Method of diagnosis 
 
List 13: Diagnosis Method of Opportunistic Event (DIAG_METH)  
Code source: IeDEA SA codes 
Table name: LU :OI :DIAG_METH 
 
Codes Diagnosis Method 
10 clinical only 
11 clinical & radiology 
12 clinical and endoscopy 
20 microscopy for infectious agent 
21 culture of infectious agent 
30 blood antibody test 
31 site specimen (non-blood) antibody test 
40 tissue histology 
90 other 
95 Not ascertained 
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2.5 Follow-up clinic visits (VIS table) 
Table 5 below details the information to be included in the VIS table. Please include all visits for 
each patient since the first visit at the reporting facility, and where possible visits at previous 
facilities. Weight, height and head circumference left blank will be assumed to have not been 
ascertained. 
 
Table 5 – Variables to be included in VIS table  
Name Format and definitions Description 
PATIENT Free (numerical or alphanumerical) Unique patient identifier 
VISIT_DMY Date (for example dd/mm/yy) Date of visit patient 
VISIT_FAC 
Numeric with codes 
 
1 = Visit at this cohort’s facility 
2 = Visit at another facility 
99 = Site of visit unknown 
Facility at which visit took place 
WEIGHT Numeric (for example 75) Weight in kilos (kg) 
HEIGHT Numeric (for example 75) Height in centimeters (cm) 
CTX 
Numeric with codes : 
 
1 = yes 
0 = No 
95 = Not ascertained 
99 = Unknown despite attempting ascertainment  
Cotrimoxazole status 
INH 
Numeric with codes : 
 
1 = Yes 
0 = No 
95 = Not ascertained 
99 = Unknown despite attempting ascertainment 
Isoniazid status 
FLU 
Numeric with codes : 
1 = Yes 
0 = No 
95 = Not ascertained 
99 = Unknown despite attempting ascertainment 
Fluconazole status 
HEADC Numeric (for example 75) Head circumference in centimeters (cm) 
SCHOOL_Y 
Numeric with codes 
 
0 = No school 
1 = At school 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite attempting ascertainment 
Schooling for children >5 years.  
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3 Variables to be included in additional tables 
3.1 Family and partner linkages (LINK table) 
 
Table 6 details the information on family members (partners, children and siblings) that should be 
included in the LINK table. 
 
All family members receiving HIV care should be listed. This includes those receiving care within 
the reporting cohort as well as those receiving care at other sites. 
 
The cohort-specific identifiers of family members receiving HIV care at the reporting site should be 
included.  
 
Table 6 – Variables to be included in the table LINK 
Name Format Description 
PATIENT Free (numerical or alphanumerical) Unique patient identifier 
LINK_REL Numeric with codes (See List 14) 
 
Relationship of family member to patient 
LINK_COHORT Text with codes (See List 15) Cohort within which family member is receiving HIV care 
LINK_ID 
Free (numerical or alphanumerical) 
-88 = Not applicable 
-95 = Not ascertained 
-99 = Unknown despite attempting 
ascertainment 
Unique patient identifier of family member 
Enter -88 if family member in care at non-IeDEA site. 
 
List 14 - Codes for relationship of family member to patient (LINK_REL)  
Code source: IeDEA SA codes 









95  Not ascertained 
99 Unknown despite attempting ascertainment 
 
List 15 - Cohort where family member is receiving care (LINK_COHORT)  
Code source: To be created by transferring site 
Table name: LU :LINK :LINK_COHORT 
 
Codes Cohort 
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3.2 Pregnancy information (PREGNANCY table)  
 
Table 7 details information to be included in the PREGNANCY table. This table contains 
information on all pregnancies since the patient was known to be HIV-infected, including 
spontaneous abortions/ miscarriages and terminated pregnancies, and their outcomes.  
 
Table 7 – Variables to be included in PREGNANCY table 
Name Format Description 
PATIENT Free (numerical or alphanumerical) Unique patient identifier for patient 
PREG_DIAG_DMY Date (dd-mm-yyyy) Exact date when patient first presents as pregnant 
PREG_DUR_DIAG Numeric (e.g. 12) 
99 = Unknown 
Estimated duration of pregnancy in weeks when patient 
first presents as pregnant 
PREG_END_DMY Date (dd-mm-yyyy) Exact date of delivery, spontaneous abortion or 
termination 
Enter exact date in this field if known. 
 If unknown leave blank and enter month and year as far 
as possible in fields below. 
PREG_END_Y Numeric (e.g. 2003) 
 
8888 = Not applicable 
(Exact date entered in field above) 
9995 = Not ascertained 
9999 = Unknown despite attempting 
ascertainment 
Year of delivery, spontaneous abortion or termination 
PREG_END_M Numeric (e.g. 9) 
 
88 = Not applicable 
(Exact date entered in field above) 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Month of delivery, spontaneous abortion or termination 
PREG_ED Numeric (e.g. 36) 
 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Estimated duration of entire pregnancy in weeks 
PREG_OUTCOME Numeric with codes  
 
1 = Live birth 
2 = Still birth 
3 = Termination of pregnancy 
4= Spontaneous abortion  
     (miscarriage) 
95 = Not ascertained 
99 = Unknown despite attempting  
        ascertainment 
Outcome of pregnancy 
INF_WT Numeric (e.g. 2.9) 
 
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Weight of delivered infant. 
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NEONATAL_DEATH Numeric with codes 
 
0 = No 
1 = Yes  
88 = Not applicable 
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Did delivered live infant die within 1 month of birth? 
If stillbirth, spontaneous abortion or termination, enter 
88 
BIRTH DEFECT_Y Numeric with codes 
 
0 = No 
1 = Yes  
95 = Not ascertained 
99 = Unknown despite attempting 
ascertainment 
Did fœtus or infant have any congenital malformations? 
BIRTH_DEFECT_TYPE Text Free text description of malformations 
 
3.3 Parental Health (PAR_HEALTH table)  
 
Table 8 details variables to be included in the table PAR_HEALTH. This table contains information 
on parental health status.  
 
This table is linked to the visit table, so ideally there is an update on parental health status at every 
visit. Alternatively, this table should be filled in at least once, either for the first visit at your facility 
or the date of start of HAART.  
 
For patients over 16 years of age, no entries are required into this table (i.e. this table is not required 
at all for sites that have only patients over 16 years of age in their care).  
 
While information on parental health is very valuable, it is acknowledged that many sites do not 
collect this information. If only information at the child’s first visit or at the start of HAART is 
collected, this should be included with the appropriate visit date. If no information on parental 
health is collected, this table can be omitted.   
 
Table 8: Variables to be included in the PAR_HEALTH table 
Name Format Description 
PATIENT Free (numerical or alphanumerical) Unique patient identifier for patient 
VIS_DMY 
Date (dd/mm/yy) 
Date of parental health evaluation  
(probably same as clinic visit date) 
MAT_DEATH Numeric with codes 
 
0 = No (Alive) 
1 = Yes (Dead) 
95 = Not ascertained 
99 = Unknown despite attempting ascertainment 
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MAT_HIV Numeric with codes 
 
0 = Negative 
1 = Positive 
95 = Not ascertained 
99 = Unknown despite attempting ascertainment 
Mother’s HIV status if available 
MAT_TTT Numeric with codes 
 
0 = No treatment 
1 = CMX only 
2 = HAART only 
12 = CMX and HAART 
88 = Not applicable (mother HIV negative or deceased) 
95 = Not ascertained 
99 = Unknown despite attempting ascertainment 
Mother’s treatment if available 
PAT_DEATH Numeric with codes 
 
0 = No (Alive) 
1 = Yes (Dead) 
95 = Not ascertained 
99 = Unknown despite attempting ascertainment 
Paternal status: Father deceased? 
PAT_HIV Numeric with codes 
 
0 = Negative 
1 = Positive 
95 = Not ascertained 
99 = Unknown despite attempting ascertainment 
Father’s HIV status if available 
PAT_TTT Numeric with codes 
 
0 = No treatment 
1 = CMX only 
2 = HAART only 
12 = CMX and HAART 
88 = Not applicable (father HIV negative or deceased) 
95 = Not ascertained 
99 = Unknown despite attempting ascertainment 
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3.4 Tuberculosis information (TB table) 
This table is for capturing details of the TB episodes during HIV follow-up.  Tests related to TB can 
be included in the LAB table.  Where possible this data can be derived from the electronic TB 
register. 
 
Table 9 – Variables to be included in the table TB 
Name Format Description 
PATIENT Free (numerical or alphanumerical) Unique patient identifier 
REG_DMY Date (dd/mm/yy) Date registered with TB 
REGID 
Text (eg. 2272007) 
-95 = Not ascertained 




TB register number 
 
RAD 
Numeric with codes 
 
0 – Not done 
1 – Normal 
20 – Abnormal unspecified 
21 – Abnormal - not consistent with current TB 
22 – Abnormal - consistent with current TB 
unspecified 
23 – Abnormal – consistent with current TB –  
Cavity on right 
24 - Abnormal – consistent with current TB –  
Cavity on left 
25 - Abnormal – consistent with current TB – 
Bilateral cavities 
26 - Abnormal – consistent with current TB -  
No cavities 
99 = Unknown despite attempting ascertainment 
Radiography findings if done 
RESISTANT 
Numeric with codes 
 
0 – No 
1 – MDR 
2 – XDR 
95 = Not ascertained 
99 = Unknown despite attempting ascertainment 
Resistance data based on sensitivities 
Note: Exact results of sensitivities should be record in the LAB table.  
Code as MDR if … to more than one drug and XDR if… 
Categories MDR and XDR should be for the worst resistance status 
during the episode.  
  
TB_START_DMY Date (dd/mm/yy) Date starting TB treatment 
TB_END_DMY Date (dd/mm/yy) Date ending TB treatment or date of outcome 
CAT 
Numeric with codes 
 
1 – Newly diagnosed for the first time 
2 – After relapse 
3 – After default 
4 – After failure 
95 = Not ascertained 
99 = Unknown despite attempting ascertainment 
TB Category 
CLASS 
Numeric with codes 
 
1 - Pulmonary 
2 – Extra-pulmonary 
3 – Both pulmonary and extra-pulmonary 
4 - Primary 
95 = Not ascertained 
99 = Unknown despite attempting ascertainment 
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Numeric with codes 
 
1 – Bones/Joints (A18.0) 
2 – Lymph nodes (A16.3) 
3 – Meningitis (A17.0) 
4 – Miliary (A19.9) 
5 – Pleura (A16.5) 
9 – Other sites (A18.8) 
88 – Not applicable as pulmonary or primary only 
95 = Not ascertained 
99 = Unknown despite attempting ascertainment 
Site of disease if extra-pulmonary component diagnosed 
REGIMEN 
Numeric with codes 
 
1 – 2HRZE 4HR - Regimen 1 
2 –2HRZES 1HRZE 5HRE - Regimen 2 
3 – 2HRZ 4HR - Regimen 3 
4 –Other Regimen 
95 = Not ascertained 
99 = Unknown despite attempting ascertainment 
TB treatment regimen  
REG_OTHER Text Text field for other regimen not included in codes for REGIMEN field above 
TB_OUTCOME 
Numeric with codes 
 
1 – Completed 
2 – Cured 
3 – Failed 
4 – Interrupted 
5 – Defaulted 
6 – Treatment ongoing 
7 - Died 
95 = Not ascertained 
99 = Unknown despite attempting ascertainment 
Outcome of TB episode 
 
3.5 Trial/research study enrolment information (TRIAL table) 
 
Table 10 details the data that should be included in the TRIAL table.  This table is only for sites 
running trials or research studies. Any trial/research study (apart from cohort analysis of routine 
data) on which a patient has been enrolled should be entered together with the dates of entering and 
leaving each trial. Sites should send an additional coding table of the trials running at their site.  
 
Table 10 – Variables to be included in the table TRIAL 
Name Format Description 
PATIENT Free (numerical or alphanumerical) Unique patient identifier 
TRIAL_START_DMY Date (for example dd/mm/yy) Date of enrolment onto trial 
TRIAL_END_DMY Date (for example dd/mm/yy) 
Date of completion/ disenrolment  
Leave blank if patient is still enrolled on trial 
TRIAL_ID Free (numeric or text) codes (See List 16) 
Name of trial on which patient is enrolled 
Each site to send their own List with coding and 
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List 16: Example of codes for trial name (TRIAL_ID)  
Code source: Site to supply own codes 
Table name: LU :TRIAL :TRIAL_ID 
 
Codes  
(Text or Numeric) 
Trial name (text field) Short description of trial (Memo field) 
INH INH trial Trial of thrice weekly vs daily INH prophylaxis 
in HIV-infected children 






This table contains information about the data transfer itself. 
 
Table 11 – Variables to be included in the table META 
Name Format Description 
COHORT Text Name of the cohort  
ENROLS_DMY Date (for example dd/mm/yy) Date of start of enrolment 
ENROLE_DMY Date (for example dd/mm/yy) Date of end of enrolment 
FU_CLOSE_DMY Date (for example dd/mm/yy) Date of last possible follow-up 
ASC_DMY Date (for example dd/mm/yy) Date of last possible outcome ascertainment 
LTF_DEF Numeric For patients classified by the site as LTF, the number of days used to define LTF 
REPORTER Text Name of person responsible for data transfer 
TRANSFER_DMY Date (for example dd/mm/yy) Date extracted 
EMAIL Text Email address of site person responsible 
 
